



(11) **EP 1 926 491 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
20.03.2013 Bulletin 2013/12

(51) Int Cl.:
C12Q 1/68 (2006.01) G01N 33/53 (2006.01)

(21) Application number: **06815404.6**

(86) International application number:
PCT/US2006/037362

(22) Date of filing: **25.09.2006**

(87) International publication number:
WO 2007/035953 (29.03.2007 Gazette 2007/13)

(54) **GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF**

MIT HERZKREISLAUF-STÖRUNGEN UND MEDIKAMENTENANSPRACHE ASSOZIIERTE
GENETISCHE POLYMORPHIEN, NACHWEISVERFAHREN UND IHRE VERWENDUNG

POLYMORPHISMES GÉNÉTIQUES ASSOCIÉS AUX TROUBLES CARDIO-VASCULAIRES ET À LA
RÉACTION AUX MÉDICAMENTS, PROCÉDÉS DE DÉTECTION ET UTILISATION

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**
Designated Extension States:
HR

(30) Priority: **23.09.2005 US 720274 P**
22.09.2006 US 526137

(43) Date of publication of application:
04.06.2008 Bulletin 2008/23

(60) Divisional application:
11188231.2 / 2 471 952
11188240.3 / 2 471 953

(73) Proprietor: **Celera Corporation**
Alameda, CA 94502 (US)

(72) Inventors:
• **IAKOUBOVA, Olga**
San Ramon, California 94582 (US)
• **DEVLIN, James, J.**
Lafayette, California 94549 (US)

(74) Representative: **Weber, Martin et al**
Jones Day
Prinzregentenstraße 11
80538 München (DE)

(56) References cited:
WO-A-2005/056837 WO-A-2008/118415
WO-A2-2004/067779 WO-A2-2005/083127

- **DATABASE NCBI SNP [Online] 20 August 2004 (2004-08-20), "Submitted SNP ss23899966; RefSNP rs20455" XP002550449 retrieved from NCBI Database accession no. ss23899966**
- **MAITLAND-VAN DER ZEE ANKE-HILSE ET AL: "Pharmacogenetics of response to statins: where do we stand?" CURRENT ATHEROSCLEROSIS REPORTS, CURRENT SCIENCE, US, vol. 7, no. 3, 1 May 2005 (2005-05-01), pages 204-208, XP009112074 ISSN: 1523-3804**
- **IAKOUBOVA ET AL: "Association of the Trp719Arg Polymorphism in Kinesin-Like Protein 6 With Myocardial Infarction and Coronary Heart Disease in 2 Prospective Trials" JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 51, no. 4, 22 January 2008 (2008-01-22), pages 435-443, XP022432404 ISSN: 0735-1097**
- **STEWART A F R ET AL: "Kinesin Family Member 6 Variant Trp719Arg Does Not Associate With Angiographically Defined Coronary Artery Disease in the Ottawa Heart Genomics Study" JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 53, no. 16, 21 April 2009 (2009-04-21), pages 1471-1472, XP026048616 ISSN: 0735-1097 [retrieved on 2009-04-14]**
- **MARIAN ET AL: "Surprises of the Genome and "Personalized" Medicine" JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 51, no. 4, 22 January 2008 (2008-01-22), pages 456-458, XP022432407 ISSN: 0735-1097**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 926 491 B1

- JOHN R DOWNS ET AL: "Primary Prevention of Acute Coronary Events With Levels: Results of AFCAPS/TexCAPS Lovastatin in Men and Women With Average Cholesterol", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 279, no. 20, 1 January 1998 (1998-01-01), pages 1615-1622, XP007912269, ISSN: 0098-7484, DOI: DOI:10.1001/JAMA.279.20.1615

Description**CROSS-REFERENCE TO RELATED APPLICATIONS**

5 **[0001]** This application claims the benefit of U.S. provisional application Serial No.: 60/720,274, filed on September 23, 2005,

FIELD OF THE INVENTION

10 **[0002]** The present invention is in the field of cardiovascular disorders and drug response, particularly acute coronary events and statin treatment of acute coronary events. In particular, the present invention relates to specific single nucleotide polymorphisms (SNPs) in the human genome, and their association with acute coronary events and/or variability in responsiveness to statin treatment (including preventive treatment) between different individuals. The naturally occurring SNPs disclosed herein can be used as targets for the design of diagnostic reagents and the development of
 15 therapeutic agents, as well as for disease association and linkage analysis. In particular, the SNPs of the present invention are useful, for example, in identifying whether an individual is likely to experience an acute coronary event (either a first or recurrent acute coronary event), for predicting the seriousness or consequences of an acute coronary event in an individual, for determining the prognosis of an individual's recovery from an acute coronary event, for evaluating the likelihood of an individual's response of to statins for the treatment/prevention of acute coronary events, for providing
 20 clinically important information for the prevention and/or treatment of acute coronary events, and for screening and selecting therapeutic agents. The SNPs disclosed herein are also useful for human identification applications. Methods, assays, kits, and reagents for detecting the presence of these polymorphisms and their encoded products are provided.

BACKGROUND OF THE INVENTION

25

ACUTE CORONARY EVENTS AND RESPONSE TO STATIN TREATMENT

[0003] The present invention relates to SNP that is associated with the occurrence of cardiovascular disorders, particularly acute coronary events such as myocardial infarction.

30 **[0004]** The present invention also relates to SNP that is associated with variability between different individuals in the responses to treatment (including preventive treatments) of cardiovascular disorders with statins (e.g., HMG-CoA reductase inhibitor).

Myocardial Infarction

35

[0005] Myocardial infarction (MI) is the most common cause of mortality in developed countries. It is a multifactorial disease that involves atherogenesis, thrombus formation and propagation. Thrombosis can result in complete or partial occlusion of coronary arteries. The luminal narrowing or blockage of coronary arteries reduces oxygen and nutrient supply to the cardiac muscle (cardiac ischemia), leading to myocardial necrosis and/or stunning. MI, unstable angina,
 40 or sudden ischemic death are clinical manifestations of cardiac muscle damage. All three endpoints are part of the Acute Coronary Syndrome since the underlying mechanisms of acute complications of atherosclerosis are considered to be the same.

[0006] Atherogenesis, the first step of pathogenesis of MI, is a complex interaction between blood elements, mechanical forces, disturbed blood flow; and vessel wall abnormality. On the cellular level, these include endothelial dysfunction, monocytes/macrophages activation by modified lipoproteins, monocytes/macrophages migration into the neointima and subsequent migration and proliferation of vascular smooth muscle cells (VSMC) from the media that results in plaque accumulation.

45

[0007] In recent years, an unstable (vulnerable) plaque was recognized as an underlying cause of arterial thrombotic events and MI. A vulnerable plaque is a plaque, often not stenotic, that has a high likelihood of becoming disrupted or eroded, thus forming a thrombogenic focus. Two vulnerable plaque morphologies have been described. A first type of vulnerable plaque morphology is a rupture of the protective fibrous cap. It can occur in plaques that have distinct morphological features such as large and soft lipid pool with distinct necrotic core and thinning of the fibrous cap in the region of the plaque shoulders. Fibrous caps have considerable metabolic activity. The imbalance between matrix synthesis and matrix degradation thought to be regulated by inflammatory mediators combined with VSMC apoptosis are the key underlying mechanisms of plaque rupture. A second type of vulnerable plaque morphology, known as "plaque erosion", can also lead to a fatal coronary thrombotic event. Plaque erosion is morphologically different from plaque rupture. Eroded plaques do not have fractures in the plaque fibrous cap, only superficial erosion of the intima. The loss of endothelial cells can expose the thrombogenic subendothelial matrix that precipitates thrombus formation. This process

55

could be regulated by inflammatory mediators. The propagation of the acute thrombi for both plaque rupture and plaque erosion events depends on the balance between coagulation and thrombolysis. MI due to a vulnerable plaque is a complex phenomenon that includes: plaque vulnerability, blood vulnerability (hypercoagulation, hypothrombolysis), and heart vulnerability (sensitivity of the heart to ischemia or propensity for arrhythmia).

[0008] Recurrent myocardial infarction (RMI) can generally be viewed as a severe form of MI progression caused by multiple vulnerable plaques that are able to undergo pre-rupture or a pre-erosive state, coupled with extreme blood coagulability.

[0009] The incidence of MI is still high despite currently available preventive measures and therapeutic intervention. More than 1,500,000 people in the US suffer acute MI each year (many without seeking help due to unrecognized MI), and one third of these people die. The lifetime risk of coronary artery disease events at age 40 years is 42.4% for men (one in two) and 24.9% for women (one in four) (Lloyd-Jones DM; Lancet, 1999 353: 89-92).

[0010] The current diagnosis of MI is based on the levels of troponin I or T that indicate the cardiac muscle progressive necrosis, impaired electrocardiogram (ECG), and detection of abnormal ventricular wall motion or angiographic data (the presence of acute thrombi). However, due to the asymptomatic nature of 25% of acute MIs (absence of atypical chest pain, low ECG sensitivity), a significant portion of MIs are not diagnosed and therefore not treated appropriately (e.g., prevention of recurrent MIs).

[0011] Despite a very high prevalence and lifetime risk of MI, there are no good prognostic markers that can identify an individual with a high risk of vulnerable plaques and justify preventive treatments. MI risk assessment and prognosis is currently done using classic risk factors or the recently introduced Framingham Risk Index. Both of these assessments put a significant weight on LDL levels to justify preventive treatment. However, it is well established that half of all MIs occur in individuals without overt hyperlipidemia. Hence, there is a need for additional risk factors for predicting predisposition to MI.

[0012] Other emerging risk factors are inflammatory biomarkers such as C-reactive protein (CRP), ICAM-1, SAA, TNF α , homocysteine, impaired fasting glucose, new lipid markers (ox LDL, Lp-a, MAD-LDL, etc.) and pro-thrombotic factors (fibrinogen, PAI-1). Despite showing some promise, these markers have significant limitations such as low specificity and low positive predictive value, and the need for multiple reference intervals to be used for different groups of people (e.g., males-females, smokers-non smokers, hormone replacement therapy users, different age groups). These limitations diminish the utility of such markers as independent prognostic markers for MI screening.

[0013] Genetics plays an important role in MI risk. Families with a positive family history of MI account for 14% of the general population, 72% of premature MIs, and 48% of all MIs (RR Williams, Am J Cardiology, 2001; 87:129). In addition, replicated linkage studies have revealed evidence of multiple regions of the genome that are associated with MI and relevant to MI genetic traits, including regions on chromosomes 14, 2, 3 and 7 (Broeckel U, Nature Genetics, 2002; 30: 210; Harrap S, Arterioscler Thromb Vasc Biol, 2002; 22: 874-878, Shearman A, Human Molecular Genetics, 2000, 9; 9,1315-1320), implying that genetic risk factors influence the onset, manifestation, and progression of MI. Recent association studies have identified allelic variants that are associated with acute complications of coronary heart disease, including allelic variants of the ApoE, ApoA5, Lpa, APOCIII, and Klotho genes.

[0014] Genetic markers such as single nucleotide polymorphisms are preferable to other types of biomarkers. Genetic markers that are prognostic for MI can be genotyped early in life and could predict individual response to various risk factors. The combination of serum protein levels and genetic predisposition revealed by genetic analysis of susceptibility genes can provide an integrated assessment of the interaction between genotypes and environmental factors, resulting in synergistically increased prognostic value of diagnostic tests.

[0015] Thus, there is an urgent need for novel genetic markers that are predictive of predisposition to MI, particularly for individuals who are unrecognized as having a predisposition to MI. Such genetic markers may enable prognosis of MI in much larger populations compared with the populations that can currently be evaluated by using existing risk factors and biomarkers. The availability of a genetic test may allow, for example, appropriate preventive treatments for acute coronary events to be provided for susceptible individuals (such preventive treatments may include, for example, statin treatments and statin dose escalation, as well as changes to modifiable risk factors), lowering of the thresholds for ECG and angiography testing, and allow adequate monitoring of informative biomarkers.

[0016] Moreover, the discovery of genetic markers associated with MI will provide novel targets for therapeutic intervention or preventive treatments of MI, and enable the development of new therapeutic agents for treating MI and other cardiovascular disorders.

Stroke

[0017] Stroke is a prevalent and serious disease. Stroke is the most common cause of disability, the second leading cause of dementia, and the third leading cause of mortality in the United States. It affects 4.7 million individuals in the United States, with 500,000 first attacks and 200,000 recurrent cases yearly. Approximately one in four men and one in five women aged 45 years will have a stroke if they live to their 85th year. About 25 percent of those who have a

stroke die within a year. For that, stroke is the third leading cause of mortality in the United States and is responsible for 170,000 deaths a year. Among those who survive the stroke attack, 30 to 50 percent do not regain functional independence. Stroke therefore is the most common cause of disability and the second leading cause of dementia.

[0018] Stroke occurs when an artery bringing oxygen or nutrients to the brain either ruptures, causing the hemorrhagic type of strokes, or gets occluded, causing the thrombotic/embolic strokes that are collectively referred to as ischemic strokes. In each case, a cascade of cellular changes due to ischemia or increased cranial pressure leads to injuries or death of the brain cells. In the United States, the majority (about 80-90%) of strokes are ischemic, including 31% large-vessel thrombotic (also referred to as large-vessel occlusive disease), 20% small-vessel thrombotic (also referred to as small-vessel occlusive disease), and 32% embolic or cardiogenic (caused by a clot originating from elsewhere in the body, e.g., from blood pooling due to atrial fibrillation, or from carotid artery stenosis). The ischemic form of stroke shares common pathological etiology with atherosclerosis and thrombosis. Approximately 10-20% of strokes are of the hemorrhagic type, involving bleeding within or around the brain. Bleeding within the brain is known as cerebral hemorrhage, which is often linked to high blood pressure. Bleeding into the meninges surrounding the brain is known as a subarachnoid hemorrhage, which could be caused by a ruptured cerebral aneurysm, an arteriovenous malformation, or a head injury. The hemorrhagic strokes, although less prevalent, pose a greater danger. Whereas about 8 percent of ischemic strokes result in death within 30 days, about 38 percent of hemorrhagic strokes result in death within the same time period.

[0019] Known risk factors for stroke can be divided into modifiable and non-modifiable risk factors. Older age, male sex, black or Hispanic ethnicity, and family history of stroke are non-modifiable risk factors. Modifiable risk factors include hypertension, smoking, increased insulin levels, asymptomatic carotid disease, cardiac vessel disease, and hyperlipidemia. Information derived from the Dutch Twin Registry estimates the heritability of stroke as 0.32 for stroke death and 0.17 for stroke hospitalization.

[0020] The acute nature of stroke leaves physicians with little time to prevent or lessen the devastation of brain damage. Strategies to diminish the impact of stroke include prevention and treatment with thrombolytic and, possibly, neuroprotective agents. The success of preventive measures will depend on the identification of risk factors and means to modulate their impact.

[0021] Although some risk factors for stroke are not modifiable, such as age and family history, other underlying pathology or risk factors of stroke such as atherosclerosis, hypertension, smoking, diabetes, aneurysm, and atrial fibrillation, are chronic and amenable to effective life-style, medical, and surgical treatments. Early recognition of patients with these risk factors, and especially those with a family history, with a non-invasive test of genetic markers will enable physicians to target the highest risk individuals for aggressive risk reduction.

Statin Treatment

[0022] Coronary heart disease (CHD) accounts for approximately two-thirds of cardiovascular mortality in the United States, with CHD accounting for 1 in every 5 deaths in 1998, which makes it the largest single cause of mortality (American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association. 2000). Stroke is the third leading cause of death, accounting for 1 of every 15 deaths. Reduction of coronary and cerebrovascular events and total mortality by treatment with HMG-CoA reductase inhibitors (statins) has been demonstrated in a number of randomized, double blinded, placebo controlled prospective trials (Waters, D.D., What do the statin trials tell us? Clin Cardiol, 2001. 24(8 Suppl): p. III3-7, Singh, B.K. and J.L. Mehta, Management of dyslipidemia in the primary prevention of coronary heart disease. Curr Opin Cardiol, 2002. 17(5): p. 503-11). These drugs have their primary effect through the inhibition of hepatic cholesterol synthesis, thereby upregulating LDL receptor in the liver. The resultant increase in LDL catabolism results in decreased circulating LDL, a major risk factor for cardiovascular disease. In addition, statins cause relatively small reductions in triglyceride levels (5 to 10%) and elevations in HDL cholesterol (5 to 10%). In a 5 year primary intervention trial (WOSCOPS), pravastatin decreased clinical events 29% compared to placebo in hypercholesterolemic subjects, achieving a 26% reduction in LDL-cholesterol (LDL-C) (Shepherd, J., et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995. 333(20): p. 1301-7). In a similar primary prevention trial (AFCAPS/TexCAPS) (Downs, J.R., et al., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Jama, 1998. 279(20): p. 1615-22) in which subjects with average cholesterol levels were treated with lovastatin, LDL-C was reduced an average of 25% and events decreased by 37%. Secondary prevention statin trials include the CARE (Sacks, F.M., et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996. 335(14): p. 1001-9) and LIPID (treatment with pravastatin) (Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998. 339(19): p. 1349-57), and 4S (treatment with simvastatin) (Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994. 344(8934):

p. 1383-9) studies. In these trials, clinical event risk was reduced from between 23% and 34% with achieved LDL-C lowering ranging between 25% and 35%.

[0023] In addition to LDL-lowering, a variety of potential non-lipid lowering effects have been suggested to play a role in cardiovascular risk reduction by statins. These include anti-inflammatory effects on various vascular cell types including foam cell macrophages, improved endothelial responses, inhibition of platelet reactivity thereby decreasing hypercoagulability, and many others (Puddu, P., G.M. Puddu, and A. Muscari, Current thinking in statin therapy. *Acta Cardiol*, 2001. 56(4): p. 225-31, Albert, M.A., et al., Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. *Jama*, 2001. 286(1): p. 64-70, Rosenson, R.S., Non-lipid-lowering effects of statins on atherosclerosis. *Curr Cardiol Rep*, 1999. 1(3): p. 225-32, Dangas, G., et al., pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. *Thromb Haemost*, 2000. 83(5): p. 688-92, Crisby, M., Modulation of the inflammatory process by statins. *Drugs Today (Barc)*, 2003. 39(2): p. 137-43, Liao, J.K., Role of statin pleiotropism in acute coronary syndromes and stroke. *Int J Clin Pract Suppl*, 2003(134): p. 51-7). However, because hypercholesterolemia is a factor in many of these additional pathophysiologic mechanisms that are reversed by statins, many of these statin benefits may be a consequence of LDL lowering.

[0024] Statins as a class of drug are generally well tolerated. The most common side effects include a variety of muscle-related complaints or myopathies. While the incidence of muscle side effects are low, the most serious side effect, myositis with rhabdomyolysis, is life threatening. This adverse effect has been highlighted by the recent withdrawal of cerivastatin when the drug was found to be associated with a relatively high level of rhabdomyolysis-related deaths. In addition, the development of a high dose sustained release formulation of simvastatin was discontinued for rhabdomyolysis-related issues (Davidson, M.H., et al., The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. *Am J Cardiol*, 1997. 79(1): p. 38-42).

[0025] Statins can be divided into two types according to their physicochemical and pharmacokinetic properties. Statins such as lovastatin, simvastatin, atorvastatin, and cerivastatin are hydrophobic in nature and, as such, diffuse across membranes and thus are highly cell permeable. Hydrophilic statins such as pravastatin are more polar, such that they require specific cell surface transporters for cellular uptake (Ziegler, K. and W. Stunkel, Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter. *Biochim Biophys Acta*, 1992. 1139(3): p. 203-9, Yamazaki, M., et al., Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. *Am J Physiol*, 1993. 264(1 Pt 1): p. G36-44, Komai, T., et al., Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. *Biochem Pharmacol*, 1992. 43(4): p. 667-70). The latter statin utilizes a transporter, OATP2, whose tissue distribution is confined to the liver and, therefore, they are relatively hepato-specific inhibitors (Hsiang, B., et al., A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. *J Biol Chem*, 1999. 274(52): p. 37161-8). The former statins, not requiring specific transport mechanisms, are available to all cells and they can directly impact a much broader spectrum of cells and tissues. These differences in properties may influence the spectrum of activities that each statin possesses, pravastatin, for instance, has a low myopathic potential in animal models and myocyte cultures compared to other hydrophobic statins (Masters, B.A., et al., In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. *Toxicol Appl Pharmacol*, 1995. 131(1): p. 163-74, Nakahara, K., et al., Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. *Toxicol Appl Pharmacol*, 1998. 152(1): p. 99-106, Reijneveld, J.C., et al., Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. *Pediatr Res*, 1996. 39(6): p. 1028-35).

[0026] Cardiovascular mortality in developed countries has decreased sharply in recent decades (Tunstall-Pedoe, H., et al., Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. *Lancet*, 2000. 355(9205): p. 688-700). This is likely due to the development and use of efficacious hypertension, thrombolytic and lipid lowering therapies (Kuulasmaa, K., et al., Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. *Lancet*, 2000. 355(9205): p. 675-87). Nevertheless, cardiovascular diseases remain the major cause of death in industrialized countries, at least in part due to the presence of highly prevalent risk factors and insufficient treatment (Wong, M.D., et al., Contribution of major diseases to disparities in mortality. *N Engl J Med*, 2002. 347(20): p. 1585-92). Even with appropriate therapy, not all patients respond equally well to statin treatment. Despite the overwhelming evidence that statins decrease risk for cardiovascular disease, both in primary and secondary intervention settings, statin therapy clearly only achieves partial risk reduction. While a decrease in risk of 23 to 37% seen in the above trials is substantial and extremely important clinically, the majority of events still are not prevented by statin treatment. This is not surprising given the complexity of cardiovascular disease etiology, which is influenced by genetics, environment, and a variety of additional risk factors including dyslipidemia, age, gender, hypertension, diabetes, obesity, and smoking. It is reasonable to assume that all of these multifactorial risks modify statin responses and determine the final benefit that each individual achieves from therapy. Furthermore, with the increasing incidence of Type 2 diabetes

and obesity in Western countries (Flegal, K.M., et al., Prevalence and trends in obesity among US adults, 1999-2000. *Jama*, 2002.288(14): p. 1723-7, Boyle, J.P., et al., Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. *Diabetes Care*, 2001. 24(11): p. 1936-40), which are two major risk factors for coronary artery disease, and the emergence of greater cardiovascular risk factors in the developing world (Yusuf, S., et al., Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. *Circulation*, 2001. 104(23): p. 2855-64, Yusuf, S., et al., Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation*, 2001. 104(22): p. 2746-53), the need for ever more effective treatment of CHD is predicted to steadily increase.

[0027] Thus, there is a growing need for ways to better identify people who have the highest chance to benefit from statins, and those who have the lowest risk of developing side-effects. As indicated above, severe myopathies represent a significant risk for a low percentage of the patient population. This would be particularly true for patients that may be treated more aggressively with statins in the future. There are currently at least three studies in progress that are investigating whether treatments aimed at lowering LDL-C to levels below current NCEP goals by administering higher statin doses to patients further reduces CHD risk or provides additional cardiovascular benefits (reviewed in Clark, L.T., Treating dyslipidemia with statins: the risk-benefit profile. *Am Heart J*, 2003. 145(3): p. 387-96). It is possible that more aggressive statin therapy than is currently standard practice will become the norm in the future if additional benefit is observed in such trials. More aggressive statin therapy will likely increase the incidence of the above adverse events as well as elevate the cost of treatment. Thus, increased emphasis will be placed on stratifying responder and non-responder patients in order for maximum benefit-risk ratios to be achieved at the lowest cost.

[0028] The Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATPIII) contains current recommendations for the management of high serum cholesterol (Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *Jama*, 2001. 285(19): p. 2486-97). A meta-analysis of 38 primary and secondary prevention trials found that for every 10% decrease in serum cholesterol, CHD mortality was reduced by 15%. These guidelines took into account additional risk factors beyond serum cholesterol when making recommendations for lipid lowering strategies. After considering additional risk factors and updated information on lipid lowering clinical trials, more patients are classified in the highest risk category of CHD or CHD risk equivalent than before and are recommended to decrease their LDL to less than 100 mg/dl. As a consequence, more aggressive therapy is recommended and drug therapy is recommended for 36.5 million Americans. In implementing these recommendations, cost-effectiveness of treatments is a primary concern. In lower risk populations, the cost of reducing one event may exceed \$125,000 compared with around \$25,000 per event in a high-risk patient group (Singh, B.K. and J.L. Mehta, Management of dyslipidemia in the primary prevention of coronary heart disease. *Curr Opin Cardiol*, 2002. 17(5): p. 503-11). The cost of preventing an event in a very low risk patient may exceed \$1 million. In the context of cost-containment, further risk stratification of patients will help to avoid unnecessary treatment of patients. In addition to the various clinical endpoints that are currently considered in determining overall risk, the determination of who and who not to treat with statins based on "statin response" genotypes could substantially increase the precision of these determinations in the future.

[0029] Evidence from gene association studies is accumulating to indicate that responses to drugs are, indeed, at least partly under genetic control. As such, pharmacogenetics - the study of variability in drug responses attributed to hereditary factors in different populations - may significantly assist in providing answers toward meeting this challenge (Roses, A.D., Pharmacogenetics and the practice of medicine. *Nature*, 2000. 405(6788): p. 857-65, Mooser, V., et al., Cardiovascular pharmacogenetics in the SNP era. *J Thromb Haemost*, 2003. 1(7): p. 1398-1402, Humma, L.M. and S.G. Terra, Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. *Am. J. Health Syst Pharm*, 2002. 59(13): p. 1241-52). Numerous associations have been reported between selected genotypes, as defined by SNPs and other sequence variations and specific responses to cardiovascular drugs. Polymorphisms in several genes have been suggested to influence responses to statins including CETP (Kuivenhoven, J.A., et al., The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. *N Engl J Med*, 1998.338(2): p. 86-93), beta-fibrinogen (de Maat, M.P., et al., -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern offibrinogen. REGRESS group. *Arterioscler Thromb Vasc Biol*, 1998. 18(2): p. 265-71), hepatic lipase (Zambon, A., et al., Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. *Circulation*, 2001. 103(6): p. 792-8, lipoprotein lipase (Jukema, J.W., et al., The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. *Circulation*, 1996. 94(8): p. 1913-8), glycoprotein IIIa (Bray, P.F., et al., The platelet PI(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. *Am J Cardiol*, 2001. 88(4): p. 347-52), stromelysin-1 (de Maat,

M.P., et al., Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. *Am J Cardiol*, 1999. 83(6): p. 852-6), and apolipoprotein E (Gerdes, L.U., et al., The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. *Circulation*, 2000. 101(12): p. 1366-71, Pedro-Botet, J., et al., Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. *Atherosclerosis*, 2001. 158(1): p. 183-93). Some of these variants were shown to effect clinical events while others were associated with changes in surrogate endpoints. The CETP variant alleles B1 and B2 were shown to be correlated with HDL cholesterol levels. Patients with B1B1 and B1B2 genotypes have lower HDL cholesterol and greater progression of angiographically-determined atherosclerosis than B2B2 subjects when on placebo during the pravastatin REGRESS clinical trial. Furthermore, B1B1 and B1B2 had significantly less progression of atherosclerosis when on pravastatin whereas B2B2 patients derived no benefit. Similarly, beta-fibrinogen promoter sequence variants were also associated with disease progression and response to pravastatin in the same study as were Stromelysin-1 promoter variants. In the Cholesterol and Recurrent Events (CARE) trial, a pravastatin secondary intervention study, glycoprotein IIIa variants were also associated with clinical event response to pravastatin. In all of the above cases, genetic subgroups of placebo-treated patients with CHD were identified who had increased risk for major coronary events. Treatment with pravastatin abolished the harmful effects associated with the "riskier" genotype, while having little effect on patients with genotypes that were associated with less risk. Finally, the impact of the apolipoprotein ε4 genotype on prognosis and the response to simvastatin or placebo was investigated in the Scandinavian Simvastatin Survival Study (Pedro-Botet, J., et al., Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. *Atherosclerosis*, 2001. 158(1): p. 183-93). Patients with at least one apolipoprotein ε4 allele had a higher risk for all cause death than those lacking the allele. As was the case with pravastatin treatment, simvastatin reversed this detrimental effect of the "riskier allele". These results suggest that, in general, high-risk patients with ischemic heart disease derive the greatest benefit from statin therapy. However, these initial observations should be repeated in other cohorts to further support the predictive value of these specific genotypes. Although it is likely that additional genes beyond the five examples above impact the final outcome of an individual's response to statins, these five examples serve to illustrate that it is possible to identify genes that associate with statin clinical responses that could be used to predict which patients will benefit from statin treatment and which will not.

SNPs

[0030] The genomes of all organisms undergo spontaneous mutation in the course of their continuing evolution, generating variant forms of progenitor genetic sequences (Gusella, *Ann. Rev. Biochem.* 55, 831-854 (1986)). A variant form may confer an evolutionary advantage or disadvantage relative to a progenitor form or may be neutral. In some instances, a variant form confers an evolutionary advantage to the species and is eventually incorporated into the DNA of many or most members of the species and effectively becomes the progenitor form. Additionally, the effects of a variant form may be both beneficial and detrimental, depending on the circumstances. For example, a heterozygous sickle cell mutation confers resistance to malaria, but a homozygous sickle cell mutation is usually lethal. In many cases, both progenitor and variant forms survive and co-exist in a species population. The coexistence of multiple forms of a genetic sequence gives rise to genetic polymorphisms, including SNPs.

[0031] Approximately 90% of all polymorphisms in the human genome are SNPs. SNPs are single base positions in DNA at which different alleles, or alternative nucleotides, exist in a population. The SNP position (interchangeably referred to herein as SNP, SNP site, SNP locus, SNP marker, or marker) is usually preceded by and followed by highly conserved sequences of the allele (e.g., sequences that vary in less than 1/100 or 1/1000 members of the populations). An individual may be homozygous or heterozygous for an allele at each SNP position. A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP is an amino acid coding sequence.

[0032] A SNP may arise from a substitution of one nucleotide for another at the polymorphic site. Substitutions can be transitions or transversions. A transition is the replacement of one purine nucleotide by another purine nucleotide, or one pyrimidine by another pyrimidine. A transversion is the replacement of a purine by a pyrimidine, or vice versa. A SNP may also be a single base insertion or deletion variant referred to as an "indel" (Weber et al., "Human diallelic insertion/deletion polymorphisms", *Am J Hum Genet* 2002 Oct;71(4):854-62).

[0033] A synonymous codon change, or silent mutation/SNP (terms such as "SNP," "polymorphism," "mutation," "mutant," "variation" and "variant" are used herein interchangeably), is one that does not result in a change of amino acid due to the degeneracy of the genetic code. A substitution that changes a codon coding for one amino acid to a codon coding for a different amino acid (i.e., a non-synonymous codon change) is referred to as a missense mutation. A nonsense mutation results in a type of non-synonymous codon change in which a stop codon is formed, thereby leading to premature termination of a polypeptide chain and a truncated protein. A read-through mutation is another type of non-synonymous codon change that causes the destruction of a stop codon, thereby resulting in an extended polypeptide product. While SNPs can be bi-, tri-, or tetra- allelic, the vast majority of the SNPs are bi-allelic, and are thus often referred

to as "bi-allelic markers" or "di-allelic markers."

[0034] As used herein, references to SNPs and SNP genotypes include individual SNPs and/or haplotypes, which are groups of SNPs that are generally inherited together. Haplotypes can have stronger correlations with diseases or other phenotypic effects compared with individual SNPs, and therefore may provide increased diagnostic accuracy in some cases (Stephens et al. Science 293, 489-493, 20 July 2001).

[0035] Causative SNPs are those SNPs that produce alterations in gene expression or in the expression, structure, and/or function of a gene product, and therefore are most predictive of a possible clinical phenotype. One such class includes SNPs falling within regions of genes encoding a polypeptide product, i.e. cSNPs. These SNPs may result in an alteration of the amino acid sequence of the polypeptide product (i.e., non-synonymous codon changes) and give rise to the expression of a defective or other variant protein. Furthermore, in the case of nonsense mutations, a SNP may lead to premature termination of a polypeptide product. Such variant products can result in a pathological condition, e.g., genetic disease. Examples of genes in which a SNP within a coding sequence causes a genetic disease include sickle cell anemia and cystic fibrosis.

[0036] Causative SNPs do not necessarily have to occur in coding regions; causative SNPs can occur in, for example, any genetic region that can ultimately affect the expression, structure, and/or activity of the protein encoded by a nucleic acid. Such genetic regions include, for example, those involved in transcription, such as SNPs in transcription factor binding domains, SNPs in promoter regions, in areas involved in transcript processing, such as SNPs at intron-exon boundaries that may cause defective splicing, or SNPs in mRNA processing signal sequences such as polyadenylation signal regions. Some SNPs that are not causative SNPs nevertheless are in close association with, and therefore segregate with, a disease-causing sequence. In this situation, the presence of a SNP correlates with the presence of, or predisposition to, or an increased risk in developing the disease. These SNPs, although not causative, are nonetheless also useful for diagnostics, disease predisposition screening, and other uses.

[0037] An association study of a SNP and a specific disorder involves determining the presence or frequency of the SNP allele in biological samples from individuals with the disorder of interest, such as those individuals who respond to statin treatment ("responders") or those individuals who do not respond to statin treatment ("non-responders"), and comparing the information to that of controls (i.e., individuals who do not have the disorder; controls may be also referred to as "healthy" or "normal" individuals) who are preferably of similar age and race. The appropriate selection of patients and controls is important to the success of SNP association studies. Therefore, a pool of individuals with well-characterized phenotypes is extremely desirable.

[0038] A SNP may be screened in diseased tissue samples or any biological sample obtained from a diseased individual, and compared to control samples, and selected for its increased (or decreased) occurrence in a specific phenotype, such as response or non-response to statin treatment of cardiovascular disease. Once a statistically significant association is established between one or more SNP(s) and a pathological condition (or other phenotype) of interest, then the region around the SNP can optionally be thoroughly screened to identify the causative genetic locus/sequence (s) (e.g., causative SNP/mutation, gene, regulatory region, etc.) that influences the pathological condition or phenotype. Association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families (linkage studies).

[0039] Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. There is a continuing need to improve pharmaceutical agent design and therapy. In that regard, SNPs can be used to identify patients most suited to therapy with particular pharmaceutical agents (this is often termed "pharmacogenomics"). Similarly, SNPs can be used to exclude patients from certain treatment due to the patient's increased likelihood of developing toxic side effects or their likelihood of not responding to the treatment. Pharmacogenomics can also be used in pharmaceutical research to assist the drug development and selection process. (Linder et al. (1997), Clinical Chemistry, 43, 254; Marshall (1997), Nature Biotechnology, 15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer et al. (1998), Nature Biotechnology, 16, 3).

SUMMARY OF THE INVENTION

[0040] The present invention relates to the identification of a SNP that is associated with myocardial infarction and response to HMG-CoA reductase inhibitor treatment (including preventive treatment) for reducing individual's risk of having myocardial infarction.

[0041] The polymorphism disclosed herein is directly useful as target for the design of diagnostic reagents and the development of therapeutic agents for use in the diagnosis and treatment of myocardial infarction.

[0042] Based on the identification of a SNP associated with myocardial infarction and/or response to HMG-CoA reductase inhibitor treatment, the present invention also provides methods of detecting the variant as well as the preparation of detection reagents needed to accomplish this task. The method of the invention specifically comprises detecting a SNP in the nucleotide sequence SEQIDNO:5 involved in myocardial infarction and/or responsiveness to HMG-CoA reductase inhibitor treatment. For reference only, isolated nucleic acid molecules (including, for example, DNA and RNA

molecules) containing the SNP variant protein encoded by nucleic acid molecules containing such SNP, antibodies to the encoded variant protein, computer-based and data storage systems containing the novel SNP information are also described herein. The present invention provides an in vitro method of detecting the SNP in a test sample, and an in vitro method of determining the risk of an individual of developing myocardial infarction.

[0043] For reference only, the description relates to methods for prognosing the severity or consequences of the acute coronary event and methods of treating an individual who has an increased risk of experiencing an acute coronary event. The invention provides an in vitro method of identifying individuals who have an altered (i.e. increased or decreased) likelihood of responding to HMG-CoA reductase inhibitor treatment for reducing the risk of having a myocardial infarction based in the presence or absence of a particular nucleotide (allele) at a SNP site disclosed herein or the detection of an encoded variant product (e.g., variant mRNA transcript or variant protein), an invitro method of identifying individuals who are more or less likely to respond to a treatment, particular HMG-coA reductase inhibitor treatment for reducing the risk of an individual having myocardial infarction (or more or less likely to experience undesirable side effects from a treatment, etc.) For reference only, described herein are also methods of screening for compounds useful in the treatment of a disorder associated with a variant gene/protein, compounds identified by these methods, methods of treating disorders mediated by a variant gene/protein, methods of using the SNP described herein for human identification, etc. The present invention also provides in vitro method for identifying individuals who possess SNP that are associated with an increased risk of developing myocardial infarction (MI), and yet can benefit from being treated with HMG-CoA reductase inhibitor because this treatment can lower their risk of developing MI. For reference only, since cardiovascular disorder/diseases share certain similar features that may be due to common genetic factors that are involved in their underlying mechanisms, the SNP identified herein as being particularly associated with acute coronary events and/or statin response may be used as diagnostic/prognostic markers or therapeutic targets for a broad spectrum of cardiovascular diseases such as coronary heart disease (CHD), atherosclerosis, cerebrovascular disease, congestive heart failure, congenital heart disease, and pathologies and symptoms associated with various heart diseases (e.g., angina, hypertension), as well as for predicting responses to drugs other than statins that are used to treat cardiovascular diseases.

[0044] The present invention is useful for selecting or formulating a treatment regimen (e.g., for determining whether or not to administer HMG-CoA reductase inhibitor treatment to an individual having cardiovascular disease, for selecting a particular HMG-CoA reductase inhibitor based treatment regimen such as dosage and frequency of administration, or a particular form/type of HMG-CoA reductase inhibitor such as a particular pharmaceutical formulation or compound, for administering an alternative, non-statin-based treatment to individuals who are predicted to be unlikely to respond positively to statin treatment, etc.), and for determining the likelihood of experiencing toxicity or other undesirable side effects from statin treatment, etc. The present invention is also useful for selecting individuals to whom a statin or other therapeutic will be administered based on the individual's genotype. Also disclosed are methods for selecting individuals for a clinical trial of a statin or other therapeutic agent based on the genotypes of the individuals (e.g., selecting individuals to participate in the trial who are most likely to respond positively from the statin treatment). The present invention is also useful for reducing the risk of an individual in having MI, using HMG-CoA reductase inhibitor statin treatment, when said individual carries the SNP identified herein as being associated with MI.

[0045] In Tables 1-2, the present specification provides gene information and identification of sequences (i.e., transcript sequence (SEQ ID NO:1), encoded amino acid sequence (SEQ ID NO:2) genomic sequence (SEQ ID NO:4), transcript-based context sequence (SEQ ID NO:3) and genomic-based context sequence (SEQ ID NO: 5) that contain the SNP associated with MI, and extensive SNP information that includes observed allele, allele frequency populations/ethnic groups in which alleles have been observed, information about the type of SNP and corresponding functional effect, and, for cSNPs, information about the encoded polypeptides product. The transcript sequence (SEQ ID NO:1), amino acid sequence (SEQ ID NO:2), genomic sequence (SEQ ID NO:4), transcript-based SNP context sequence (SEQ ID NO:3), and genomic-based SNP context sequence (SEQ ID NO:5) are provided in the Sequence Listing.

[0046] For reference only, SNP that occurs naturally in the human genome is described herein as isolated nucleic acid molecule. The SNP is associated with MI and/or response to HMG-CoA reductase inhibitor treatment, such that they can have a variety of uses in the detection and/or treatment for reducing an individual's risk of having MI and particularly in the treatment of MI with HMG-CoA reductase inhibitor. As used herein a nucleic acid is an amplified polynucleotide, which is produced by amplification of a SNP-containing nucleic acid template. The method of the invention comprises detecting a variant protein which is encoded by a nucleic acid molecule containing a SNP disclosed herein.

[0047] In yet another embodiment of the invention, the use of a reagent for detecting a SNP in the context of its naturally-occurring flanking nucleotide sequences (which can be, e.g., either DNA or mRNA) is provided. In particular, such a reagent may be in the form of, for example, a hybridization probe or an amplification primer that is useful in the specific detection of a SNP of interest. In an alternative embodiment, the use of a protein detection reagent to detect a variant protein that is encoded by a nucleic acid molecule containing a SNP is disclosed herein. A preferred embodiment of a protein detection reagent is an antibody or an antigen-reactive antibody fragment.

[0048] Various embodiments of the invention also provide the use of test kits comprising SNP detection reagents, and methods for detecting the SNP disclosed herein by employing detection reagents. In a specific embodiment, the present

invention provides for a method of identifying an individual having an increased or decreased risk of developing myocardial infarction by detecting the presence or absence of the SNP allele disclosed herein. The present invention also provides methods for evaluating whether an individual is likely (or unlikely) to respond to HMG-CoA reductase inhibitor treatment of myocardial infarction by detecting the presence or absence of the SNP allele disclosed herein.

[0049] For reference only, the nucleic acid molecules described herein can be inserted in an expression vector, such as to produce a variant protein in a host cell. Thus, described herein is a vector comprising a SNP-containing nucleic acid molecule, genetically-engineered host cells containing the vector, and methods for expressing a recombinant variant protein using such host cells. For reference only, described herein are host cells, SNP-containing nucleic acid molecules, and/or variant proteins that can be used as targets in a method for screening and identifying therapeutic agents or pharmaceutical compounds useful in the treatment of cardiovascular diseases. For reference only, described is the use of an effective amount of statins in the preparation of a medicament for treating MI, in a human subject wherein said human subject harbors a SNP, gene, transcript, and/or encoded protein identified in Tables 1-2, wherein said medicament is to administered to said human subject counteracting the effects of the disorder, such as by inhibiting (or stimulating) the activity of the gene, transcript, and/or encoded protein identified in Tables 1-2.

[0050] For reference only, described herein, is a method for identifying an agent useful in therapeutically or prophylactically treating MI in a human subject wherein said human subject harbors a SNP, gene, transcript, and/or encoded protein identified in Tables 1-2, which method comprises contacting the gene, transcript, or encoded protein with a candidate agent (e.g., statin) under conditions suitable to allow formation of a binding complex between the gene, transcript, or encoded protein and the candidate agent (such as a statin) and detecting the formation of the binding complex, wherein the presence of the complex identifies said agent.

[0051] Described herein is an effective amount of HMG-CoA reductase inhibitor for use in the preparation of a medicament for treating a cardiovascular disorder in a human subject so as to reduce a human subject's risk of having a MI, wherein prior to the use of such agents the presence of a SNP, gene, transcript, and/or encoded protein identified in Tables 1-2 in said human subject is determined.

[0052] Many other uses and advantages of the present invention will be apparent to those skilled in the art upon review of the detailed description of the preferred embodiments herein. Solely for clarity of discussion, the invention is described in the sections below by way of non-limiting examples.

DESCRIPTION OF THE SEQUENCE LISTING

[0053]

1) The Sequence Listing provides the transcript sequence (SEQ ID NO:1) and protein sequence (SEQ ID NO:2), and genomic sequence (SEQ ID NO:4) for each gene that contains one or more SNPs described herein. Also provided in the Sequence Listing are context sequences flanking each SNP, including both transcript-based context sequence (SEQ ID NO:3) and genomic-based context sequence (SEQ ID NO:5). The context sequences generally provide 100bp upstream (5') and 100bp downstream (3') of each SNP, with the SNP in the middle of the context sequence, for a total of 200bp of context sequence surrounding each SNP.

DESCRIPTION OF TABLE 1 AND TABLE 2

[0054] Table 1 and Table 2 disclose the SNPs and associated gene/transcript/protein information comprised in the method of the present invention. For gene number 6, Table 1 and Table 2 each provide a header containing gene/transcript/protein information, followed by SNP information regarding the SNP found in that gene/transcript.

[0055] NOTE: The SNP is described in both Table 1 and Table 2, whereby Table 1 presents the SNP relative to its transcript sequence information and encoded protein sequence information and Table 2 presents the SNP relative to their genomic sequence information.

[0056] For references only, the SNP described herein can readily be cross-referenced between Tables based on their hCV (or, in some instances, hDV) identification numbers.

[0057] The gene/transcript/protein information includes:

- a gene number
- a Celera hCG and UID internal identification numbers for the gene
- a Celera hCT and UID internal identification numbers for the transcript (Table 1 only)
- a public Genbank accession number (e.g., RefSeq NM number) for the transcript (Table 1 only)
- a Celera hCP and UID internal identification numbers for the protein encoded by the hCT transcript (Table 1 only)
- a public Genbank accession number (e.g., RefSeq NP number) for the protein (Table 1 only)
- an art-known gene symbol

- an art-known gene/protein name
- Celera genomic axis position (indicating start nucleotide position-stop nucleotide position)
- the number of the chromosome on which the gene is located
- an OMIM (Online Mendelian Inheritance in Man; Johns Hopkins University/NCBI) public reference number for obtaining further information regarding the medical significance of each gene
- alternative gene/protein name(s) and/or symbol(s) in the OMIM entry.

[0058] Following the gene/transcript/protein information is a transcript sequence number and protein sequence number (in Table 1) or a genomic sequence number (in Table 2), for each gene, as follows:

- transcript sequence (Table 1 only) (SEQ ID NO :1)

with SNP identified by their IUB codes (transcript sequences can include 5' UTR, protein coding, and 3' UTR regions)

[0059] NOTE: If there are differences between the nucleotide sequence of the hCT transcript and the corresponding public transcript sequence identified by the Genbank accession number, the hCT transcript sequence (and encoded protein) is provided, unless the public sequence is a RefSeq transcript sequence identified by an NM number, in which case the RefSeq NM transcript sequence (and encoded protein) is provided. However, whether the hCT transcript or RefSeq NM transcript is used as the transcript sequence, the disclosed SNP is represented by their IUB codes within the transcript.

- the encoded protein sequence (Table 1 only; SEQ ID NO :2)
- the genomic sequence of the gene (Table 2 only), including 6kb on each side of the gene boundaries (i.e., 6kb on the 5' side of the gene plus 6kb on the 3' side of the gene; SEQ ID NO : 4)

NOTE: The transcript, protein, and transcript-based SNP context sequences are provided in the Sequence Listing. The genomic and genomic-based SNP context sequences are provided in the Sequence Listing. SEQ ID NOS are indicated in Table 1 for the transcript sequence (SEQ ID NO: 1), protein sequence (SEQ ID NO:2), and transcript-based SNP context sequence (SEQ ID NO:3), and SEQ ID NOS are indicated in Table 2 for each genomic sequence (SEQ ID NO: 4), and genomic-based SNP context sequence (SEQ ID NO:5).

[0060] The SNP information includes:

- context sequence number (taken from the transcript sequence information in Table 1, and the genomic sequence information in Table 2) with the SNP represented by its IUB code, including 100 base pairs upstream (5') of the SNP position plus 100 base pairs downstream (3') of the SNP position (the transcript-based SNP context sequence indicated in Table 1 is provided in the Sequence Listing as SEQ ID NO:3; the genomic-based SNP context sequence indicated in Table 2 is provided in the Sequence Listing as SEQ ID NO:5)
- Celera hCV internal identification number for the SNP (in some instances, an "hDV" number is given instead of an "hCV" number)
- SNP position (position of the SNP within the given transcript sequence [Table 1] or within the given genomic sequence [Table 2])
- SNP source (may include any combination of one or more of the following five codes, depending on which internal sequencing projects and/or public databases the SNP has been observed in: "Applera" = SNP observed during the re-sequencing of genes and regulatory regions of 39 individuals, "Celera" = SNP observed during shotgun sequencing and assembly of the Celera human genome sequence, "Celera Diagnostics" = SNP observed during re-sequencing of nucleic acid samples from individuals who have cardiovascular disorders [e.g., experienced an acute coronary event], and/or have undergone statin treatment, "dbSNP" = SNP observed in the dbSNP public database, "HGBASE" = SNP observed in the HGBASE public database, "HGMD" = SNP observed in the Human Gene Mutation Database [HGMD] public database, "HapMap" = SNP observed in the International HapMap Project public database, "CSNP" = SNP observed in an internal Applied Biosystems [Foster City, CA] database of coding SNPs [cSNPs])
NOTE: Multiple "Applera" source entries for a single SNP indicate that the same SNP was covered by multiple overlapping amplification products and the re-sequencing results (e.g., observed allele counts) from each of these amplification products is being provided.
- population/allele/allele count information in the format of [population1(first_allele,count|second_allele,count)

population2(first_allele,count|second_allele,count) total (first_allele,total count|second_allele,total count))

[0061] NOTE: The information in this field includes populations/ethnic groups in which particular SNP alleles have been observed ("cau" = Caucasian, "his" = Hispanic, "chn" = Chinese, and "afr" = African-American, "jpn" = Japanese, "ind" = Indian, "mex" = Mexican, "ain" = "American Indian, "cra" = Celera donor, "no_pop" = no population information available), identified SNP alleles, and observed allele counts (within each population group and total allele counts), where available ("-" in the allele field represents a deletion allele of an insertion/deletion ["indel"] polymorphism, in which case the corresponding insertion allele, which may be comprised of one or more nucleotides, is indicated in the allele field on the opposite side of the "|"; "-" in the count field indicates that allele count information is not available).

[0062] NOTE: For SNPs of "Applera" SNP source, genes/regulatory regions of 39 individuals (20 Caucasians and 19 African Americans) were re-sequenced and, since each SNP position is represented by two chromosomes in each individual (with the exception of SNPs on X and Y chromosomes in males, for which each SNP position is represented by a single chromosome), up to 78 chromosomes were genotyped for each SNP position. Thus, the sum of the African-American ("afr") allele counts is up to 38, the sum of the Caucasian allele counts ("cau") is up to 40, and the total sum of all allele counts is up to 78.

[0063] NOTE: Semicolons separate population/allele/count information corresponding to each indicated SNP source; i.e., if four SNP sources are indicated, such as "Celera", "dbSNP", "HGBASE", and "HGMD", then population/allele/count information is provided in four groups which are separated by semicolons and listed in the same order as the listing of SNP sources, with each population/allele/count information group corresponding to the respective SNP source based on order; thus, in this example, the first population/allele/count information group would correspond to the first listed SNP source (Celera) and the third population/allele/count information group separated by semicolons would correspond to the third listed SNP source (HGBASE); if population/allele/count information is not available for any particular SNP source, then a pair of semicolons is still inserted as a place-holder in order to maintain correspondence between the list of SNP sources and the corresponding listing of population/allele/count information.

- SNP type (e.g., location within gene/transcript and/or predicted functional effect) ["MISSENSE MUTATION" = SNP causes a change in the encoded amino acid (i.e., a non-synonymous coding SNP); "SILENT MUTATION" = SNP does not cause a change in the encoded amino acid (i.e., a synonymous coding SNP); "STOP CODON MUTATION" = SNP is located in a stop codon; "NONSENSE MUTATION" = SNP creates or destroys a stop codon; "UTR 5" = SNP is located in a 5' UTR of a transcript; "UTR 3" = SNP is located in a 3' UTR of a transcript; "PUTATIVE UTR 5" = SNP is located in a putative 5' UTR; "PUTATIVE UTR 3" = SNP is located in a putative 3' UTR; "DONOR SPLICE SITE" = SNP is located in a donor splice site (5' intron boundary); "ACCEPTOR SPLICE SITE" = SNP is located in an acceptor splice site (3' intron boundary); "CODING REGION" = SNP is located in a protein-coding region of the transcript; "EXON" = SNP is located in an exon; "INTRON" = SNP is located in an intron; "hmCS" = SNP is located in a human-mouse conserved segment; "TFBS" = SNP is located in a transcription factor binding site; "UNKNOWN" = SNP type is not defined; "INTERGENIC" = SNP is intergenic, i.e., outside of any gene boundary]
- protein coding information (Table 1 only) where relevant, in the format of [protein SEQ ID NO:#, amino acid position, (amino acid-1, codon1) (amino acid-2, codon2)]

[0064] NOTE: The information in this field includes the SEQ ID NO of the encoded protein sequence, position of the amino acid residue within the protein identified by the SEQ ID NO that is encoded by the codon containing the SNP, amino acids (represented by one-letter amino acid codes) that are encoded by the alternative SNP alleles (in the case of stop codons, "X" is used for the one-letter amino acid code), and alternative codons containing the alternative SNP nucleotides which encode the amino acid residues (thus, for example, for missense mutation-type SNPs, at least two different amino acids and at least two different codons are generally indicated; for silent mutation-type SNPs, one amino acid and at least two different codons are generally indicated, etc.). In instances where the SNP is located outside of a protein-coding region (e.g., in a UTR region), "None" is indicated following the protein SEQ ID NO.

DESCRIPTION OF TABLES 5-21

[0065] Tables 5-21 provide the allelic frequencies and results of statistical analyses for SNPs disclosed herein and in Tables 1-2 (SNPs can be cross-referenced between tables based on their hCV identification numbers). The results shown in Tables 5-21 provide support for the association of these SNPs with cardiovascular disorders, particularly acute coronary events such as myocardial infarction/ recurrent MI, and/or the association of these SNPs with drug response, such as statins administered as a preventive treatment for acute coronary events. As one example, the statistical results in Tables 5-21 show that the association of these SNPs with risk of MI/RMI and/or response to statin treatment in the prevention of MI is supported by P values < 0.05 in genotypic association tests.

[0066] Tables 5-10, 17 and 18 present statistics from the analysis of the genetic polymorphism hCV3054799 in gene

c6orf102. Table 5 lists the number of case and control samples genotyped in the CARE and WOSCOPS studies, and the number of patients in each treatment arm, placebo and pravastatin. Also shown in this table are the frequencies of the major and minor alleles (i.e., higher and lower frequency alleles, respectively). Table 6 shows the genotypic frequencies for hCV3054799 in the CARE and WOSCOPS studies, while Table 7 lists the number of cases and controls of combined genotypes (major homozygous plus heterozygous, minor homozygous plus heterozygous) that are used in calculating dominant and recessive modes of association with MI risk.

[0067] The association of SNP hCV3054799 with MI risk and response to statin treatment was evaluated using the allelic/genotypic frequencies from the counts obtained in Tables 5-7. Table 8 presents statistical data for the association of hCV3054799 with MI risk, in two replicated studies (in the case of the CARE study patients, recurrent MI specifically). Because this SNP is also associated with a positive response to statin treatment (see Table 10), statistics in Table 8 are presented for patients stratified by treatment group (placebo vs. pravastatin), as well as for all patients unstratified. The risk estimates in Table 8 are not adjusted for conventional MI risk factors such as age, sex, and smoking/non-smoking status.

[0068] Table 9 presents the MI risk estimates for placebo-treated individuals that are heterozygous or homozygous for the rare (minor) allele of SNP hCV3054799. Odds ratios for the minor homozygous patients (Min hom) are derived from a comparison of the risk estimate for minor with major homozygote carriers; odds ratios for the heterozygous (Het) are derived from a comparison of the risk estimate for heterozygote with major homozygote carriers. In the CARE patients, risk estimates are justified by a stepwise logistic regression analysis, which serves to adjust for conventional risk factors such as age, sex, smoking/non-smoking status, and baseline LDL and HDL. In the WOSCOPS patients, logistic regression was done to adjust for baseline LDL and HDL. No adjustment was done for the sex stratum in WOSCOPS because all patients were male; likewise, no adjustment was done for smoking status or age, because cases and controls in WOSCOPS were matched for these parameters. This adjustment confirms the association of hCV3054799 with MI risk, independent of conventional risk factors.

[0069] Table 10 presents the statistical association of hCV3054799 with prevention of MI by statin treatment (i.e., response to pravastatin as an MI-preventive treatment) in two replicated studies. (In the CARE study, association of statins with prevention of recurrent MI is presented.) Also shown are the risk estimates of this SNP for MI/RMI in the placebo-treated patient group (data also shown in Table 8).

[0070] Comparing Tables 8-10 shows that this c6orf102 SNP is associated with MI risk AND response to statin treatment. Individuals in the placebo groups in both the CARE and WOSCOPS studies, who were heterozygous or homozygous for the minor allele, had a significantly higher risk of experiencing an MI than individuals who were homozygous for the major allele. Importantly, these statistics indicate that CARE individuals who were heterozygous or minor-allele homozygous were also significantly protected by pravastatin treatment against an adverse coronary event, relative to those individuals homozygous for the major allele. Tables 17 and 18 provide further analysis showing the association of hCV3054799 with MI risk and its association with prevention of MI by statin treatment.

[0071] Tables 11-13 provide genotypic counts for other significant polymorphisms identified in the CARE study, by treatment arm. Tables 14 and 15 demonstrate the statistical associations of these SNPs with RMI risk, in placebo-treated patients (Table 14) and in all patients, unstratified by treatment arm (Table 15).

[0072] Table 16 shows significant markers from the CARE study and the statistical associations of their genotypes with RMI prevention by means of statin treatment (i.e., response to pravastatin as an MI-preventive treatment). Results are justified as a significant risk difference between placebo- and statin-treated groups, where the Breslow Day P values are < 0.05 for each SNP. Tables 19 and 20 provide additional analysis showing that individuals carrying the markers listed in tables 19 and 20 can have their risk of developing MI/RMI reduced by statin treatment, given that those markers are MI/RMI-associated markers as shown in Table 14. There are six markers in table 20.

[0073] Table 21 provides a list of the sample LD SNPs that are related to and derived from an interrogated SNP. These LD SNPs are provided as an example of the groups of SNPs which can also serve as markers for disease association based on their being in LD with the interrogated SNP. The criteria and process of selecting such LD SNPs, including the calculation of the r^2 value and the r^2 threshold value, are described in Example 3, below.

[0074] In Table 21, the column labeled "Interrogated SNP" presents each marker as identified by its unique identifier, the hCV number. The column labeled "Interrogated SNP rs" presents the publicly known identifier rs number for the corresponding hCV number. The column labeled "LD SNP" presents the hCV numbers of the LD SNPs that are derived from their corresponding interrogated SNPs. The column labeled "LD SNP rs" presents the publicly known rs number for the corresponding hCV number. The column labeled "Power" presents the level of power where the r^2 threshold is set. For example, when power is set at 51%, the threshold r^2 value calculated therefrom is the minimum r^2 that an LD SNP must have in reference to an interrogated SNP, in order for the LD SNP to be classified as a marker capable of

being associated with a disease phenotype at greater than 51 % probability. The column labeled "Threshold r^2 " presents the minimum value of r^2 that an LD SNP must meet in reference to an interrogated SNP in order to qualify as

EP 1 926 491 B1

an LD SNP. The column labeled " r^2 " presents the actual r^2 value of the LD SNP in reference to the interrogated SNP to which it is related.

[0075] NOTE: SNPs can be cross-referenced between Tables 1-21 based on the identification number (hCV number) provided for each SNP.

[0076] Follows are descriptions of the column headings used in the various Tables presented herein.

Tables 5-9	
Column Heading	Definition
Study	CARE = Cholesterol and Recurrent Events. WOSCOPS = West of Scotland Coronary Prevention Study.
Stratum	Subpopulation used for analysis (placebo- or pravastatin-treated, or all patients, unstratified by treatment).
All Count, Case Count, Cont Count	Number of individuals analyzed in each study, separated into Case and Control groups according to MI status, or ALL samples combined.
Allele	Particular SNP variant investigated.
Case Freq, Cont Freq	Total number of chromosomes with each allele in each study, divided by twice the total number of individuals tested (i.e., two alleles per individual) for Cases or Controls.
Major Allele Minor Allele	Major = high frequency allele. Minor = rare (low frequency) allele.
Genot	Diploid genotypes present for this SNP.
Major homozygous Minor homozygous Heterozygous	Carriers of 0 rare alleles. Carriers of 2 rare alleles. Carriers of 1 rare allele.
Maj hom + Het Het + Min hom	All carriers of 0 or 1 rare allele. All carriers of 1 or 2 rare alleles.
Heterozygous Carriers (Het vs. Maj hom) OR	Odds ratio of an MI event for a carrier with 1 rare allele, using carriers with 0 rare alleles as a reference. ("95% CI" is the confidence interval.)
Dominant ([Het + Min hom] vs. Maj hom) OR	Odds ratio of an MI event for a carrier with 1 or 2 rare alleles, using carriers with 0 rare alleles as a reference. ("95% CI" is the confidence interval.)
Recessive (Min hom vs. [Maj hom + Het]) OR	OR of an MI event for a carrier with 2 rare alleles, using carriers with 0 rare alleles as a reference. ("95% CI" is the confidence interval.)
Allelic OR	Odds ratio of an MI event in those patients with genotypes possessing the rare allele vs. patients with no rare allele.

Table 10	
Column Heading	Description
MI/RMI risk estimation (Het vs. Maj hom) OR	Odds ratio of an MI event with a genotype containing one rare allele vs. odds of MI in a genotype with no rare alleles. (Data from placebo-treated patients only.)
Risk Reduction by Statin (Heterozygous carriers) OR	Odds ratio of an MI event in pravastatin-treated vs. placebo-treated patients. (Data from heterozygous carriers only.)

Tables 11-21	
Column Heading	See Descriptions in previous tables and the Examples

DESCRIPTION OF THE FIGURE

[0077]

Figure 1 provides a diagrammatic representation of a computer-based discovery system containing the SNP information of the present invention in computer readable form.

DETAILED DESCRIPTION OF THE INVENTION

[0078] The present invention provides an in vitro method of identifying an individual having an altered risk for developing myocardial infarction (MI), comprising detecting the single nucleotide polymorphism (SNP) in the nucleotide sequence of SEQ ID NO: 5 in said individual's nucleic acids, wherein the individual has an increased risk for developing myocardial infarction due to the presence of G at position 101 of SEQ ID NO: 5 or the presence of C at position 101 of its complement.

[0079] Another aspect of the present invention is an in vitro method of evaluating an individual's likelihood of responding to HMG-CoA reductase inhibitor treatment for reducing the individual's risk of having myocardial infarction, comprising detecting the single nucleotide polymorphism (SNP) in the nucleotide sequence of SEQ ID NO: 5 in said individual's nucleic acids, wherein the individual has a greater likelihood of responding to HMG-CoA reductase inhibitor treatment due to the presence of G at position 101 of SEQ ID NO: 5 or the presence of C at position 101 of its complement.

[0080] The present invention further comprises the use of an amplified polynucleotide containing the single nucleotide polymorphism (SNP) at position 101 of SEQ ID NO: 5, or the complement thereof, in the methods of the present invention, wherein the amplified polynucleotide is between about 16 and about 1,000 nucleotides in length. Furthermore, the present invention comprises the use of an isolated polynucleotide which specifically hybridizes to a nucleic acid molecule containing the single nucleotide polymorphism (SNP) at position 101 of SEQ ID NO: 5, or the complement thereof, in the methods of the present invention. Additionally, the present invention comprises the use of a test kit comprising the polynucleotide as defined herein, a buffer, and an enzyme in the methods of the present invention.

[0081] Another aspect of the present invention is an in vitro method of identifying an individual having an altered risk for developing myocardial infarction (MI), comprising detecting the presence of arginine (R) or tryptophan (W) at position 170 of the amino acid sequence of SEQ ID NO: 2, wherein the individual has an increased risk for developing MI due to the presence of R at position 170 of the amino acid sequence of SEQ ID NO: 2.

[0082] The present invention also provides an in vitro method of evaluating an individual's likelihood of responding to HMG-CoA reductase inhibitor treatment for reducing the individual's risk of having myocardial infarction, comprising detecting the presence of arginine (R) or tryptophan (W) at position 170 of the amino acid sequence of SEQ ID NO: 2, wherein the individual has a greater likelihood of responding to HMG-CoA reductase inhibitor treatment due to the presence of R at position 170 of the amino acid sequence of SEQ ID NO: 2.

[0083] Another aspect of the present invention is the use of a protein detection reagent in the method of the present invention, wherein said protein detection reagent selectively binds to a protein having R at position 170 of the amino acid sequence of SEQ ID NO: 2 as compared to a variant form of said protein having the amino acid sequence of SEQ ID NO: 2 with W at position 170.

[0084] The present invention further provides methods and reagents for the detection of the SNP in the nucleotide sequence SEQ ID NO: 5 in an individual's nucleic acids, uses of the SNP for the development of detection reagents, and assays or kits that utilize such reagents. The HMG-CoA reductase inhibitor response-associated SNP disclosed herein is useful for diagnosing, screening for, and evaluating response to HMG-CoA reductase inhibitor treatment of myocardial infarction in humans. Furthermore, such SNP and its encoded product are useful targets for the development of therapeutic agents. For reference only, a large number of SNPs have been identified from re-sequencing DNA from 39 individuals, and they are indicated as "Aplera" SNP source in Tables 1-2. Their allele frequencies observed in each of the Caucasian and African-American ethnic groups are provided. Additional SNPs included herein were previously identified during shotgun sequencing and assembly of the human genome, and they are indicated as "Celera" SNP source in Tables 1-2. Furthermore, the information provided in Table 1-2, particularly the allele frequency information obtained from 39 individuals and the identification of the precise position of each SNP within each gene/transcript, allows haplotypes (i.e., groups of SNPs that are co-inherited) to be readily inferred.

[0085] Thus, the present invention describes a SNP associated with myocardial infarction and a SNP associated with responsiveness to HMG-CoA reductase inhibitor for the treatment of myocardial infarction. For reference only, described herein is a SNP in genetic regions associated with myocardial infarction and/or HMG-CoA reductase inhibitor response,

polymorphic/variant transcript sequence (SEQ ID NO:1) and genomic sequences (SEQ ID NO :4) containing SNP, encoded amino acid sequence (SEQ ID NO:2), and both transcript-based SNP context sequence (SEQ ID NO:3) and genomic-based SNP context sequence (SEQ ID NO:5) (transcript sequences, protein sequences, and transcript-based SNP context sequences, genomic sequences and genomic-based SNP context sequences are provided in the Sequence Listing).

[0086] The present invention further provides methods of detecting the SNP at position 101 of SEQ ID NO:5 in a test sample, methods of determining the risk of an individual of having or developing a myocardial infarction, methods of determining response to HMG-CoA reductase inhibitor treatment of myocardial infarction, methods of screening of compounds useful for treating myocardial infarction, compounds identified by these screening methods, and methods of using the disclosed SNP to select a treatment strategy.

[0087] Since cardiovascular disorders/diseases share certain similar features that may be due to common genetic factors that are involved in their underlying mechanisms, the SNPs identified herein as being particularly associated with myocardial infarction and/or HMG-CoA reductase inhibitor response may be used as diagnostic/prognostic markers or therapeutic targets for a broad spectrum of cardiovascular diseases such as coronary heart disease (CHD), atherosclerosis, cerebrovascular disease, congestive heart failure, congenital heart disease, and pathologies and symptoms associated with various heart diseases (e.g., angina, hypertension), as well as for predicting responses to drugs other than statins that are used to treat cardiovascular diseases.

[0088] The present invention is useful : for selecting or formulating a treatment regimen (e.g. for determining whether or not to administer HMG-CoA reductase inhibitor treatment to an individual having myocardial infarction, for selecting a particular HMG-CoA reductase inhibitor based treatment regimen such as dosage and frequency of administration of HMG-CoA reductase inhibitor, or a particular form / type of HMG-CoA reductase inhibitor such as a particular pharmaceutical formulation or compound, for administering an alternative, non-statin-based treatment to individuals who are predicted to be unlikely to respond positively to statin treatment, etc.), and for determining the likelihood of experiencing toxicity or other undesirable side effects from HMG-CoA reductase inhibitor treatment etc.. The present invention also is useful for identifying individuals to whom a statin or other therapeutic will be administered based on the individual's genotype. For reference only, the SNP described herein is useful for identifying individuals for a clinical trial of a HMG-CoA reductase inhibitor or other therapeutic agent based on the genotypes of the individuals (e.g., selecting individuals to participate in the trial who are most likely to respond positively from the statin treatment).

[0089] The present invention relates to a SNP associated with myocardial infarction and/or response to HMG-CoA reductase inhibitor treatment. The SNP described herein was previously known in the art, but was not previously known to be associated with myocardial infarction and / or HMG-CoA reductase inhibitor response.

[0090] Accordingly, the present invention provides novel methods of using the known, but previously unassociated, SNP in methods relating to evaluating an individual's likelihood of having or developing a myocardial infarction, predicting the likelihood of an individual experiencing a reoccurrence of a myocardial infarction prognosing the severity of a myocardial infarction in an individual, or prognosing an individual's recovery from a myocardial infarction and methods relating to evaluating an individual's likelihood of responding HMG-CoA reductase inhibitor treatment for myocardial infarction. In Tables 1-2, the SNP is identified based on the public database in which it has been observed, which is indicated as one or more of the following SNP types: "dbSNP" = SNP observed in dbSNP, "HGBASE" = SNP observed in HGBASE, and "HGMD" = SNP observed in the Human Gene Mutation Database (HGMD).

[0091] The SNP allele used in the method of the present invention can be associated with an increased risk of having a myocardial infarction or of responding to HMG-CoA reductase inhibitor treatment of myocardial infarction.

[0092] For reference only, whereas certain SNPs (or their encoded products) can be assayed to determine whether an individual possesses a SNP allele that is indicative of an increased likelihood of experiencing a coronary event or of responding to statin treatment, other SNPs (or their encoded products) can be assayed to determine whether an individual possesses a SNP allele that is indicative of a decreased likelihood of experiencing a coronary event or of responding to statin treatment. Similarly, particular SNP alleles can be associated with either an increased or decreased likelihood of having a reoccurrence of a cardiovascular disorder, of fully recovering from a cardiovascular disorder, of experiencing toxic effects from a particular treatment or therapeutic compound, etc. The term "altered" may be used herein to encompass either of these two possibilities (e.g., an increased or a decreased risk/likelihood). SNP alleles that are associated with a decreased risk of having or developing a cardiovascular disorder such as myocardial infarction may be referred to as "protective" alleles, and SNP alleles that are associated with an increased risk of having or developing a cardiovascular disorder may be referred to as "susceptibility" alleles, "risk" alleles, or "risk factors".

[0093] Those skilled in the art will readily recognize that nucleic acid molecules may be double-stranded molecules and that reference to a particular site on one strand refers, as well, to the corresponding site on a complementary strand. In defining a SNP position, SNP allele, or nucleotide sequence, reference to an adenine, a thymine (uridine), a cytosine, or a guanine at a particular site on one strand of a nucleic acid molecule also defines the thymine (uridine), adenine, guanine, or cytosine (respectively) at the corresponding site on a complementary strand of the nucleic acid molecule. Thus, reference may be made to either strand in order to refer to a particular SNP position, SNP allele, or nucleotide

sequence. Probes and primers, may be designed to hybridize to either strand and SNP genotyping methods disclosed herein may generally target either strand. Throughout the specification, in identifying a SNP position, reference is generally made to the protein-encoding strand, only for the purpose of convenience.

[0094] References to variant peptides, polypeptides, or proteins for use in the method of the present invention include peptides, polypeptides, proteins, or fragments thereof, that contain at least one amino acid residue that differs from the corresponding amino acid sequence of the art-known peptide/polypeptide/protein (the art-known protein may be interchangeably referred to as the "wild-type", "reference", or "normal" protein). Such variant peptides/polypeptides/proteins can result from a codon change caused by a nonsynonymous nucleotide substitution at a protein-coding SNP position (i.e., a missense mutation) described herein. Variant peptides/polypeptides/proteins described herein can also result from a nonsense mutation, i.e. a SNP that creates a premature stop codon, a SNP that generates a read-through mutation by abolishing a stop codon, or due to any SNP that otherwise alters the structure, function/activity, or expression of a protein, such as a SNP in a regulatory region (e.g. a promoter or enhancer) or a SNP that leads to alternative or defective splicing, such as a SNP in an intron or a SNP at an exon/intron boundary. As used herein, the terms "polypeptide", "peptide", and "protein" are used interchangeably.

ISOLATED NUCLEIC ACID MOLECULES AND SNP DETECTION REAGENTS & KITS

[0095] Tables 1 and 2 provide a variety of information about the SNP useful in the method of the present invention that is associated with myocardial infarction and/or responsiveness to HMG-CoA reductase inhibitor treatment, including indication of the transcript sequence number (SEQ ID NO:1), genomic sequence (SEQ ID NO:4), and protein sequence (SEQ ID NO:2) of the encoded gene product (with the SNP indicated by IUB codes in the nucleic acid sequences). In addition, Tables 1 and 2 include SNP context sequences, which generally include 100 nucleotide upstream (5') plus 100 nucleotides downstream (3') of the respective SNP position (SEQ ID NO:3 correspond to the transcript-based SNP context sequence indicated in Table 1, and SEQ ID NO:5 correspond to the genomic-based context sequence indicated in Table 2), the alternative nucleotides (allele;) at the SNP position, and additional information about the variant where relevant, such as SNP type (coding, missense, splice site, UTR, etc.), human populations in which the SNP was observed, observed allele frequencies, information about the encoded protein, etc.

ISOLATED NUCLEIC ACID MOLECULES

[0096] Described herein is an isolated nucleic acid molecule that contains the SNP disclosed Table 1 and/or Table 2.

[0097] Isolated nucleic acid molecules containing the SNPs disclosed in Tables 1-2 may be interchangeably referred to throughout the present text as "SNP-containing nucleic acid molecule". Isolated nucleic acid molecules may optionally encode a full-length variant protein or fragment thereof. The isolated nucleic acid molecules described herein also include probes and primers (which are described in greater detail below in the section entitled "SNP Detection Reagents"), which may be used for assaying the disclosed SNPs, and isolated full-length genes, transcripts, cDNA molecules, and fragments thereof, which may be used for such purposes as expressing an encoded protein.

[0098] As used herein, an "isolated nucleic acid molecule" generally is one that contains a SNP described herein or one that hybridizes to such molecule such as a nucleic acid with a complementary sequence, and is separated from most other nucleic acids present in the natural source of the nucleic acid molecule. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule containing a SNP described herein, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. A nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered "isolated." Nucleic acid molecules present in non-human transgenic animals, which do not naturally occur in the animal, are also considered "isolated". For example, recombinant DNA molecules contained in a vector are considered "isolated". Further examples of "isolated" DNA molecules include recombinant DNA molecules maintained in heterologous host cells, and purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the isolated SNP-containing DNA molecules described herein. Isolated nucleic acid molecules described herein further include such molecules produced synthetically.

[0099] For reference only, an isolated SNP-containing nucleic acid molecule comprises one or more SNP positions with flanking nucleotide sequences on either side of the SNP positions. A flanking sequence can include nucleotide residues that are naturally associated with the SNP site and/or heterologous nucleotide sequences. Preferably the flanking sequence is up to about 500, 300, 100, 60, 50, 30, 25, 20, 15, 10, 8, or 4 nucleotides (or any other length in-between) on either side of a SNP position, or as long as the full-length gene or entire protein-coding sequence (or any portion thereof such as an exon), especially if the SNP-containing nucleic acid molecule is to be used to produce a protein or protein fragment.

[0100] For full-length genes and entire protein-coding sequences, a SNP flanking sequence can be, for example, up to about 5KB, 4KB, 3KB, 2KB, 1KB on either side of the SNP. Furthermore, in such instances, the isolated nucleic acid

molecule comprises exonic sequences (including protein-coding and/or non-coding exonic sequences), but may also include intronic sequences. Thus, any protein coding sequence may be either contiguous or separated by introns. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences and is of appropriate length such that it can be subjected to the specific manipulations or uses described herein such as recombinant protein expression, preparation of probes and primers for assaying the SNP position, and other uses specific to the SNP-containing nucleic acid sequences. For reference only, an isolated SNP-containing nucleic acid molecule can comprise, for example, a full-length gene or transcript, such as a gene isolated from genomic DNA (e.g., by cloning or PCR amplification), a cDNA molecule, or an mRNA transcript molecule. Polymorphic transcript sequence (SEQ ID NO:1), and polymorphic genomic sequence SEQ ID NO:4 are provided in the Sequence Listing. Furthermore, fragments of such full-length genes and transcripts that contain the SNP disclosed herein may be used, for example, to express any part of a protein, such as a particular functional domain or an antigenic epitope.

[0101] Also encompassed are fragments of the nucleic acid sequences provided in Tables 1-2 (transcript sequences indicated in Table 1 as SEQ ID NO 1, genomic sequence indicated in Table 2 as SEQ NO:4, transcript-based SNP context sequence indicated in Table 1 as SEQ ID NO: 3, and genomic-based SNP context sequence: indicated in Table 2 as SEQ ID NO:5) and their complements. A fragment typically comprises a contiguous nucleotide sequence at least about 8 or more nucleotides, more preferably at least about 12 or more nucleotides, and even more preferably at least about 16 or more nucleotides. Further, a fragment could comprise at least about 18, 20, 22, 25, 30, 40, 50, 60, 80, 100, 150, 200, 250 or 500 (or any other number in-between) nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope-bearing regions of a variant peptide or regions of a variant peptide that differ from the normal/wild-type protein, or can be useful as a polynucleotide probe or primer. Such fragments can be isolated using the nucleotide sequences provided in the Sequence Listing for the synthesis of a polynucleotide probe. A labeled probe can then be used, for example, to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in amplification reactions, such as for purposes of assaying one or more SNPs sites or for cloning specific regions of a gene.

[0102] An isolated nucleic acid molecule further encompasses a SNP-containing polynucleotide that is the product of any one of a variety of nucleic acid amplification methods, which are used to increase the copy numbers of a polynucleotide of interest in a nucleic acid sample. Such amplification methods are well known in the art, and they include but are not limited to, polymerase chain reaction (PCR) (U.S. Patent Nos. 4,683,195; and 4,683,202; *PCR, Technology: Principles and Applications for DNA Amplification*, ed. H.A. Erlich, Freeman Press, NY, NY, 1992), ligase chain reaction (LCR) (Wu and Wallace, *Genomics* 4:560, 1989; Landegren *et al.*, *Science* 241:1077, 1988), strand displacement amplification (SDA) (U.S. Patent Nos. 5,270,184; and 5,422,252), transcription-mediated amplification (TMA) (U.S. Patent No. 5,399,491), linked linear amplification (LLA) (U.S. Patent No. 6,027,923), and the like, and isothermal amplification methods such as nucleic acid sequence based amplification (NASBA), and self-sustained sequence replication (Guatelli *et al.*, *Proc. Natl. Acad. Sci. USA* 87: 1874, 1990). Based on such methodologies, a person skilled in the art can readily design primers in any suitable regions 5' and 3' to a SNP disclosed herein. Such primers may be used to amplify DNA of any length so long that it contains the SNP of interest in its sequence.

[0103] As used herein, an "amplified polynucleotide" is a SNP-containing nucleic acid molecule whose amount has been increased at least two fold by any nucleic acid amplification method performed *in vitro* as compared to its starting amount in a test sample. In other preferred embodiments, an amplified polynucleotide is the result of at least ten fold, fifty fold, one hundred fold, one thousand fold, or even ten thousand fold increase as compared to its starting amount in a test sample. In a typical PCR amplification, a polynucleotide of interest is often amplified at least fifty thousand fold in amount over the unamplified genomic DNA, but the precise amount of amplification needed for an assay depends on the sensitivity of the subsequent detection method used.

[0104] Generally, an amplified polynucleotide is at least about 16 nucleotides in length. More typically, an amplified polynucleotide is at least about 20 nucleotides in length. In a preferred embodiment of the invention, an amplified polynucleotide is at least about 30 nucleotides in length. In a more preferred embodiment of the invention, an amplified polynucleotide is at least about 32, 40, 45, 50, or 60 nucleotides in length. In yet another preferred embodiment of the invention, an amplified polynucleotide is at least about 100, 200, 300, 400, or 500 nucleotides in length. While the total length of an amplified polynucleotide of the invention can be as long as an exon, an intron or the entire gene where the SNP of interest resides, an amplified product is typically up to about 1,000 nucleotides in length (although certain amplification methods may generate amplified products greater than 1000 nucleotides in length). More preferably, an amplified polynucleotide is not greater than about 600-700 nucleotides in length. It is understood that irrespective of the length of an amplified polynucleotide, a SNP of interest may be located anywhere along its sequence.

[0105] In a specific embodiment of the invention, the amplified product is at least about 201 nucleotides in length, comprises the transcript-based context sequences or the genomic-based context sequence indicated in Tables 1-2. Such a product may have additional sequences on its 5' end or 3' end or both. In another embodiment, the amplified product is about 101 nucleotides in length, and it contains a SNP disclosed herein. Preferably, the SNP is located at the middle of the amplified product (e.g., at position 101 in an amplified product that is 201 nucleotides in length, or at position

51 in an amplified product that is 101 nucleotides in length), or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, or 20 nucleotides from the middle of the amplified product (however, as indicated above, the SNP of interest may be located anywhere along the length of the amplified product).

[0106] The present invention provides the use of isolated nucleic acid molecules that comprises, consists of, or consists essentially of a polynucleotide sequence that contains the SNP disclosed herein

[0107] Accordingly, the present invention provides nucleic acid molecules that consist of a nucleotide sequence indicated in Table 1 and/or Table 2 (transcript sequences SEQ ID NO:1, genomic sequence SEQ ID NO:4, transcript-based SNP context sequence SEQ NO:3 and genomic-based SNP context sequence SEQ ID NO:5), or a nucleic acid molecule that encodes the variant protein provided in Table 1 (SEQ ID NO:2). A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

[0108] Also, described herein are nucleic acid molecules that consist essentially of any of the nucleotide sequences indicated in Table 1 and/or Table 2 (transcript sequence SEQ ID NO:1 genomic sequence SEQ ID NO:4, transcript-based SNP context sequence SEQ ID NO:3, and genomic-based SNP context sequence SEQ ID NO:5), or a nucleic acid molecule that encodes the variant protein provided in Table 1 (SEQ ID NO:2). A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleotide residues in the final nucleic acid molecule.

[0109] Also, described herein are nucleic acid molecules that comprise any of the nucleotide sequences indicated in Table 1 and/or Table 2 or a SNP-containing fragment thereof (transcript sequence SEQ ID NO:1 genomic sequence SEQ ID NO:4, transcript-based SNP context sequence SEQ ID NO:3, and genomic-based SNP context sequence SEQ ID NO:5, or a nucleic acid molecule that encodes the variant protein indicated in Table 1 (SEQ ID NO:2). A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleotide residues, such as residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have one to a few additional nucleotides or can comprise many more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made and isolated is provided below, and such techniques are well known to those of ordinary skill in the art (Sambrook and Russell, 2000; Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, NY).

[0110] The isolated nucleic acid molecules can encode mature proteins plus additional amino or carboxyl-terminal amino acids or both, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life, or facilitate manipulation of a protein for assay or production. As generally is the case *in situ*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

[0111] Thus, the isolated nucleic acid molecules include, but are not limited to, nucleic acid molecules having a sequence encoding a peptide alone, a sequence encoding a mature peptide and additional coding sequences such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), a sequence encoding a mature peptide with or without additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5' and 3' sequences such as transcribed but untranslated sequences that play a role in, for example, transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding, and/or stability of mRNA. In addition, the nucleic acid molecules may be fused to heterologous marker sequences encoding, for example, a peptide that facilitates purification.

[0112] Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA, which may be obtained, for example, by molecular cloning or produced by chemical synthetic techniques or by a combination thereof (Sambrook and Russell, 2000, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, NY). Furthermore, isolated nucleic acid molecules, particularly SNP detection reagents such as probes and primers, can also be partially or completely in the form of one or more types of nucleic acid analogs, such as peptide nucleic acid (PNA) (U.S. Patent Nos. 5,539,082; 5,527,675; 5,623,049; 5,714,331). The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the complementary non-coding strand (antisense strand). DNA, RNA, or PNA segments can be assembled, for example, from fragments of the human genome (in the case of DNA or RNA) or single nucleotides, short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic nucleic acid molecule. Nucleic acid molecules can be readily synthesized using the sequences provided herein as a reference; oligonucleotide and PNA oligomer synthesis techniques are well known in the art (see, e.g., Corey, "Peptide nucleic acids: expanding the scope of nucleic acid recognition", Trends Biotechnol. 1997 Jun;15(6):224-9, and Hyrup et al., "Peptide nucleic acids (PNA): synthesis, properties and potential applications", Bioorg Med Chem. 1996 Jan;4(1):5-23). Furthermore, large-scale automated oligonucleotide/PNA synthesis (including synthesis on an array or bead surface or other solid support) can readily be accomplished using commercially available nucleic acid synthesizers, such as the Applied Biosystems (Foster City, CA) 3900 High-Throughput DNA Synthesizer or Expedite 8909 Nucleic Acid Synthesis System, and the sequence information provided

herein.

[0113] The present invention encompasses the use of nucleic acid analogs that contain modified, synthetic, or non-naturally occurring nucleotides or structural elements or other alternative/modified nucleic acid chemistries known in the art. Such nucleic acid analogs are useful, for example, as detection reagents (e.g., primers/probes) for detecting the SNP identified in Table 1 and/or Table 2. Furthermore, kits/systems (such as beads, arrays, etc.) that include these analogs are also described herein. For example, PNA oligomers that are based on the polymorphic sequences of the present invention are specifically contemplated. PNA oligomers are analogs of DNA in which the phosphate backbone is replaced with a peptide-like backbone (Lagriffoul et al., *Bioorganic & Medicinal Chemistry Letters*, 4: 1081-1082 (1994), Petersen et al., *Bioorganic & Medicinal Chemistry Letters*, 6: 793-796 (1996), Kumar et al., *Organic Letters* 3(9): 1269-1272 (2001), WO96/04000). PNA hybridizes to complementary RNA or DNA with higher affinity and specificity than conventional oligonucleotides and oligonucleotide analogs. The properties of PNA enable novel molecular biology and biochemistry applications unachievable with traditional oligonucleotides and peptides.

[0114] Additional examples of nucleic acid modifications that improve the binding properties and/or stability of a nucleic acid include the use of base analogs such as inosine, intercalators (U.S. Patent No. 4,835,263) and the minor groove binders (U.S. Patent No. 5,801,115). Thus, references herein to nucleic acid molecules, SNP-containing nucleic acid molecules, SNP detection reagents (e.g., probes and primers), oligonucleotides/polynucleotides include PNA oligomers and other nucleic acid analogs. Other examples of nucleic acid analogs and alternative/modified nucleic acid chemistries known in the art are described in *Current Protocols in Nucleic Acid Chemistry*, John Wiley & Sons, N.Y. (2002).

[0115] Also provided is the use of nucleic acid molecules that encode fragments of the variant polypeptides disclosed herein as well as nucleic acid molecules that encode obvious variants of such variant polypeptides. Such nucleic acid molecules may be naturally occurring, such as paralogs (different locus) and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, the variants can contain nucleotide substitutions, deletions, inversions and insertions (in addition to the SNP disclosed in Tables 1-2). Variation can occur in either or both the coding and non-coding regions. The variation can produce conservative and/or non-conservative amino acid substitutions.

[0116] Further variants of the nucleic acid molecules disclosed in Tables 1-2, such as naturally occurring allelic variants (as well as orthologs and paralogs) and synthetic variants produced by mutagenesis techniques, can be identified and/or produced using methods well known in the art. Such further variants can comprise a nucleotide sequence that shares at least 70-80%, 80-85%, 85-90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with a nucleic acid sequence disclosed in Table 1 and/or Table 2 (or a fragment thereof) and that includes the SNP allele disclosed in Table 1 and/or Table 2. Further, variants can comprise a nucleotide sequence that encodes a polypeptide that shares at least 70-80%, 80-85%, 85-90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with a polypeptide sequence disclosed in Table 1 (or a fragment thereof) and that includes the SNP allele disclosed in Table 1 and/or Table 2.

[0117] The use of isolated nucleic acid molecules that have a certain degree of sequence variation compared with the sequences shown in Tables 1-2, but that contain the SNP allele disclosed herein is also contemplated. In other words, as long as an isolated nucleic acid molecule contains the SNP allele disclosed herein, other portions of the nucleic acid molecule that flank the SNP allele can vary to some degree from the specific transcript, genomic, and context sequences indicated in Tables 1-2, and can encode a polypeptide that varies to some degree from the specific polypeptide sequences shown in Table 1.

[0118] To determine the percent identity of two amino acid sequences or two nucleotide sequences of two molecules that share sequence homology, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein, amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

[0119] The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part 1*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity

between two amino acid sequences is determined using the Needleman and Wunsch algorithm (J. Mol. Biol. (48):444-453 (1970)) which has been incorporated into the GAP program in the GCG software package, using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

[0120] In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., et al., Nucleic Acids Res. 12(1):387 (1984)), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.

[0121] The nucleotide and amino acid sequences described herein can further be used as a "query sequence" to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (J. Mol. Biol. 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (Nucleic Acids Res. 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. In addition to BLAST, examples of other search and sequence comparison programs used in the art include, but are not limited to, FASTA (Pearson, Methods Mol. Biol. 25, 365-389 (1994)) and KERR (Dufresne et al., Nat Biotechnol 2002 Dec;20(12):1269-71). For further information regarding bioinformatics techniques, see Current Protocols in Bioinformatics, John Wiley & Sons, Inc., N.Y.

[0122] Also, described herein are non-coding fragments of the nucleic acid molecules disclosed in Table 1 and/or Table 2. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, intronic sequences, 5' untranslated regions (UTRs), 3' untranslated regions, gene modulating sequences and gene termination sequences. Such fragments are useful, for example, in controlling heterologous gene expression and in developing screens to identify gene-modulating agents.

SNP DETECTION REAGENTS

[0123] The SNP used in the method of the present invention, disclosed in Table 1 and/or Table 2, and its associated transcript sequence (provided in the Sequence Listing as SEQ ID NO:1 genomic sequence provided in the Sequence Listing as SEQ ID NO:4), and context sequence (transcript-based context sequence; SEQ ID NO:3; genomic-based context sequence SEQ ID NO:5), can be used for the design of SNP detection reagents. As used herein, a "SNP detection reagent" is a reagent that specifically detects a specific target SNP position disclosed herein, and that is preferably specific for a particular nucleotide (allele) of the target SNP position (i.e., the detection reagent preferably can differentiate between different alternative nucleotides at a target SNP position, thereby allowing the identity of the nucleotide present at the target SNP position to be determined). Typically, such detection reagent hybridizes to a target SNP-containing nucleic acid molecule by complementary base-pairing in a sequence specific manner, and discriminates the target variant sequence from other nucleic acid sequences such as an art-known form in a test sample. An example of a detection reagent is a probe that hybridizes to a target nucleic acid containing the SNP provided in Table 1 and/or Table 2. In a preferred embodiment, such a probe can differentiate between nucleic acids having a particular nucleotide (allele) at a target SNP position from other nucleic acids that have a different nucleotide at the same target SNP position. In addition, a detection reagent may hybridize to a specific region 5' and/or 3' to a SNP position, particularly a region corresponding to the context sequences provided in Table 1 and/or Table 2 (transcript-based context sequence is provided in the Sequence Listing as SEQ ID NO:3; genomic-based context sequence is provided in the Sequence Listing as SEQ ID NO: 5). Another example of a detection reagent is a primer which acts as an initiation point of nucleotide extension along a complementary strand of a target polynucleotide. The SNP sequence information provided herein is also useful for designing primers, e.g. allele-specific primers, to amplify (e.g., using PCR) the SNP used in the method of the present invention.

[0124] In one preferred embodiment, a SNP detection reagent for the use of the present invention is an isolated or synthetic DNA or RNA polynucleotide probe or primer that hybridizes to a segment of a target nucleic acid molecule containing a SNP identified in Table 1 and/or Table 2. A detection reagent in the form of a polynucleotide may optionally contain modified base analogs, intercalators or minor groove binders. Multiple detection reagents such as probes may be, for example, affixed to a solid support (e.g., arrays or beads) or supplied in solution (e.g., probe/primer sets for enzymatic reactions such as PCR, RT-PCR, TaqMan assays, or primer-extension reactions) to form a SNP detection kit.

[0125] A probe or primer typically is a substantially purified oligonucleotide or PNA oligomer. Such oligonucleotide typically comprises a region of complementary nucleotide sequence that hybridizes under stringent conditions to at least

about 8, 10, 12, 16, 18, 20, 22, 25, 30, 40, 50, 55, 60, 65, 70, 80, 90, 100, 120 (or any other number in-between) or more consecutive nucleotides in a target nucleic acid molecule. Depending on the particular assay, the consecutive nucleotides can either include the target SNP position, or be a specific region in close enough proximity 5' and/or 3' to the SNP position to carry out the desired assay.

[0126] Other preferred primer and probe sequences can readily be determined using the transcript sequence (SEQ ID NO:1), genomic sequence (SEQ ID NO:4), and SNP context sequence (transcript-based context sequence SEQ ID NO:3; genomic-based context sequence SEQ ID NO:5) disclosed in the Sequence Listing. It will be apparent to one of skill in the art that such primers and probes are directly useful as reagents for genotyping the SNP used in the method of the present invention, and can be incorporated into any kit/system format.

[0127] In order to produce a probe or primer specific for a target SNP-containing sequence, the gene/transcript and/or context sequence surrounding the SNP of interest is typically examined using a computer algorithm which starts at the 5' or at the 3' end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene/SNP context sequence, have a GC content within a range suitable for hybridization, lack predicted secondary structure that may interfere with hybridization, and/or possess other desired characteristics or that lack other undesired characteristics. A primer or probe for use in the method of the present invention is typically at least about 8 nucleotides in length.

[0128] In one embodiment of the method of the invention, the used primer or a probe is at least about 10 nucleotides in length. In a preferred embodiment, the used primer or a probe is at least about 12 nucleotides in length. In a more preferred embodiment, the used primer or probe is at least about 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length. While the maximal length of a probe can be as long as the target sequence to be detected, depending on the type of assay in which it is employed, it is typically less than about 50, 60, 65, or 70 nucleotides in length. In the case of a primer, it is typically less than about 30 nucleotides in length. In a specific preferred embodiment of the method of the invention, a primer or a probe is within the length of about 18 and about 28 nucleotides. However, in other embodiments, such as nucleic acid arrays and other embodiments in which probes are affixed to a substrate, the probes can be longer, such as on the order of 30-70, 75, 80, 90, 100, or more nucleotides in length (see the section below entitled "SNP Detection Kits and Systems").

[0129] For analyzing SNPs, it may be appropriate to use oligonucleotides specific for alternative SNP alleles. Such oligonucleotides which detect single nucleotide variations in target sequences may be referred to by such terms as "allele-specific oligonucleotides," "allele-specific probes," or "allele-specific primers." The design and use of allele-specific probes for analyzing polymorphisms is described in, e.g., Mutation Detection A Practical Approach, ed. Cotton et al. Oxford University Press, 1998; Saiki et al., Nature 324, 163-166 (1986); Dattagupta, EP235,726; and Saiki, WO 89/11548.

[0130] While the design of each allele-specific primer or probe depends on variables such as the precise composition of the nucleotide sequences flanking a SNP position in a target nucleic acid molecule, and the length of the primer or probe, another factor in the use of primers and probes is the stringency of the condition under which the hybridization between the probe or primer and the target sequence is performed. Higher stringency conditions utilize buffers with lower ionic strength and/or a higher reaction temperature, and tend to require a more perfect match between probe/primer and a target sequence in order to form a stable duplex. If the stringency is too high, however, hybridization may not occur at all. In contrast, lower stringency conditions utilize buffers with higher ionic strength and/or a lower reaction temperature, and permit the formation of stable duplexes with more mismatched bases between a probe/primer and a target sequence. By way of example and not limitation, exemplary conditions for high stringency hybridization conditions using an allele-specific probe are as follows: Prehybridization with a solution containing 5X standard saline phosphate EDTA (SSPE), 0.5% NaDodSO₄ (SDS) at 55°C, and incubating probe with target nucleic acid molecules in the same solution at the same temperature, followed by washing with a solution containing 2X SSPE, and 0.1% SDS at 55°C or room temperature.

[0131] Moderate stringency hybridization conditions may be used for allele-specific primer extension reactions with a solution containing, e.g., about 50mM KCl at about 46°C. Alternatively, the reaction may be carried out at an elevated temperature such as 60°C. In another embodiment, a moderately stringent hybridization condition suitable for oligonucleotide ligation assay (OLA) reactions wherein two probes are ligated if they are completely complementary to the target sequence may utilize a solution of about 100mM KCl at a temperature of 46°C.

[0132] In a hybridization-based assay, allele-specific probes can be designed that hybridize to a segment of target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms (e.g., alternative SNP alleles/nucleotides) in the respective DNA segments from the two individuals. Hybridization conditions should be sufficiently stringent that there is a significant detectable difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles or significantly more strongly to one allele. While a probe may be designed to hybridize to a target sequence that contains a SNP site such that the SNP site aligns anywhere along the sequence of the probe, the probe is preferably designed to hybridize to a segment of the target sequence such that the SNP site aligns with a central position of the probe (e.g., a position within the probe that is at least three nucleotides from either end of the probe).

This design of probe generally achieves good discrimination in hybridization between different allelic forms.

[0133] In another embodiment, a probe or primer may be designed to hybridize to a segment of target DNA such that the SNP aligns with either the 5' most end or the 3' most end of the probe or primer. In a specific preferred embodiment that is particularly suitable for use in an oligonucleotide ligation assay (U.S. Patent No. 4,988,617), the 3'most nucleotide of the probe aligns with the SNP position in the target sequence.

[0134] Oligonucleotide probes and primers may be prepared by methods well known in the art. Chemical synthetic methods include, but are limited to, the phosphotriester method described by Narang et al., 1979, Methods in Enzymology 68:90; the phosphodiester method described by Brown et al., 1979, Methods in Enzymology 68:109, the diethylphosphoamidate method described by Beaucage et al., 1981, Tetrahedron Letters 22:1859; and the solid support method described in U.S. Patent No. 4,458,066.

[0135] Allele-specific probes are often used in pairs (or, less commonly, in sets of 3 or 4, such as if a SNP position is known to have 3 or 4 alleles, respectively, or to assay both strands of a nucleic acid molecule for a target SNP allele), and such pairs may be identical except for a one nucleotide mismatch that represents the allelic variants at the SNP position. Commonly, one member of a pair perfectly matches a reference form of a target sequence that has a more common SNP allele (i.e., the allele that is more frequent in the target population) and the other member of the pair perfectly matches a form of the target sequence that has a less common SNP allele (i.e., the allele that is rarer in the target population). In the case of an array, multiple pairs of probes can be immobilized on the same support for simultaneous analysis of multiple different polymorphisms.

[0136] In one type of PCR-based assay, an allele-specific primer hybridizes to a region on a target nucleic acid molecule that overlaps a SNP position and only primes amplification of an allelic form to which the primer exhibits perfect complementarity (Gibbs, 1989, Nucleic Acid Res. 17 2427-2448). Typically, the primer's 3'-most nucleotide is aligned with and complementary to the SNP position of the target nucleic acid molecule. This primer is used in conjunction with a second primer that hybridizes at a distal site. Amplification proceeds from the two primers, producing a detectable product that indicates which allelic form is present in the test sample. A control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site. The single-base mismatch prevents amplification or substantially reduces amplification efficiency, so that either no detectable product is formed or it is formed in lower amounts or at a slower pace. The method generally works most effectively when the mismatch is at the 3'-most position of the oligonucleotide (i.e., the 3'-most position of the oligonucleotide aligns with the target SNP position) because this position is most destabilizing to elongation from the primer (see, e.g., WO 93/22456). This PCR-based assay can be utilized as part of the TaqMan assay, described below.

[0137] In a specific embodiment of the invention, a primer for use in the method of the invention contains a sequence substantially complementary to a segment of a target SNP-containing nucleic acid molecule except that the primer has a mismatched nucleotide in one of the three nucleotide positions at the 3'-most end of the primer, such that the mismatched nucleotide does not base pair with a particular allele at the SNP site. In a preferred embodiment, the mismatched nucleotide in the primer is the second from the last nucleotide at the 3'-most position of the primer. In a more preferred embodiment, the mismatched nucleotide in the primer is the last nucleotide at the 3'-most position of the primer.

[0138] In another embodiment of the invention, a SNP detection reagent for use in the method of the invention is labeled with a fluorogenic reporter dye that emits a detectable signal. While the preferred reporter dye is a fluorescent dye, any reporter dye that can be attached to a detection reagent such as an oligonucleotide probe or primer is suitable for use in the invention. Such dyes include, but are not limited to, Acridine, AMCA, BODIPY, Cascade Blue, Cy2, Cy3, Cy5, Cy7, Dabcyl, Edans, Eosin, Erythrosin, Fluorescein, 6-Fam, Tet, Joe, Hex, Oregon Green, Rhodamine, Rhodol Green, Tamra, Rox, and Texas Red.

[0139] In yet another embodiment of the invention, the detection reagent may be further labeled with a quencher dye such as Tamra, especially when the reagent is used as a self-quenching probe such as a TaqMan (U.S. Patent Nos. 5,210,015 and 5,538,848) or Molecular Beacon probe (U.S. Patent Nos. 5,118,801 and 5,312,728), or other stemless or linear beacon probe (Livak et al., 1995, PCR Method Appl. 4:357-362; Tyagi et al., 1996, Nature Biotechnology 14: 303-308; Nazarenko et al., 1997, Nucl. Acids Res. 25:2516-2521; U.S. Patent Nos. 5,866,336 and 6,117,635).

[0140] The detection reagents may also contain other labels, including but not limited to, biotin for streptavidin binding, hapten for antibody binding, and oligonucleotide for binding to another complementary oligonucleotide such as pairs of zipcodes.

[0141] Also contemplated are reagents that do not contain (or that are complementary to) a SNP nucleotide identified herein but that are used to assay the SNP disclosed herein. For example, primers that flank, but do not hybridize directly to a target SNP position provided herein are useful in primer extension reactions in which the primers hybridize to a region adjacent to the target SNP position (i.e., within one or more nucleotides from the target SNP site). During the primer extension reaction, a primer is typically not able to extend past a target SNP site if a particular nucleotide (allele) is present at that target SNP site, and the primer extension product can be detected in order to determine which SNP allele is present at the target SNP site. For example, particular ddNTP are typically used in the primer extension reaction to terminate primer extension once a ddNTP is incorporated into the extension product (described herein is a primer

extension product which includes a ddNTP at the 3'-most end of the primer extension product, and in which the ddNTP is a nucleotide of a SNP disclosed herein. For reference only, described herein are reagents that bind to a nucleic acid molecule in a region adjacent to a SNP site and that are used for assaying the SNP site, even though the bound sequences do not necessarily include the SNP site itself.

USE OF TEST KITS FOR DETECTING SNP

[0142] A person skilled in the art will recognize that, based on the SNP and associated sequence information disclosed herein, detection reagents can be developed and used to assay the SNP used in the method of the present invention individually or in combination, and such detection reagents can be readily incorporated into one of the established kit or system formats which are well known in the art. The terms "kits" and "systems", as used herein in the context of SNP detection reagents, are intended to refer to such things as combinations of multiple SNP detection reagents, or one or more SNP detection reagents in combination with one or more other types of elements or components (e.g., other types of biochemical reagents, containers, packages such as packaging intended for commercial sale, substrates to which SNP detection reagents are attached, electronic hardware components, etc.). For reference only, described herein is a SNP detection kit and systems, including but not limited to, packaged probe and primer sets (e.g., TaqMan probe/primer sets), arrays/microarrays of nucleic acid molecules, and beads that contain one or more probes, primers, or other detection reagents for detecting SNP described herein. The kits/systems can optionally include various electronic hardware components; for example, arrays ("DNA chips") and microfluidic systems ("lab-on-a-chip" systems) provided by various manufacturers typically comprise hardware components. Other kits/systems (e.g., probe/primer sets) may not include electronic hardware components, but may be comprised of, for example, one or more SNP detection reagents (along with, optionally, other biochemical reagents) packaged in one or more containers.

[0143] In some embodiments, a SNP detection kit for use in the method of the present invention contains a detection reagent and other components (e.g., a buffer, and an enzyme such as DNA polymerases or ligases necessary to carry out an assay or reaction, such as amplification and/or detection of a SNP-containing nucleic acid molecule. For reference only, a kit may further contain means for determining the amount of a target nucleic acid, and means for comparing the amount with a standard, and can comprise instructions for using the kit to detect the SNP-containing nucleic acid molecule of interest. In one embodiment a kit for use in the method of the present invention contains the necessary reagents to carry out assays to detect a SNP disclosed herein. In a preferred embodiment, SNP detection kits/systems are in the form of nucleic acid arrays, or compartmentalized kits, including microfluidic/lab-on-a-chip systems.

[0144] SNP detection kits/systems may contain, for example, one or more probes, or pairs of probes, that hybridize to a nucleic acid molecule at or near each target SNP position. Multiple pairs of allele-specific probes may be included in the kit/system to simultaneously assay large numbers of SNPs. In some kits/systems, the allele-specific probes are immobilized to a substrate such as an array or bead. For example, the same substrate can comprise allele-specific probes for detecting at least 1; 10; 100; 1000; 10,000; 100,000 (or any other number in-between) or the SNP shown in Table 1 and/or Table 2.

[0145] The terms "arrays", "microarrays", and "DNA chips" are used herein interchangeably to refer to an array of distinct polynucleotides affixed to a substrate, such as glass, plastic, paper, nylon or other type of membrane, filter, chip, or any other suitable solid support. The polynucleotides can be synthesized directly on the substrate, or synthesized separate from the substrate and then affixed to the substrate. In one embodiment, the microarray is prepared and used according to the methods described in U.S. Patent No. 5,837,832, Chee et al., PCT application W095/11995 (Chee et al.), Lockhart, D. J. et al. (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. et al. (1996; Proc. Natl. Acad. Sci. 93: 10614-10619). In other embodiments, such arrays are produced by the methods described by Brown et al., U.S. Patent No. 5,807,522.

[0146] Nucleic acid arrays are reviewed in the following references: Zammattéo et al., "New chips for molecular biology and diagnostics", *Biotechnol Annu Rev.* 2002;8:85-101; Sosnowski et al., "Active microelectronic array system for DNA hybridization, genotyping and pharmacogenomic applications", *Psychiatr Genet.* 2002 Dec;12(4):181-92; Heller, "DNA microarray technology: devices, systems, and applications", *Annu Rev Biomed Eng.* 2002;4:129-53. Epub 2002 Mar 22; Kolchinsky et al., "Analysis of SNPs and other genomic variations using gel-based chips", *Hum Mutat.* 2002 Apr;19(4):343-60; and McGall et al., "High-density genechip oligonucleotide probe arrays", *Adv Biochem Eng Biotechnol.* 2002; 77:21-42.

[0147] Any number of probes, such as allele-specific probes, may be implemented in an array, and each probe or pair of probes can hybridize to a different SNP position. In the case of polynucleotide probes, they can be synthesized at designated areas (or synthesized separately and then affixed to designated areas) on a substrate using a light-directed chemical process. Each DNA chip can contain, for example, thousands to millions of individual synthetic polynucleotide probes arranged in a grid-like pattern and miniaturized (e.g., to the size of a dime). Preferably, probes are attached to a solid support in an ordered, addressable array.

[0148] A microarray can be composed of a large number of unique, single-stranded polynucleotides, usually either

synthetic antisense polynucleotides or fragments of cDNAs, fixed to a solid support. Typical polynucleotides are preferably about 6-60 nucleotides in length, more preferably about 15-30 nucleotides in length, and most preferably about 18-25 nucleotides in length. For certain types of microarrays or other detection kits/systems, it may be preferable to use oligonucleotides that are only about 7-20 nucleotides in length. In other types of arrays, such as arrays used in conjunction with chemiluminescent detection technology, preferred probe lengths can be, for example, about 15-80 nucleotides in length, preferably about 50-70 nucleotides in length, more preferably about 55-65 nucleotides in length, and most preferably about 60 nucleotides in length. The microarray or detection kit can contain polynucleotides that cover the known 5' or 3' sequence of a gene/transcript or target SNP site, sequential polynucleotides that cover the full-length sequence of a gene/transcript; or unique polynucleotides selected from particular areas along the length of a target gene/transcript sequence, particularly areas corresponding to the SNP disclosed in Table 1 and/or Table 2. Polynucleotides used in the microarray or detection kit can be specific to a SNP or SNPs of interest (e.g., specific to a particular SNP allele at a target SNP site, or specific to particular SNP alleles at multiple different SNP sites), or specific to a polymorphic gene/transcript or genes/transcripts of interest.

[0149] Hybridization assays based on polynucleotide arrays rely on the differences in hybridization stability of the probes to perfectly matched and mismatched target sequence variants. For SNP genotyping, it is generally preferable that stringency conditions used in hybridization assays are high enough such that nucleic acid molecules that differ from one another at as little as a single SNP position can be differentiated (e.g., typical SNP hybridization assays are designed so that hybridization will occur only if one particular nucleotide is present at a SNP position, but will not occur if an alternative nucleotide is present at that SNP position). Such high stringency conditions may be preferable when using, for example, nucleic acid arrays of allele-specific probes for SNP detection. Such high stringency conditions are described in the preceding section, and are well known to those skilled in the art and can be found in, for example, Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.

[0150] In other embodiments, the arrays are used in conjunction with chemiluminescent detection technology. The following patents and patent applications, provide additional information pertaining to chemiluminescent detection: U.S. patent applications 10/620332 and 10/620333 describe chemiluminescent approaches for microarray detection; U.S. Patent Nos. 6124478, 6107024, 5994073, 5981768, 5871938, 5843681, 5800999, and 5773628 describe methods and compositions of dioxetane for performing chemiluminescent detection; and U.S. published application US2002/0110828 discloses methods and compositions for microarray controls.

[0151] A nucleic acid array can comprise an array of probes of about 15-25 nucleotides in length. A nucleic acid array can comprise any number of probes, in which at least one probe is capable of detecting the SNP disclosed in Table 1 and/or Table 2, and/or at least one probe comprises a fragment of one of the sequences selected from the group consisting of those indicated in Table 1. Table 2 and shown in the Sequence Listing, and sequences complementary thereto, said fragment comprising at least about 8 consecutive nucleotides, preferably 10, 12, 15, 16, 18, 20, more preferably 22, 25, 30, 40, 47, 50, 55, 60, 65, 70, 80, 90, 100, or more consecutive nucleotides (or any other number in-between) and containing (or being complementary to) a SNP allele disclosed in Table 1 and/or Table 2. In some embodiments, the nucleotide complementary to the SNP site is within 5, 4, 3, 2, or 1 nucleotide from the center of the probe, more preferably at the center of said probe.

[0152] A polynucleotide probe can be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Balteschweiler et al.). In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more polynucleotides, or any other number which lends itself to the efficient use of commercially available instrumentation.

[0153] Using such arrays or other kits/systems, the present invention provides methods of identifying the SNP disclosed herein in a test sample. Such methods typically involve incubating a test sample of nucleic acids with an array comprising a probe corresponding to the SNP position described herein and assaying for binding of a nucleic acid from the test sample with the probe. Conditions for incubating a SNP detection reagent (or a kit/system that employs such SNP detection reagents) with a test sample vary. Incubation conditions depend on such factors as the format employed in the assay, the detection methods employed, and the type and nature of the detection reagents used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification and array assay formats can readily be adapted to detect the SNP used in the method of the present invention.

[0154] SNP detection kit/system may include components that are used to prepare nucleic acids from a test sample for the subsequent amplification and/or detection of a SNP-containing nucleic acid molecule. Such sample preparation components can be used to produce nucleic acid extracts (including DNA and/or RNA), proteins or membrane extracts from any bodily fluids (such as blood, serum, plasma, urine, saliva, phlegm, gastric juices, semen, tears, sweat, etc.), skin, hair, cells (especially nucleated cells), biopsies, buccal swabs or tissue specimens. The test samples used in the

above-described methods will vary based on such factors as the assay format, nature of the detection method, and the specific tissues, cells or extracts used as the test sample to be assayed. Methods of preparing nucleic acids, proteins, and cell extracts are well known in the art and can be readily adapted to obtain a sample that is compatible with the system utilized. Automated sample preparation systems for extracting nucleic acids from a test sample are commercially available, and examples are Qiagen's BioRobot 9600, Applied Biosystems' PRISM 6700, and Roche Molecular Systems' COBAS AmpliPrep System.

[0155] Another form of kit contemplated by the present invention is a compartmentalized kit. A compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include, for example, small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allow one to efficiently transfer reagents from one compartment to another compartment such that the test samples and reagents are not cross-contaminated, or from one container to another vessel not included in the kit, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another or to another vessel. Such containers may include, for example, one or more containers which will accept the test sample, one or more containers which contain at least one probe or other SNP detection reagent for detecting a SNP used in the method of the present invention, one or more containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and one or more containers which contain the reagents used to reveal the presence of the bound probe or other SNP detection reagents. The kit can optionally further comprise compartments and/or reagents for, for example, nucleic acid amplification or other enzymatic reactions such as primer extension reactions, hybridization, ligation, electrophoresis (preferably capillary electrophoresis), mass spectrometry, and/or laser-induced fluorescent detection. The kit may also include instructions for using the kit. Exemplary compartmentalized kits include microfluidic devices known in the art (see, e.g., Weigl et al., "Lab-on-a-chip for drug development", *Adv Drug Deliv Rev.* 2003 Feb 24;55(3):349-77). In such microfluidic devices, the containers may be referred to as, for example, microfluidic "compartments", "chambers", or "channels".

[0156] Microfluidic devices, which may also be referred to as "lab-on-a-chip" systems, biomedical micro-electro-mechanical systems (bioMEMs), or multicomponent integrated systems, are exemplary kits/systems for use in the present invention for analyzing SNPs. Such systems miniaturize and compartmentalize processes such as probe/target hybridization, nucleic acid amplification, and capillary electrophoresis reactions in a single functional device. Such microfluidic devices typically utilize detection reagents in at least one aspect of the system, and such detection reagents may be used to detect the SNP disclosed herein. One example of a microfluidic system is disclosed in U.S. Patent No. 5,589,136, which describes the integration of PCR amplification and capillary electrophoresis in chips. Exemplary microfluidic systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer included on a microchip. The movements of the samples may be controlled by electric, electroosmotic or hydrostatic forces applied across different areas of the microchip to create functional microscopic valves and pumps with no moving parts. Varying the voltage can be used as a means to control the liquid flow at intersections between the micro-machined channels and to change the liquid flow rate for pumping across different sections of the microchip. See, for example, U.S. Patent Nos. 6,153,073, Dubrow et al., and 6,156,181, Parce et al.

[0157] For genotyping SNPs, an exemplary microfluidic system may integrate, for example, nucleic acid amplification, primer extension, capillary electrophoresis, and a detection method such as laser induced fluorescence detection. In a first step of an exemplary process for using such an exemplary system, nucleic acid samples are amplified, preferably by PCR. Then, the amplification products are subjected to automated primer extension reactions using ddNTPs (specific fluorescence for each ddNTP) and the appropriate oligonucleotide primers to carry out primer extension reactions which hybridize just upstream of the targeted SNP. Once the extension at the 3' end is completed, the primers are separated from the unincorporated fluorescent ddNTPs by capillary electrophoresis. The separation medium used in capillary electrophoresis can be, for example, polyacrylamide, polyethyleneglycol or dextran. The incorporated ddNTP in the single nucleotide primer extension products are identified by laser-induced fluorescence detection. Such an exemplary microchip can be used to process, for example, at least 96 to 384 samples, or more, in parallel.

USES OF NUCLEIC ACID MOLECULES

[0158] For reference only, the nucleic acid molecules described herein have a variety of uses, especially in predicting an individual's risk for developing a myocardial infarction (particularly the risk for experiencing a first or recurrent acute coronary event such as a myocardial infarction), for prognosing the progression of a cardiovascular disorder in an individual (e.g., the severity or consequences of an acute coronary event), in evaluating the likelihood of an individual who has a cardiovascular disorder of responding to treatment of the cardiovascular disorder with statin, and/or predicting the likelihood that the individual will experience toxicity or other undesirable side effects from the statin treatment, etc. For example, the nucleic acid molecules are useful as hybridization probes, such as for genotyping SNPs in messenger RNA, transcript, cDNA, genomic DNA, amplified DNA or other nucleic acid molecules, and for isolating full-length cDNA and genomic clones encoding the variant peptides disclosed in Table 1 as well as their orthologs.

[0159] A probe can hybridize to any nucleotide sequence along the entire length of a nucleic acid molecule provided in Table 1 and/or Table 2. Preferably, a probe for use in the method of the present invention hybridizes to a region of a target sequence that encompasses a SNP position indicated in Table 1 and/or Table 2. More preferably, a probe for use in the method of the present invention hybridizes to a SNP-containing target sequence in a sequence-specific manner such that it distinguishes the target sequence from other nucleotide sequences which vary from the target sequence only by which nucleotide is present at the SNP site. Such a probe is particularly useful for detecting the presence of a SNP-containing nucleic acid in a test sample, or for determining which nucleotide (allele) is present at a particular SNP site (i.e., genotyping the SNP site).

[0160] A nucleic acid hybridization probe may be used for determining the presence, level, form, and/or distribution of nucleic acid expression. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes specific for the SNP described herein in Tables 1 and 2 can be used to assess the presence, expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in gene expression relative to normal levels. *In vitro* techniques for detection of mRNA include, for example, Northern blot hybridizations and *in situ* hybridizations. *In vitro* techniques for detecting DNA include Southern blot hybridizations and *in situ* hybridizations (Sambrook and Russell, 2000, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY).

[0161] Probes can be used as part of a diagnostic test kit for identifying cells or tissues in which a variant protein is expressed, such as by measuring the level of a variant protein-encoding nucleic acid (e.g., mRNA) in a sample of cells from a subject or determining if a polynucleotide contains a SNP of interest.

[0162] Thus, the nucleic acid molecules for use in the method of the invention can be used as hybridization probe to detect the SNP disclosed herein, thereby determining whether an individual with the polymorphisms is likely to develop a myocardial infarction or the likelihood that an individual will respond positively to HMG-CoA reductase inhibitor treatment for reducing an individual's risk of having a myocardial infarction. Detection of a SNP associated with a disease phenotype provides a diagnostic tool for an active disease and/or genetic predisposition to the disease. Furthermore, the nucleic acid molecules for use in the method of the invention are therefore useful for detecting a gene (gene information is disclosed in Table 2, for example) which contains a SNP disclosed in Table 1 and/or Table 2 and/or products of such genes, such as expressed mRNA transcript molecules (transcript information is disclosed in Table 1, for example), and are thus useful for detecting gene expression. The nucleic acid molecules can optionally be implemented in, for example, an array or kit format for use in detecting gene expression. The nucleic acid molecules for use in the method of the invention are also useful as primers to amplify any given region of a nucleic acid molecule, particularly a region containing a SNP identified in Table 1 and/or Table 2. For reference only, the nucleic acid molecules disclosed herein are also useful for constructing recombinant vectors (described in greater detail below). Such vectors include expression vectors that express a portion of, or all of, any of the variant peptide sequences provided in Table 1. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter *in situ* expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced SNPs.

[0163] The nucleic acid molecules disclosed herein are also useful for expressing antigenic portions of the variant proteins, particularly antigenic portions that contain a variant amino acid sequence (e.g., an amino acid substitution) caused by a SNP disclosed in Table 1 and/or Table 2. For reference only, the nucleic acid molecules disclosed herein are also useful for constructing vectors containing a gene regulatory region of the nucleic acid molecules described herein.

[0164] For reference only, the nucleic acid molecules described herein are also useful for designing ribozymes corresponding to all, or a part, of an mRNA molecule expressed from a SNP-containing nucleic acid molecule described herein. For reference only, the nucleic acid molecules described herein are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and variant peptides. For reference only, the nucleic acid molecules described herein are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and variant peptides. The production of recombinant cells and transgenic animals having nucleic acid molecules which contain the SNPs disclosed in Table 1 and/or Table 2 allow, for example, effective clinical design of treatment compounds and dosage regimens. For reference only, the nucleic acid molecules described herein are also useful in assays for drug screening to identify compounds that, for example, modulate nucleic acid expression. For reference only, the nucleic acid molecules described herein are also useful in gene therapy in patients whose cells have aberrant gene expression. Thus, recombinant cells, which include a patient's cells that have been engineered *ex vivo* and returned to the patient, can be introduced into an individual where the recombinant cells produce the desired protein to treat the individual.

SNP GENOTYPING METHODS

[0165] The process of determining which specific nucleotide (i.e., allele) is present at each of one or more SNP positions, such as a SNP position in a nucleic acid molecule disclosed in Table 1 and/or Table 2, is referred to as SNP genotyping. The present invention provides methods comprising SNP genotyping, such as for use in evaluating an

individual's risk for developing myocardial infarction and for evaluating an individual's prognosis for disease severity and recovery, for predicting the likelihood that an individual who has previously experienced a myocardial infarction will experience one or more recurrent myocardial infarction, for implementing a preventive or treatment regimen for an individual based on that individual having an increased susceptibility for developing myocardial infarctions or strokes), in evaluating an individual's likelihood of responding to HMG-CoA reductase inhibitor treatment for reducing the risk of myocardial infarction in selecting a treatment regimen (e.g. in deciding whether or not to administer HMG-CoA reductase inhibitor treatment to an individual having myocardial infarction, or in formulating or selecting a particular HMG-CoA reductase inhibitor based treatment regimen such as dosage and/or frequency of administration of HMG-CoA reductase inhibitor treatment or choosing which form/type of HMG-CoA reductase inhibitor to be administered such as a particular pharmaceutical composition or compound etc.), determining the likelihood of experiencing toxicity of other undesirable side effects from the HMG-CoA reductase inhibitor treatment, or selecting individuals for a clinical trial of a statin (e.g., selecting individuals to participate in the trial who are most likely to respond positively from the statin treatment), etc.

[0166] Nucleic acid samples can be genotyped to determine which allele(s) is/are present at any given genetic region (e.g., SNP position) of interest by methods well known in the art. The neighboring sequence can be used to design SNP detection reagents such as oligonucleotide probes, which may optionally be implemented in a kit format. Exemplary SNP genotyping methods are described in Chen et al., "Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput", *Pharmacogenomics J.* 2003;3(2):77-96; Kwok et al., "Detection of single nucleotide polymorphisms", *Curr Issues Mol Biol.* 2003 Apr;5(2):43-60; Shi, "Technologies for individual genotyping: detection of genetic polymorphisms in drug targets and disease genes", *Am J Pharmacogenomics.* 2002;2(3):197-205; and Kwok, "Methods for genotyping single nucleotide polymorphisms", *Annu Rev Genomic Hum Genet* 2001;2:235-58. Exemplary techniques for high-throughput SNP genotyping are described in Mamellos, "High-throughput SNP analysis for genetic association studies", *Curr Opin Drug Discov Devel.* 2003 May;6(3):317-21. Common SNP genotyping methods include, but are not limited to, TaqMan assays, molecular beacon assays, nucleic acid arrays, allele-specific primer extension, allele-specific PCR, arrayed primer extension, homogeneous primer extension assays, primer extension with detection by mass spectrometry, pyrosequencing, multiplex primer extension sorted on genetic arrays, ligation with rolling circle amplification, homogeneous ligation, OLA (U.S. Patent No. 4,988,167), multiplex ligation reaction sorted on genetic arrays, restriction-fragment length polymorphism, single base extension-tag assays, and the Invader assay. Such methods may be used in combination with detection mechanisms such as, for example, luminescence or chemiluminescence detection, fluorescence detection, time-resolved fluorescence detection, fluorescence resonance energy transfer, fluorescence polarization, mass spectrometry, and electrical detection.

[0167] Various methods for detecting polymorphisms include, but are not limited to, methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al., *Science* 230: 1242 (1985); Cotton et al., *PNAS* 85:4397 (1988); and Saleeba et al., *Meth. Enzymol.* 217:286-295 (1992)), comparison of the electrophoretic mobility of variant and wild type nucleic acid molecules (Orita et al., *PNAS* 86:2766 (1989); Cotton et al., *Mutat. Res.* 285:125-144 (1993); and Hayashi et al., *Genet. Anal. Tech. Appl.* 9:73-79 (1992)), and assaying the movement of polymorphic or wild-type fragments in polyacrylamide gels containing a gradient of denaturant using denaturing gradient gel electrophoresis (DGGE) (Myers et al., *Nature* 313:495 (1985)). Sequence variations at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or chemical cleavage methods.

[0168] In a preferred embodiment, SNP genotyping is performed using the TaqMan assay, which is also known as the 5' nuclease assay (U.S. Patent Nos. 5,210,015 and 5,538,848). The TaqMan assay detects the accumulation of a specific amplified product during PCR. The TaqMan assay utilizes an oligonucleotide probe labeled with a fluorescent reporter dye and a quencher dye. The reporter dye is excited by irradiation at an appropriate wavelength, it transfers energy to the quencher dye in the same probe via a process called fluorescence resonance energy transfer (FRET). When attached to the probe, the excited reporter dye does not emit a signal. The proximity of the quencher dye to the reporter dye in the intact probe maintains a reduced fluorescence for the reporter. The reporter dye and quencher dye may be at the 5' most and the 3' most ends, respectively, or vice versa. Alternatively, the reporter dye may be at the 5' or 3' most end while the quencher dye is attached to an internal nucleotide, or vice versa. In yet another embodiment, both the reporter and the quencher may be attached to internal nucleotides at a distance from each other such that fluorescence of the reporter is reduced.

[0169] During PCR, the 5' nuclease activity of DNA polymerase cleaves the probe, thereby separating the reporter dye and the quencher dye and resulting in increased fluorescence of the reporter. Accumulation of PCR product is detected directly by monitoring the increase in fluorescence of the reporter dye. The DNA polymerase cleaves the probe between the reporter dye and the quencher dye only if the probe hybridizes to the target SNP-containing template which is amplified during PCR, and the probe is designed to hybridize to the target SNP site only if a particular SNP allele is present.

[0170] Preferred TaqMan primer and probe sequences can readily be determined using the SNP and associated nucleic acid sequence information provided herein. A number of computer programs, such as Primer Express (Applied

Biosystems, Foster City, CA), can be used to rapidly obtain optimal primer/probe sets. It will be apparent to one of skill in the art that such primers and probes for detecting the SNP for use in the method of the present invention are useful in screening for individuals who are susceptible to developing myocardial infarction or in screening individuals who have a cardiovascular disorder for their likelihood of responding to HMG-CoA reductase inhibitor treatment. These probes and primers can be readily incorporated into a kit format. The present description also discloses modifications of the Taqman assay well known in the art such as the use of Molecular Beacon probes (U.S. Patent Nos. 5,118,801 and 5,312,728) and other variant formats (U.S. Patent Nos. 5,866,336 and 6,117,635). Another preferred method for genotyping the SNP for use in the method of the present invention is the use of two oligonucleotide probes in an OLA (see, e.g., U.S. Patent No. 4,988,617). In this method, one probe hybridizes to a segment of a target nucleic acid with its 3' most end aligned with the SNP site. A second probe hybridizes to an adjacent segment of the target nucleic acid molecule directly 3' to the first probe. The two juxtaposed probes hybridize to the target nucleic acid molecule, and are ligated in the presence of a linking agent such as a ligase if there is perfect complementarity between the 3' most nucleotide of the first probe with the SNP site. If there is a mismatch, ligation would not occur. After the reaction, the ligated probes are separated from the target nucleic acid molecule, and detected as indicators of the presence of a SNP.

[0171] The following patents, patent applications, and published international patent applications, provide additional information pertaining to techniques for carrying out various types of OLA: U.S. Patent Nos. 6027889, 6268148, 5494810, 5830711, and 6054564 describe OLA strategies for performing SNP detection; WO 97/31256 and WO 00/56927 describe OLA strategies for performing SNP detection using universal arrays, wherein a zipcode-sequence can be introduced into one of the hybridization probes, and the resulting product, or amplified product, hybridized to a universal zip code array; U.S. application US01/17329 (and 09/584,905) describes OLA (or LDR) followed by PCR, wherein zipcodes are incorporated into OLA probes, and amplified PCR products are determined by electrophoretic or universal zipcode array readout; U.S. applications 60/427818, 60/445636, and 60/445494 describe SNplex methods and software for multiplexed SNP detection using OLA followed by PCR, wherein zipcodes are incorporated into OLA probes, and amplified PCR products are hybridized with a zipchute reagent, and the identity of the SNP determined from electrophoretic readout of the zipchute. In some embodiments, OLA is carried out prior to PCR (or another method of nucleic acid amplification). In other embodiments, PCR (or another method of nucleic acid amplification) is carried out prior to OLA.

[0172] Another method for SNP genotyping is based on mass spectrometry. Mass spectrometry takes advantage of the unique mass of each of the four nucleotides of DNA. SNPs can be unambiguously genotyped by mass spectrometry by measuring the differences in the mass of nucleic acids having alternative SNP alleles. MALDI-TOF (Matrix Assisted Laser Desorption Ionization - Time of Flight) mass spectrometry technology is preferred for extremely precise determinations of molecular mass, such as SNPs. Numerous approaches to SNP analysis have been developed based on mass spectrometry. Preferred mass spectrometry-based methods of SNP genotyping include primer extension assays, which can also be utilized in combination with other approaches, such as traditional gel-based formats and microarrays.

[0173] Typically, the primer extension assay involves designing and annealing a primer to a template PCR amplicon upstream (5') from a target SNP position. A mix of dideoxynucleotide triphosphates (ddNTPs) and/or deoxynucleotide triphosphates (dNTPs) are added to a reaction mixture containing template (e.g., a SNP-containing nucleic acid molecule which has typically been amplified, such as by PCR), primer, and DNA polymerase. Extension of the primer terminates at the first position in the template where a nucleotide complementary to one of the ddNTPs in the mix occurs. The primer can be either immediately adjacent (i.e., the nucleotide at the 3' end of the primer hybridizes to the nucleotide next to the target SNP site) or two or more nucleotides removed from the SNP position. If the primer is several nucleotides removed from the target SNP position, the only limitation is that the template sequence between the 3' end of the primer and the SNP position cannot contain a nucleotide of the same type as the one to be detected, or this will cause premature termination of the extension primer. Alternatively, if all four ddNTPs alone, with no dNTPs, are added to the reaction mixture, the primer will always be extended by only one nucleotide, corresponding to the target SNP position. In this instance, primers are designed to bind one nucleotide upstream from the SNP position (i.e., the nucleotide at the 3' end of the primer hybridizes to the nucleotide that is immediately adjacent to the target SNP site on the 5' side of the target SNP site). Extension by only one nucleotide is preferable, as it minimizes the overall mass of the extended primer, thereby increasing the resolution of mass differences between alternative SNP nucleotides. Furthermore, mass-tagged ddNTPs can be employed in the primer extension reactions in place of unmodified ddNTPs. This increases the mass difference between primers extended with these ddNTPs, thereby providing increased sensitivity and accuracy, and is particularly useful for typing heterozygous base positions. Mass-tagging also alleviates the need for intensive sample-preparation procedures and decreases the necessary resolving power of the mass spectrometer.

[0174] The extended primers can then be purified and analyzed by MALDI-TOF mass spectrometry to determine the identity of the nucleotide present at the target SNP position. In one method of analysis, the products from the primer extension reaction are combined with light absorbing crystals that form a matrix. The matrix is then hit with an energy source such as a laser to ionize and desorb the nucleic acid molecules into the gas-phase. The ionized molecules are then ejected into a flight tube and accelerated down the tube towards a detector. The time between the ionization event, such as a laser pulse, and collision of the molecule with the detector is the time of flight of that molecule. The time of

flight is precisely correlated with the mass-to-charge ratio (m/z) of the ionized molecule. Ions with smaller m/z travel down the tube faster than ions with larger m/z and therefore the lighter ions reach the detector before the heavier ions. The time-of-flight is then converted into a corresponding, and highly precise, m/z . In this manner, SNPs can be identified based on the slight differences in mass, and the corresponding time of flight differences, inherent in nucleic acid molecules having different nucleotides at a single base position. For further information regarding the use of primer extension assays in conjunction with MALDI-TOF mass spectrometry for SNP genotyping, see, e.g., Wise et al., "A standard protocol for single nucleotide primer extension in the human genome using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry", *Rapid Commun Mass Spectrom.* 2003;17(11):1195-202.

[0175] The following references provide further information describing mass spectrometry-based methods for SNP genotyping: Bocker, "SNP and mutation discovery using base-specific cleavage and MALDI-TOF mass spectrometry", *Bioinformatics.* 2003 Jul;19 Suppl 1:I44-I53; Storm et al., "MALDI-TOF mass spectrometry-based SNP genotyping", *Methods Mol Biol.* 2003;212:241-62; Jurinke et al., "The use of MassARRAY technology for high throughput genotyping", *Adv Biochem Eng Biotechnol.* 2002;77:57-74; and Jurinke et al., "Automated genotyping using the DNA MassArray technology", *Methods Mol Biol.* 2002;187:179-92.

[0176] SNPs can also be scored by direct DNA sequencing. A variety of automated sequencing procedures can be utilized ((1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO94/16101; Cohen et al., *Adv. Chromatogr.* 36:127-162 (1996); and Griffin et al., *Appl. Biochem. Biotechnol.* 38:147-159 (1993)). The nucleic acid sequences of the present invention enable one of ordinary skill in the art to readily design sequencing primers for such automated sequencing procedures. Commercial instrumentation, such as the Applied Biosystems 377, 3100, 3700, 3730, and 3730x1 DNA Analyzers (Foster City, CA), is commonly used in the art for automated sequencing.

[0177] Other methods that can be used to genotype the SNP of the present invention include single-strand conformational polymorphism (SSCP), and denaturing gradient gel electrophoresis (DGGE) (Myers et al., *Nature* 313:495 (1985)). SSCP identifies base differences by alteration in electrophoretic migration of single stranded PCR products, as described in Orita et al., *Proc. Nat. Acad.* Single-stranded PCR products can be generated by heating or otherwise denaturing double stranded PCR products. Single-stranded nucleic acids may refold or form secondary structures that are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification products are related to base-sequence differences at SNP positions. DGGE differentiates SNP alleles based on the different sequence-dependent stabilities and melting properties inherent in polymorphic DNA and the corresponding differences in electrophoretic migration patterns in a denaturing gradient gel (Erich, ed., *PCR Technology, Principles and Applications for DNA Amplification*, W.H. Freeman and Co, New York, 1992, Chapter 7).

[0178] Sequence-specific ribozymes (U.S. Patent No. 5,498,531) can also be used to score SNPs based on the development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature. If the SNP affects a restriction enzyme cleavage site, the SNP can be identified by alterations in restriction enzyme digestion patterns, and the corresponding changes in nucleic acid fragment lengths determined by gel electrophoresis.

[0179] SNP genotyping can include the steps of, for example, collecting a biological sample from a human subject (e.g., sample of tissues, cells, fluids, secretions, etc.), isolating nucleic acids (e.g., genomic DNA, mRNA or both) from the cells of the sample, contacting the nucleic acids with one or more primers which specifically hybridize to a region of the isolated nucleic acid containing a target SNP under conditions such that hybridization and amplification of the target nucleic acid region occurs, and determining the nucleotide present at the SNP position of interest, or, in some assays, detecting the presence or absence of an amplification product (assays can be designed so that hybridization and/or amplification will only occur if a particular SNP allele is present or absent). In some assays, the size of the amplification product is detected and compared to the length of a control sample; for example, deletions and insertions can be detected by a change in size of the amplified product compared to a normal genotype.

[0180] SNP genotyping is useful for numerous practical applications, as described below. Examples of such applications include, but are not limited to, SNP-disease association analysis, disease predisposition screening, disease diagnosis, disease prognosis, disease progression monitoring, determining therapeutic strategies based on an individual's genotype ("pharmacogenomics"), developing therapeutic agents based on SNP genotypes associated with a disease or likelihood of responding to a drug, stratifying a patient population for clinical trial for a treatment regimen, predicting the likelihood that an individual will experience toxic side effects from a therapeutic agent, and human identification applications such as forensics.

ANALYSIS OF GENETIC ASSOCIATION BETWEEN SNP AND PHENOTYPIC TRAITS

[0181] SNP genotyping for disease diagnosis, disease predisposition screening, disease prognosis, determining drug responsiveness (pharmacogenomics), drug toxicity screening, and other uses described herein, typically relies on initially establishing a genetic association between a specific SNP and the particular phenotypic traits of interest.

[0182] Different study designs may be used for genetic association studies (Modern Epidemiology, Lippincott Williams & Wilkins (1998), 609-622). Observational studies are most frequently carried out in which the response of the patients is not interfered with. The first type of observational study identifies a sample of persons in whom the suspected cause of the disease is present and another sample of persons in whom the suspected cause is absent, and then the frequency of development of disease in the two samples is compared. These sampled populations are called cohorts, and the study is a prospective study. The other type of observational study is case-control or a retrospective study. In typical case-control studies, samples are collected from individuals with the phenotype of interest (cases) such as certain manifestations of a disease, and from individuals without the phenotype (controls) in a population (target population) that conclusions are to be drawn from. Then the possible causes of the disease are investigated retrospectively. As the time and costs of collecting samples in case-control studies are considerably less than those for prospective studies, case-control studies are the more commonly used study design in genetic association studies, at least during the exploration and discovery stage.

[0183] In both types of observational studies, there may be potential confounding factors that should be taken into consideration. Confounding factors are those that are associated with both the real cause(s) of the disease and the disease itself, and they include demographic information such as age, gender, ethnicity as well as environmental factors. When confounding factors are not matched in cases and controls in a study, and are not controlled properly, spurious association results can arise. If potential confounding factors are identified, they should be controlled for by analysis methods explained below.

[0184] In a genetic association study, the cause of interest to be tested is a certain allele or a SNP or a combination of alleles or a haplotype from several SNPs. Thus, tissue specimens (e.g., whole blood) from the sampled individuals may be collected and genomic DNA genotyped for the SNP(s) of interest. In addition to the phenotypic trait of interest, other information such as demographic (e.g., age, gender, ethnicity, etc.), clinical, and environmental information that may influence the outcome of the trait can be collected to further characterize and define the sample set. In many cases, these factors are known to be associated with diseases and/or SNP allele frequencies. There are likely gene-environment and/or gene-gene interactions as well. Analysis methods to address gene-environment and gene-gene interactions (for example, the effects of the presence of both susceptibility alleles at two different genes can be greater than the effects of the individual alleles at two genes combined) are discussed below.

[0185] After all the relevant phenotypic and genotypic information has been obtained, statistical analyses are carried out to determine if there is any significant correlation between the presence of an allele or a genotype with the phenotypic characteristics of an individual. Preferably, data inspection and cleaning are first performed before carrying out statistical tests for genetic association. Epidemiological and clinical data of the samples can be summarized by descriptive statistics with tables and graphs. Data validation is preferably performed to check for data completion, inconsistent entries, and outliers. Chi-square tests and t-tests (Wilcoxon rank-sum tests if distributions are not normal) may then be used to check for significant differences between cases and controls for discrete and continuous variables, respectively. To ensure genotyping quality, Hardy-Weinberg disequilibrium tests can be performed on cases and controls separately. Significant deviation from Hardy-Weinberg equilibrium (HWE) in both cases and controls for individual markers can be indicative of genotyping errors. If HWE is violated in a majority of markers, it is indicative of population substructure that should be further investigated. Moreover, Hardy-Weinberg disequilibrium in cases only can indicate genetic association of the markers with the disease (Genetic Data Analysis, Weir B., Sinauer (1990)).

[0186] To test whether an allele of a single SNP is associated with the case or control status of a phenotypic trait, one skilled in the art can compare allele frequencies in cases and controls. Standard chi-square tests and Fisher exact tests can be carried out on a 2x2 table (2 SNP alleles x 2 outcomes in the categorical trait of interest). To test whether genotypes of a SNP are associated, chi-square tests can be carried out on a 3x2 table (3 genotypes x 2 outcomes). Score tests are also carried out for genotypic association to contrast the three genotypic frequencies (major homozygotes, heterozygotes and minor homozygotes) in cases and controls, and to look for trends using 3 different modes of inheritance, namely dominant (with contrast coefficients 2, -1, -1), additive (with contrast coefficients 1, 0, -1) and recessive (with contrast coefficients 1, 1, -2). Odds ratios for minor versus major alleles, and odds ratios for heterozygote and homozygote variants versus the wild type genotypes are calculated with the desired confidence limits, usually 95%.

[0187] In order to control for confounders and to test for interaction and effect modifiers, stratified analyses may be performed using stratified factors that are likely to be confounding, including demographic information such as age, ethnicity, and gender, or an interacting element or effect modifier, such as a known major gene (e.g., APOE for Alzheimer's disease or HLA genes for autoimmune diseases), or environmental factors such as smoking in lung cancer. Stratified association tests may be carried out using Cochran-Mantel-Haenszel tests that take into account the ordinal nature of genotypes with 0, 1, and 2 variant alleles. Exact tests by StatXact may also be performed when computationally possible. Another way to adjust for confounding effects and test for interactions is to perform stepwise multiple logistic regression analysis using statistical packages such as SAS or R. Logistic regression is a model-building technique in which the best fitting and most parsimonious model is built to describe the relation between the dichotomous outcome (for instance, getting a certain disease or not) and a set of independent variables (for instance, genotypes of different associated

genes, and the associated demographic and environmental factors). The most common model is one in which the logit transformation of the odds ratios is expressed as a linear combination of the variables (main effects) and their cross-product terms (interactions) (Applied Logistic Regression, Hosmer and Lemeshow, Wiley (2000)). To test whether a certain variable or interaction is significantly associated with the outcome, coefficients in the model are first estimated and then tested for statistical significance of their departure from zero.

[0188] In addition to performing association tests one marker at a time, haplotype association analysis may also be performed to study a number of markers that are closely linked together. Haplotype association tests can have better power than genotypic or allelic association tests when the tested markers are not the disease-causing mutations themselves but are in linkage disequilibrium with such mutations. The test will even be more powerful if the disease is indeed caused by a combination of alleles on a haplotype (e.g., APOE is a haplotype formed by 2 SNPs that are very close to each other). In order to perform haplotype association effectively, marker-marker linkage disequilibrium measures, both D' and R^2 , are typically calculated for the markers within a gene to elucidate the haplotype structure. Recent studies (Daly et al, Nature Genetics, 29, 232-235, 2001) in linkage disequilibrium indicate that SNPs within a gene are organized in block pattern, and a high degree of linkage disequilibrium exists within blocks and very little linkage disequilibrium exists between blocks. Haplotype association with the disease status can be performed using such blocks once they have been elucidated.

[0189] Haplotype association tests can be carried out in a similar fashion as the allelic and genotypic association tests. Each haplotype in a gene is analogous to an allele in a multi-allelic marker. One skilled in the art can either compare the haplotype frequencies in cases and controls or test genetic association with different pairs of haplotypes. It has been proposed (Schaid et al, Am. J. Hum. Genet., 70, 425-434, 2002) that score tests can be done on haplotypes using the program "haplo.score". In that method, haplotypes are first inferred by EM algorithm and score tests are carried out with a generalized linear model (GLM) framework that allows the adjustment of other factors.

[0190] An important decision in the performance of genetic association tests is the determination of the significance level at which significant association can be declared when the p-value of the tests reaches that level. In an exploratory analysis where positive hits will be followed up in subsequent confirmatory testing, an unadjusted p-value <0.1 (a significance level on the lenient side) may be used for generating hypotheses for significant association of a SNP with certain phenotypic characteristics of a disease. It is preferred that a p-value <0.05 (a significance level traditionally used in the art) is achieved in order for a SNP to be considered to have an association with a disease. It is more preferred that a p-value <0.01 (a significance level on the stringent side) is achieved for an association to be declared. When hits are followed up in confirmatory analyses in more samples of the same source or in different samples from different sources, adjustment for multiple testing will be performed as to avoid excess number of hits while maintaining the experiment-wise error rates at 0.05. While there are different methods to adjust for multiple testing to control for different kinds of error rates, a commonly used but rather conservative method is Bonferroni correction to control the experiment-wise or family-wise error rate (Multiple comparisons and multiple tests, Westfall et al, SAS Institute (1999)). Permutation tests to control for the false discovery rates, FDR, can be more powerful (Benjamini and Hochberg, Journal of the Royal Statistical Society, Series B 57, 1289-1300, 1995, Resampling-based Multiple Testing, Westfall and Young, Wiley (1993)). Such methods to control for multiplicity would be preferred when the tests are dependent and controlling for false discovery rates is sufficient as opposed to controlling for the experiment-wise error rates.

[0191] In replication studies using samples from different populations after statistically significant markers have been identified in the exploratory stage, meta-analyses can then be performed by combining evidence of different studies (Modern Epidemiology, Lippincott Williams & Wilkins, 1998, 643-673). If available, association results known in the art for the same SNPs can be included in the meta-analyses.

[0192] Since both genotyping and disease status classification can involve errors, sensitivity analyses may be performed to see how odds ratios and p-values would change upon various estimates on genotyping and disease classification error rates.

[0193] It has been well known that subpopulation-based sampling bias between cases and controls can lead to spurious results in case-control association studies (Ewens and Spielman, Am. J. Hum. Genet. 62, 450-458, 1995) when prevalence of the disease is associated with different subpopulation groups. Such bias can also lead to a loss of statistical power in genetic association studies. To detect population stratification, Pritchard and Rosenberg (Pritchard et al. Am. J. Hum. Gen. 1999, 65:220-228) suggested typing markers that are unlinked to the disease and using results of association tests on those markers to determine whether there is any population stratification. When stratification is detected, the genomic control (GC) method as proposed by Devlin and Roeder (Devlin et al. Biometrics 1999, 55:997-1004) can be used to adjust for the inflation of test statistics due to population stratification. GC method is robust to changes in population structure levels as well as being applicable to DNA pooling designs (Devlin et al. Genet. Epidemiol. 2000, 21: 273-284).

[0194] While Pritchard's method recommended using 15-20 unlinked microsatellite markers, it suggested using more than 30 biallelic markers to get enough power to detect population stratification. For the GC method, it has been shown (Bacanu et al. Am. J. Hum. Genet. 2000, 66:1933-1944) that about 60-70 biallelic markers are sufficient to estimate the

inflation factor for the test statistics due to population stratification. Hence, 70 intergenic SNPs can be chosen in unlinked regions as indicated in a genome scan (Kehoe et al. Hum. Mol. Genet. 1999, 8:237-245).

[0195] Once individual risk factors, genetic or non-genetic, have been found for the predisposition to disease, the next step is to set up a classification/prediction scheme to predict the category (for instance, disease or no-disease) that an individual will be in depending on his genotypes of associated SNPs and other non-genetic risk factors. Logistic regression for discrete trait and linear regression for continuous trait are standard techniques for such tasks (Applied Regression Analysis, Draper and Smith, Wiley (1998)). Moreover, other techniques can also be used for setting up classification. Such techniques include, but are not limited to, MART, CART, neural network, and discriminant analyses that are suitable for use in comparing the performance of different methods (The Elements of Statistical Learning, Hastie, Tibshirani & Friedman, Springer (2002)).

DISEASE DIAGNOSIS AND PREDISPOSITION SCREENING

[0196] Information on association/correlation between genotypes and disease-related phenotypes can be exploited in several ways. For example, in the case of a highly statistically significant association between one or more SNPs with predisposition to a disease for which treatment is available, detection of such a genotype pattern in an individual may justify immediate administration of treatment, or at least the institution of regular monitoring of the individual. Detection of the susceptibility alleles associated with serious disease in a couple contemplating having children may also be valuable to the couple in their reproductive decisions. In the case of a weaker but still statistically significant association between a SNP and a human disease, immediate therapeutic intervention or monitoring may not be justified after detecting the susceptibility allele or SNP. Nevertheless, the subject can be motivated to begin simple life-style changes (e.g., diet, exercise) that can be accomplished at little or no cost to the individual but would confer potential benefits in reducing the risk of developing conditions for which that individual may have an increased risk by virtue of having the susceptibility allele(s).

[0197] The SNP for use in the method of the invention may contribute to myocardial infarction or to responsiveness of an individual to HMG-CoA reductase inhibitor treatment, in different ways. Some polymorphisms occur within a protein coding sequence and contribute to disease phenotype by affecting protein structure. Other polymorphisms occur in noncoding regions but may exert phenotypic effects indirectly via influence on, for example, replication, transcription, and/or translation. A single SNP may affect more than one phenotypic trait. Likewise, a single phenotypic trait may be affected by multiple SNPs in different genes.

[0198] As used herein, the terms "diagnose", "diagnosis", and "diagnostics" include, but are not limited to any of the following: detection of a cardiovascular disorders that an individual may presently have, predisposition/susceptibility screening (e.g., determining whether an individual has an increased risk of experiencing myocardial infarction in the future, or determining whether an individual has a decreased risk of experiencing myocardial infarction in the future), determining a particular type or subclass of cardiovascular disorder in an individual known to currently have or to have previously experienced a myocardial infarction, confirming or reinforcing a previously made diagnosis of a cardiovascular disorder, evaluating an individual's likelihood of responding to HMG-CoA reductase inhibitor treatment for reducing the risk of having a myocardial infarction, predisposition screening (e.g., evaluating an individual's likelihood of responding to HMG-CoA reductase inhibitor treatment if the individual were to develop a myocardial infarction in the future), determining a particular type or subclass of responder/non-responder in an individual known to respond or not respond to HMG-CoA reductase inhibitor treatment, confirming or reinforcing a previously made classification of an individual as a responder/non-responder to HMG-CoA reductase inhibitor treatment, pharmacogenomic evaluation of an individual to determine which therapeutic strategy that individual is most likely to positively respond to or to predict whether a patient is likely to respond to HMG-CoA reductase inhibitor treatment, predicting whether a patient is likely to experience toxic effects from a particular treatment or therapeutic compound, and evaluating the future prognosis of an individual having a myocardial infarction. Such diagnostic uses are based on the SNPs individually or in a unique combination or SNP haplotypes of the present invention.

[0199] Haplotypes are particularly useful in that, for example, fewer SNPs can be genotyped to determine if a particular genomic region harbors a locus that influences a particular phenotype, such as in linkage disequilibrium-based SNP association analysis.

[0200] Linkage disequilibrium (LD) refers to the co-inheritance of alleles (e.g., alternative nucleotides) at two or more different SNP sites at frequencies greater than would be expected from the separate frequencies of occurrence of each allele in a given population. The expected frequency of co-occurrence of two alleles that are inherited independently is the frequency of the first allele multiplied by the frequency of the second allele. Alleles that co-occur at expected frequencies are said to be in "linkage equilibrium". In contrast, LD refers to any non-random genetic association between allele(s) at two or more different SNP sites, which is generally due to the physical proximity of the two loci along a chromosome. LD can occur when two or more SNPs sites are in close physical proximity to each other on a given chromosome and therefore alleles at these SNP sites will tend to remain unseparated for multiple generations with the

consequence that a particular nucleotide (allele) at one SNP site will show a non-random association with a particular nucleotide (allele) at a different SNP site located nearby. Hence, genotyping one of the SNP sites will give almost the same information as genotyping the other SNP site that is in LD.

[0201] Various degrees of LD can be encountered between two or more SNPs with the result being that some SNPs are more closely associated (i.e., in stronger LD) than others. Furthermore, the physical distance over which LD extends along a chromosome differs between different regions of the genome, and therefore the degree of physical separation between two or more SNP sites necessary for LD to occur can differ between different regions of the genome.

[0202] For diagnostic purposes and similar uses, if a particular SNP site is found to be useful for, for example, predicting an individual's susceptibility to an acute coronary event or an individual's response to statin treatment, then the skilled artisan would recognize that other SNP sites which are in LD with this SNP site would also be useful for predicting an individual's response to statin treatment. Various degrees of LD can be encountered between two or more SNPs with the result being that some SNPs are more closely associated (i.e., in stronger LD) than others. Furthermore, the physical distance over which LD extends along a chromosome differs between different regions of the genome, and therefore the degree of physical separation between two or more SNP sites necessary for LD to occur can differ between different regions of the genome. Thus, polymorphisms (e.g., SNPs and/or haplotypes) that are not the actual disease-causing (causative) polymorphisms, but are in LD with such causative polymorphisms, are also useful. In such instances, the genotype of the polymorphism(s) that is/are in LD with the causative polymorphism is predictive of the genotype of the causative polymorphism and, consequently, predictive of the phenotype (e.g., responder/non-responder to statin treatment) that is influenced by the causative SNP(s). Therefore, polymorphic markers that are in LD with causative polymorphisms are useful as diagnostic markers, and are particularly useful when the actual causative polymorphism(s) is/are unknown.

[0203] Examples of polymorphisms that can be in LD with one or more causative polymorphisms (and/or in LD with one or more polymorphisms that have a significant statistical association with a condition) and therefore useful for diagnosing the same condition that the causative/associated SNP(s) is used to diagnose, include, for example, other SNPs in the same gene, protein-coding, or mRNA transcript-coding region as the causative/associated SNP, other SNPs in the same exon or same intron as the causative/associated SNP, other SNPs in the same haplotype block as the causative/associated SNP, other SNPs in the same intergenic region as the causative/associated SNP, SNPs that are outside but near a gene (e.g., within 6kb on either side, 5' or 3', of a gene boundary) that harbors a causative/associated SNP, etc.

[0204] Linkage disequilibrium in the human genome is reviewed in: Wall et al., "Haplotype blocks and linkage disequilibrium in the human genome", *Nat Rev Genet.* 2003 Aug;4(8):587-97; Garner et al., "On selecting markers for association studies: patterns of linkage disequilibrium between two and three diallelic loci", *Genet Epidemiol.* 2003 Jan; 24(1):57-67; Ardlie et al., "Patterns of linkage disequilibrium in the human genome", *Nat Rev Genet.* 2002 Apr;3 (4): 299-309 (erratum in *Nat Rev Genet* 2002 Jul;3(7):566); and Remm et al., "High-density genotyping and linkage disequilibrium in the human genome using chromosome 22 as a model", *Curr Opin Chem Biol.* 2002 Feb;6(1):24-30; Haldane JBS (1919) The combination of linkage values, and the calculation of distances between the loci of linked factors. *J Genet* 8:299-309; Mendel, G. (1866) Versuche über Pflanzen-Hybriden. *Verhandlungen des naturforschenden Vereines in Brünn* [Proceedings of the Natural History Society of Brünn]; Lewin B (1990) *Genes IV*. Oxford University Press, New York, USA; Hartl DL and Clark AG (1989) *Principles of Population Genetics* 2nd ed Sinauer Associates, Inc. Sunderland, Mass., USA; Gillespie JH (2004) *Population Genetics: A Concise Guide*. 2nd ed Johns Hopkins University Press. USA; Lewontin RC (1964) The interaction of selection and linkage. I. General considerations; heterotic models. *Genetics* 49: 49-67; Hoel PG (1954) *Introduction to Mathematical Statistics* 2nd ed. John Wiley & Sons, Inc. New York, USA; Hudson RR (2001) Two-locus sampling distributions and their application. *Genetics* 159:1805-1817; Dempster AP, Laird NM, Rubin DB (1977) Maximum likelihood from incomplete data via the EM algorithm. *J R Stat Soc* 39:1-38; Excoffier L, Slatkin M (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. *Mol Biol Evol* 12(5):921-927; Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL (2004) A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. *Ann Hum Genet* 68(Pt 2):165-177; Long AD and Langley CH (1999) The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits. *Genome Research* 9:720-731; Agresti A (1990) *Categorical Data Analysis*. John Wiley & Sons, Inc. New York, USA; Lange K (1997) *Mathematical and Statistical Methods for Genetic Analysis*. Springer-Verlag New York, Inc. New York, USA; The International HapMap Consortium (2003) The International HapMap Project. *Nature* 426:789-796; The International HapMap Consortium (2005) A haplotype map of the human genome. *Nature* 437:1299-1320; Thorisson GA, Smith AV, Krishnan L, Stein LD (2005), The International HapMap Project Web Site. *Genome Research* 15:1591-1593; McVean G, Spencer CCA, Chaix R (2005) Perspectives on human genetic variation from the HapMap project. *PLoS Genetics* 1 (4):413-418; Hirschhorn JN, Daly MJ (2005) Genome-wide association studies for common diseases and complex traits. *Nat Genet* 6:95-108; Schrodin SJ (2005) A probabilistic approach to large-scale association scans: a semi-Bayesian method to detect disease-predisposing alleles. *SAGMB* 4(1):31; Wang WYS, Barratt BJ, Clayton DG, Todd JA (2005) Genome-wide association studies: theoretical and practical concerns. *Nat Rev Genet* 6:109-118. Pritchard JK, Przeworski

M (2001) Linkage disequilibrium in humans: models and data. Am J Hum Genet 69:1-14.

[0205] As discussed above, the discovery that SNPs which are in certain LD distance with the interrogated SNP can also be used as valid markers for identifying an increased or decreased risks of having or developing CHD. As used herein, the term "interrogated SNP" refers to a SNP that has been found to be associated with an increased or decreased risk of disease using genotyping results and analysis, or other appropriate experimental method as exemplified in the working examples described in this application. As used herein, the term "LD SNP" refers to a SNP that has been characterized as a SNP associating with an increased or decreased risk of diseases due to their being in LD with the "interrogated SNP" under the methods of calculation described in the application. Below, applicants describe the methods of calculation with which one of ordinary skilled in the art may determine if a particular SNP is in LD with an interrogated SNP. The parameter r^2 is commonly used in the genetics art to characterize the extent of linkage disequilibrium between markers (Hudson, 2001). As used herein, the term "in LD with" refers to a particular SNP that is measured at above the threshold of a parameter such as r^2 with an interrogated SNP.

[0206] It is now common place to directly observe genetic variants in a sample of chromosomes obtained from a population. Suppose one has genotype data at two genetic markers located on the same chromosome, for the markers A and B. Further suppose that two alleles segregate at each of these two markers such that alleles A_1 and A_2 can be found at marker A and alleles B_1 and B_2 at marker B. Also assume that these two markers are on a human autosome. If one is to examine a specific individual and find that they are heterozygous at both markers, such that their two-marker genotype is $A_1A_2B_1B_2$, then there are two possible configurations: the individual in question could have the alleles A_1B_1 on one chromosome and A_2B_2 on the remaining chromosome; alternatively, the individual could have alleles A_1B_2 on one chromosome and A_2B_1 on the other. The arrangement of alleles on a chromosome is called a haplotype. In this illustration, the individual could have haplotypes A_1B_1/A_2B_2 or A_1B_2/A_2B_1 (see Hartl and Clark (1989) for a more complete description). The concept of linkage equilibrium relates the frequency of haplotypes to the allele frequencies.

[0207] Assume that a sample of individuals is selected from a larger population. Considering the two markers described above, each having two alleles, there are four possible haplotypes: A_1B_1 , A_1B_2 , A_2B_1 and A_2B_2 . Denote the frequencies of these four haplotypes with the following notation.

$$P_{11} = \text{freq}(A_1B_1) \quad (1)$$

$$P_{12} = \text{freq}(A_1B_2) \quad (2)$$

$$P_{21} = \text{freq}(A_2B_1) \quad (3)$$

$$P_{22} = \text{freq}(A_2B_2) \quad (4)$$

[0208] The allele frequencies at the two markers are then the sum of different haplotype frequencies, it is straightforward to write down a similar set of equations relating single-marker allele frequencies to two-marker haplotype frequencies:

$$p_1 = \text{freq}(A_1) = P_{11} + P_{12} \quad (5)$$

$$p_2 = \text{freq}(A_2) = P_{21} + P_{22} \quad (6)$$

$$q_1 = \text{freq}(B_1) = P_{11} + P_{21} \quad (7)$$

$$q_2 = \text{freq}(B_2) = P_{12} + P_{22} \quad (8)$$

[0209] Note that the four haplotype frequencies and the allele frequencies at each marker must sum to a frequency of 1.

$$P_{11} + P_{12} + P_{21} + P_{22} = 1 \quad (9)$$

$$p_1 + p_2 = 1 \quad (10)$$

$$q_1 + q_2 = 1 \quad (11)$$

[0210] If there is no correlation between the alleles at the two markers, one would expect that the frequency of the haplotypes would be approximately the product of the composite alleles. Therefore,

$$P_{11} \approx p_1 q_1 \quad (12)$$

$$P_{12} \approx p_1 q_2 \quad (13)$$

$$P_{21} \approx p_2 q_1 \quad (14)$$

$$P_{22} \approx p_2 q_2 \quad (15)$$

[0211] These approximating equations (12)-(15) represent the concept of linkage equilibrium where there is independent assortment between the two markers - the alleles at the two markers occur together at random. These are represented as approximations because linkage equilibrium and linkage disequilibrium are concepts typically thought of as properties of a sample of chromosomes; and as such they are susceptible to stochastic fluctuations due to the sampling process. Empirically, many pairs of genetic markers will be in linkage equilibrium, but certainly not all pairs.

[0212] Having established the concept of linkage equilibrium above, applicants can now describe the concept of linkage disequilibrium (LD), which is the deviation from linkage equilibrium. Since the frequency of the $A_1 B_1$ haplotype is approximately the product of the allele frequencies for A_1 and B_1 under the assumption of linkage equilibrium as stated mathematically in (12), a simple measure for the amount of departure from linkage equilibrium is the difference in these two quantities, D ,

$$D = P_{11} - p_1 q_1 \quad (16)$$

[0213] $D = 0$ indicates perfect linkage equilibrium. Substantial departures from $D = 0$ indicates LD in the sample of chromosomes examined. Many properties of D are discussed in Lewontin (1964) including the maximum and minimum values that D can take. Mathematically, using basic algebra, it can be shown that D can also be written solely in terms of haplotypes:

$$D = P_{11}P_{22} - P_{12}P_{21} \quad (17)$$

[0214] If one transforms D by squaring it and subsequently dividing by the product of the allele frequencies of A_1 , A_2 , B_1 and B_2 , the resulting quantity, called r^2 , is equivalent to the square of the Pearson's correlation coefficient commonly used in statistics (e.g. Hoel, 1954).

$$r^2 = \frac{D^2}{P_1 P_2 q_1 q_2} \quad (18)$$

[0215] As with D , values of r^2 close to 0 indicate linkage equilibrium between the two markers examined in the sample set. As values of r^2 increase, the two markers are said to be in linkage disequilibrium. The range of values that r^2 can

take are from 0 to 1. $r^2 = 1$ when there is a perfect correlation between the alleles at the two markers.

[0216] In addition, the quantities discussed above are sample-specific. And as such, it is necessary to formulate notation specific to the samples studied. In the approach discussed here, three types of samples are of primary interest: (i) a sample of chromosomes from individuals affected by a disease-related phenotype (cases), (ii) a sample of chromosomes obtained from individuals not affected by the disease-related phenotype (controls), and (iii) a standard sample set used for the construction of haplotypes and calculation pairwise linkage disequilibrium. For the allele frequencies used in the development of the method described below, an additional subscript will be added to denote either the case or control sample sets.

$$p_{1,c} = \text{freq}(A_1 \text{ in cases}) \quad (19)$$

$$p_{2,c} = \text{freq}(A_2 \text{ in cases}) \quad (20)$$

$$q_{1,c} = \text{freq}(B_1 \text{ in cases}) \quad (21)$$

$$q_{2,c} = \text{freq}(B_2 \text{ in cases}) \quad (22)$$

[0217] Similarly,

$$p_{1,c} = \text{freq}(A_1 \text{ in controls}) \quad (23)$$

$$p_{2,c} = \text{freq}(A_2 \text{ in controls}) \quad (24)$$

$$q_{1,c} = \text{freq}(B_1 \text{ in controls}) \quad (25)$$

$$q_{2,c} = \text{freq}(B_2 \text{ in controls}) \quad (26)$$

[0218] As a well-accepted sample set is necessary for robust linkage disequilibrium calculations, data obtained from the International HapMap project (The International HapMap Consortium 2003, 2005; Thorisson et al, 2005; McVean et al, 2005) can be used for the calculation of pairwise r^2 values. Indeed, the samples genotyped for the International HapMap Project were selected to be representative examples from various human sub-populations with sufficient numbers of chromosomes examined to draw meaningful and robust conclusions from the patterns of genetic variation observed. The International HapMap project website (hapmap.org) contains a description of the project, methods utilized and samples examined. It is useful to examine empirical data to get a sense of the patterns present in such data.

[0219] Haplotype frequencies were explicit arguments in equation (18) above. However, knowing the 2-marker haplotype frequencies requires that phase to be determined for doubly heterozygous samples. When phase is unknown in the data examined, various algorithms can be used to infer phase from the genotype data. This issue was discussed earlier where the doubly heterozygous individual with a 2-SNP genotype of $A_1A_2B_1B_2$ could have one of two different sets of chromosomes: A_1B_1/A_2B_2 or A_1B_2/A_2B_1 . One such algorithm to estimate haplotype frequencies is the expectation-maximization (EM) algorithm first formalized by Dempster et al (1977). This algorithm is often used in genetics to infer haplotype frequencies from genotype data (e.g. Excoffier and Slatkin, 1995; Tregouet et al, 2004). It should be noted that for the two-SNP case explored here, EM algorithms have very little error provided that the allele frequencies and sample sizes are not too small. The impact on r^2 values is typically negligible.

[0220] As correlated genetic markers share information, interrogation of SNP markers in LD with a disease-associated SNP marker can also have sufficient power to detect disease association (Long and Langley, 1999). The relationship between the power to directly find disease-associated alleles and the power to indirectly detect disease-association was investigated by Pritchard and Przeworski (2001). In a straight-forward derivation, it can be shown that the power to detect disease association indirectly at a marker locus in linkage disequilibrium with a disease-association locus is approximately the same as the power to detect disease-association directly at the disease- association locus if the sample size is

increased by a factor of $\frac{1}{r^2}$ (the reciprocal of equation 18) at the marker in comparison with the disease- association locus.

[0221] Therefore, if one calculated the power to detect disease-association indirectly with an experiment having N samples, then equivalent power to directly detect disease-association (at the actual disease-susceptibility locus) would necessitate an experiment using approximately $r^2 N$ samples. This elementary relationship between power, sample size and linkage disequilibrium can be used to derive an r^2 threshold value useful in determining whether or not genotyping markers in linkage disequilibrium with a SNP marker directly associated with disease status has enough power to indirectly detect disease-association.

[0222] To commence a derivation of the power to detect disease-associated markers through an indirect process, define the effective chromosomal sample size as

$$n = \frac{4N_{cs}N_{ct}}{N_{cs} + N_{ct}}; \quad (27)$$

where N_{cs} and N_{ct} are the numbers of diploid cases and controls, respectively. This is necessary to handle situations where the numbers of cases and controls are not equivalent. For equal case and control sample sizes, $N_{cs} = N_{ct} = N$, the value of the effective number of chromosomes is simply $n = 2N$ - as expected. Let power be calculated for a significance level α (such that traditional P-values below α will be deemed statistically significant). Define the standard Gaussian distribution function as $\Phi(\bullet)$. Mathematically,

$$\Phi(x) = \frac{1}{\sqrt{2\pi}} \int_{-\infty}^x e^{-\frac{\theta^2}{2}} d\theta \quad (28)$$

[0223] Alternatively, the following error function notation (Erf) may also be used,

$$\Phi(x) = \frac{1}{2} \left[1 + \text{Erf} \left(\frac{x}{\sqrt{2}} \right) \right] \quad (29)$$

[0224] For example, $\Phi(1.644854) = 0.95$. The value of r^2 may be derived to yield a pre-specified minimum amount of power to detect disease association though indirect interrogation. Noting that the LD SNP marker could be the one that is carrying the disease- association allele, therefore that this approach constitutes a lower-bound model where all indirect power results are expected to be at least as large as those interrogated.

[0225] Denote by β the error rate for not detecting truly disease-associated markers. Therefore, $1 - \beta$ is the classical definition of statistical power. Substituting the Pritchard-Pzeworski result into the sample size, the power to detect disease association at a significance level of α is given by the approximation

$$1 - \beta \cong \Phi \left[\frac{|q_{1,cs} - q_{1,ct}|}{\sqrt{\frac{q_{1,cs}(1 - q_{1,cs}) + q_{1,ct}(1 - q_{1,ct})}{r^2 n}}} - Z_{1-\alpha/2} \right]; \quad (30)$$

where Z_u is the inverse of the standard normal cumulative distribution evaluated at u ($u \in (0,1)$). $Z_u = \Phi^{-1}(u)$, where Φ

($\Phi^{-1}(u) = \Phi^{-1}(\Phi(u)) = u$). For example, setting $\alpha = 0.05$, and therefore $1 - \frac{\alpha}{2} = 0.975$, we obtain $Z_{0.975} = 1.95996$.

Next, setting power equal to a threshold of a minimum power of T ,

$$T = \Phi \left[\frac{|q_{1,c} - q_{1,c}|}{\sqrt{\frac{q_{1,c}(1-q_{1,c}) + q_{1,c}(1-q_{1,c})}{r^2 n}}} - Z_{1-\alpha/2} \right] \quad (31)$$

and solving for r^2 , the following threshold r^2 is obtained:

$$r_T^2 = \frac{[q_{1,c}(1-q_{1,c}) + q_{1,c}(1-q_{1,c})]}{n(q_{1,c} - q_{1,c})^2} \left[\Phi^{-1}(T) + Z_{1-\alpha/2} \right] \quad (32)$$

[0226] Or,

$$r_T^2 = \left(\frac{Z_T + Z_{1-\alpha/2}}{n} \right) \left[\frac{q_{1,c} - (q_{1,c})^2 + q_{1,c} - (q_{1,c})^2}{(q_{1,c} - q_{1,c})^2} \right] \quad (33)$$

[0227] Suppose that r^2 is calculated between an interrogated SNP and a number of other SNPs with varying levels of

LD with the interrogated SNP. The threshold value r_T^2 is the minimum value of linkage disequilibrium between the interrogated SNP and the potential LD SNPs such that the LD SNP still retains a power greater or equal to T for detecting disease-association. For example, suppose that SNP rs200 is genotyped in a case-control disease-association study and it is found to be associated with a disease phenotype. Further suppose that the minor allele frequency in 1,000 case chromosomes was found to be 16% in contrast with a minor allele frequency of 10% in 1,000 control chromosomes. Given those measurements one could have predicted, prior to the experiment, that the power to detect disease association at a significance level of 0.05 was quite high - approximately 98% using a test of allelic association. Applying equation (32) one can calculate a minimum value of r^2 to indirectly assess disease association assuming that the minor allele at SNP rs200 is truly disease-predisposing for a threshold level of power. If one sets the threshold level of power to be

80%, then $r_T^2 = 0.489$ given the same significance level and chromosome numbers as above. Hence, any SNP with a pairwise r^2 value with rs200 greater than 0.489 is expected to have greater than 80% power to detect the disease association. Further, this is assuming the conservative model where the LD SNP is disease-associated only through linkage disequilibrium with the interrogated SNP rs200.

[0228] The contribution or association of particular SNPs and/or SNP haplotypes with disease phenotypes, such as susceptibility to acute coronary events or responsiveness to statin treatment, enables the SNP disclosed herein to be used to develop superior diagnostic tests capable of identifying individuals who express a detectable trait, such as predisposition to acute coronary events or responder/non-responder to statin treatment, as the result of a specific genotype, or individuals whose genotype places them at an increased or decreased risk of developing a detectable trait at a subsequent time as compared to individuals who do not have that genotype. For reference only, as described herein, diagnostics may be based on a single SNP or a group of SNPs. Combined detection of a plurality of SNPs (for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 25, 30, 32, 48, 50, 64, 96, 100, or any other number in-between, or more, of the SNPs provided in Tables disclosed herein) typically increases the probability of an accurate diagnosis. For example, the presence of a single SNP known to correlate with response to statin treatment might indicate a probability of 20% that an individual will respond to statin treatment, whereas detection of five SNPs, each of which correlates with response to statin treatment, might indicate a probability of 80% that an individual will respond to statin treatment. To further increase the accuracy of diagnosis or predisposition screening, analysis of the SNP used in the method of the present invention can be combined with that of other polymorphisms or other risk factors that correlate with response to statin treatment, such as family history.

[0229] It will, of course, be understood by practitioners skilled in the treatment or diagnosis of cardiovascular disorders that the present invention generally does not intend to provide an absolute identification of individuals who will or will not experience a myocardial infarction or develop another cardiovascular disorder, or those individuals who will or will not respond to HMG-CoA reductase inhibitor treatment for reducing the risk of having a myocardial infarction, but rather

to indicate a certain increased (or decreased) degree or likelihood of responding to HMG-CoA reductase inhibitor treatment based on statistically significant association results.

[0230] However, this information is extremely valuable as it can, for example, indicate that an individual having a risk of having a myocardial infarction should follow a particular HMG-CoA reductase inhibitor based treatment regimen, or should follow an alternative treatment regimen that does not involve HMG-CoA reductase inhibitor. This information can also be used to initiate preventive treatments or to allow an individual carrying one or more significant SNPs or SNP haplotypes to foresee warning signs such as minor clinical symptoms of cardiovascular disease, or to have regularly scheduled physical exams to monitor for cardiovascular disorders in order to identify and begin treatment of the disorder at an early stage. Particularly with diseases that are extremely debilitating or fatal if not treated on time, the knowledge of a potential predisposition to the disease or likelihood of responding to available treatments, even if this predisposition or likelihood is not absolute, would likely contribute in a very significant manner to treatment efficacy.

[0231] The diagnostic techniques described herein may employ a variety of methodologies to determine whether a test subject has a SNP or a SNP pattern associated with an increased or decreased risk of developing a detectable trait or whether the individual suffers from a detectable trait as a result of a particular polymorphism/mutation, including, for example, methods which enable the analysis of individual chromosomes for haplotyping, family studies, single sperm DNA analysis, or somatic hybrids. The trait analyzed using the diagnostics described herein may be any detectable trait that is commonly observed in myocardial infarction or during the course of HMG-CoA reductase inhibitor treatment.

[0232] Another aspect of the present invention relates to a method of determining whether an individual has an altered risk of developing myocardial infarction as a consequence of possessing a SNP at position 101 of SEQ ID NO:5. These methods generally involve obtaining a nucleic acid sample from an individual and assaying the nucleic acid sample to determine which nucleotide(s) is/are present at SNP position 101 of SEQ ID NO:5 wherein the assayed nucleotide(s) is/are indicative of an increased or decreased risk of developing myocardial infarction as a result of possessing a G at position 101 of SEQ ID NO:5 or the presence of C at position 101 of its complement.

[0233] In another embodiment, the SNP detection reagent for use in the method of the present invention are used to determine whether an individual has a SNP allele affecting the level (e.g., the concentration of mRNA or protein in a sample, etc.) or pattern (e.g., the kinetics of expression, rate of decomposition, stability profile, Km, Vmax, etc.) of gene expression (collectively, the "gene response" of a cell or bodily fluid). Such a determination can be accomplished by screening for mRNA or protein expression (e.g., by using nucleic acid arrays, RT-PCR, TaqMan assays, or mass spectrometry), identifying genes having altered expression in an individual, genotyping the SNP disclosed in Table 1 and/or Table 2 that could affect the expression of the genes having altered expression (e.g., SNP that is in and/or around the gene(s) having altered expression, SNPs in regulatory/control region or SNP in and/or around other genes that are involved in pathways that could affect the expression of the gene(s) having altered expression.), and correlating SNP genotype with altered gene expression. In this manner, a specific SNP allele at a particular SNP site can be identified that affect gene expression.

PHARMACOGENOMICS AND THERAPEUTICS/ DRUG DEVELOPMENT

[0234] Described herein are methods for assessing the pharmacogenomics of a subject harboring particular SNP alleles or haplotypes to a particular therapeutic agent or pharmaceutical compound, or to a class of such compounds. Pharmacogenomics deals with the roles which clinically significant hereditary variations (e.g., SNPs) play in the response to drugs due to altered drug disposition and/or abnormal action in affected persons. See, e.g., Roses, *Nature* 405, 857.-865 (2000); Gould Rothberg, *Nature Biotechnology* 19, 209-211 (2001); Eichelbaum, *Clin. Exp. Pharmacol. Physiol.* 23 (10-11):983-985 (1996); and Linder, *Clin. Chem.* 43(2):254-266 (1997). The clinical outcomes of these variations can result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the SNP genotype of an individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. For example, SNPs in drug metabolizing enzymes can affect the activity of these enzymes, which in turn can affect both the intensity and duration of drug action, as well as drug metabolism and clearance.

[0235] The discovery of SNPs in drug metabolizing enzymes, drug transporters, proteins for pharmaceutical agents, and other drug targets has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. SNPs can be expressed in the phenotype of the extensive metabolizer and in the phenotype of the poor metabolizer. Accordingly, SNPs may lead to allelic variants of a protein in which one or more of the protein functions in one population are different from those in another population. SNPs and the encoded variant peptides thus provide targets to ascertain a genetic predisposition that can affect treatment modality. For example, in a ligand-based treatment, SNPs may give rise to amino terminal extracellular domains and/or other ligand-binding regions of a receptor-that are more or less active in ligand binding, thereby affecting subsequent protein activation. Accordingly, ligand dosage would necessarily be modified to maximize the therapeutic effect within a given population containing particular SNP alleles or haplotypes.

[0236] As an alternative to genotyping, specific variant proteins containing variant amino acid sequences encoded by alternative SNP alleles could be identified. Thus, pharmacogenomic characterization of an individual permits the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic uses based on the individual's SNP genotype, thereby enhancing and optimizing the effectiveness of the therapy. Furthermore, the production of recombinant cells and transgenic animals containing particular SNPs/haplotypes allow effective clinical design and testing of treatment compounds and dosage regimens. For example, transgenic animals can be produced that differ only in specific SNP alleles in a gene that is orthologous to a human disease susceptibility gene.

[0237] Pharmacogenomic uses of the SNP used in the method of the present invention provide several significant advantages for patient care, particularly in predicting an individual's predisposition to myocardial infarction and in predicting an individual's responsiveness to the use of HMG-CoA reductase inhibitor for treating myocardial infarction. Pharmacogenomic characterization of an individual, based on an individual's SNP genotype, can identify those individuals unlikely to respond to treatment with a particular medication and thereby allows physicians to avoid prescribing the ineffective medication to those individuals. On the other hand, SNP genotyping of an individual may enable physicians to select the appropriate medication and dosage regimen that will be most effective based on an individual's SNP genotype. This information increases a physician's confidence in prescribing medications and motivates patients to comply with their drug regimens. Furthermore, pharmacogenomics may identify patients predisposed to toxicity and adverse reactions to particular drugs or drug dosages. Adverse drug reactions lead to more than 100,000 avoidable deaths per year in the United States alone and therefore represent a significant cause of hospitalization and death, as well as a significant economic burden on the healthcare system (Pfoest et al., Trends in Biotechnology, Aug. 2000.). Thus, pharmacogenomics based on the SNPs disclosed herein has the potential to both save lives and reduce healthcare costs substantially.

[0238] Pharmacogenomics in general is discussed further in Rose et al., "Pharmacogenetic analysis of clinically relevant genetic polymorphisms", Methods Mol Med. 2003;85:225-37. Pharmacogenomics as it relates to Alzheimer's disease and other neurodegenerative disorders is discussed in Cacabelos, "Pharmacogenomics for the treatment of dementia", Ann Med. 2002;34(5):357-79, Maimone et al., "Pharmacogenomics of neurodegenerative diseases", Eur J Pharmacol. 2001 Feb 9;413(1):11-29, and Poirier, "Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease", Mol Diagn. 1999 Dec;4(4):335-41. Pharmacogenomics as it relates to cardiovascular disorders is discussed in Siest et al., "Pharmacogenomics of drugs affecting the cardiovascular system", Clin Chem Lab Med. 2003 Apr;41(4):590-9, Mukherjee et al., "Pharmacogenomics in cardiovascular diseases", Prog Cardiovasc Dis. 2002 May-Jun;44(6):479-98, and Mooser et al., "Cardiovascular pharmacogenetics in the SNP era", J Thromb Haemost. 2003 Jul;1(7):1398-402. Pharmacogenomics as it relates to cancer is discussed in McLeod et al., "Cancer pharmacogenomics: SNPs, chips, and the individual patient". Cancer Invest. 2003;21(4):630-40 and Watters et al., "Cancer pharmacogenomics: current and future applications", Biochim Biophys Acta. 2003 Mar 17;1603(2):99-111.

[0239] The SNP described herein also can be used to identify novel therapeutic targets for cardiovascular disorders. For example, genes containing the disease-associated variants ("variant genes") or their products, as well as genes or their products that are directly or indirectly regulated by or interacting with these variant genes or their products, can be targeted for the development of therapeutics that, for example, treat the disease or prevent or delay disease onset. The therapeutics may be composed of, for example, small molecules, proteins, protein fragments or peptides, antibodies, nucleic acids, or their derivatives or mimetics which modulate the functions or levels of the target genes or gene products.

[0240] The SNP-containing nucleic acid molecules disclosed herein, and their complementary nucleic acid molecules, may be used as antisense constructs to control gene expression in cells, tissues, and organisms. Antisense technology is well established in the art and extensively reviewed in Antisense Drug Technology: Principles, Strategies, and Applications, Crooke (ed.), Marcel Dekker, Inc.: New York (2001). An antisense nucleic acid molecule is generally designed to be complementary to a region of mRNA expressed by a gene so that the antisense molecule hybridizes to the mRNA and thereby blocks translation of mRNA into protein. Various classes of antisense oligonucleotides are used in the art, two of which are cleavers and blockers. Cleavers, by binding to target RNAs, activate intracellular nucleases (e.g., RNaseH or RNase L) that cleave the target RNA. Blockers, which also bind to target RNAs, inhibit protein translation through steric hindrance of ribosomes. Exemplary blockers include peptide nucleic acids, morpholinos, locked nucleic acids, and methylphosphonates (see, e.g., Thompson, Drug Discovery Today, 7 (17): 912-917 (2002)). Antisense oligonucleotides are directly useful as therapeutic agents, and are also useful for determining and validating gene function (e.g., in gene knock-out or knock-down experiments).

[0241] Antisense technology is further reviewed in: Lavery et al., "Antisense and RNAi: powerful tools in drug target discovery and validation", Curr Opin Drug Discov Devel. 2003 Jul;6(4):561-9; Stephens et al., "Antisense oligonucleotide therapy in cancer", Curr Opin Mol Ther. 2003 Apr;5(2):118-22; Kurreck, "Antisense technologies. Improvement through novel chemical modifications.", Eur J Biochem. 2003 Apr;270(8): 1628-44; Dias et al., "Antisense oligonucleotides: basic concepts and mechanisms", Mol Cancer Ther. 2002 Mar;1(5):347-55; Chen, "Clinical development of antisense oligonucleotides as anti-cancer therapeutics", Methods Mol Med. 2003;75:621-36; Wang et al., "Antisense anticancer oligonucleotide therapeutics", Curr Cancer Drug Targets. 2001 Nov;1(3):177-96; and Bennett, "Efficiency of antisense oligo-

nucleotide drug discovery", *Antisense Nucleic Acid Drug Dev.* 2002 Jun;12(3):215-24.

[0242] The SNP described herein are particularly useful for designing antisense reagents that are specific for particular nucleic acid variants. Based on the SNP information disclosed herein, antisense oligonucleotides can be produced that specifically target mRNA molecules that contain one or more particular SNP nucleotides. In this manner, expression of mRNA molecules that contain one or more undesired polymorphisms (e.g., SNP nucleotides that lead to a defective protein such as an amino acid substitution in a catalytic domain) can be inhibited or completely blocked. Thus, antisense oligonucleotides can be used to specifically bind a particular polymorphic form (e.g., a SNP allele that encodes a defective protein), thereby inhibiting translation of this form, but which do not bind an alternative polymorphic form (e.g., an alternative SNP nucleotide that encodes a protein having normal function).

[0243] Antisense molecules can be used to inactivate mRNA in order to inhibit gene expression and production of defective proteins. Accordingly, these molecules can be used to treat a disorder, such as a cardiovascular disorder, characterized by abnormal or undesired gene expression or expression of certain defective proteins. This technique can involve cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible mRNA regions include, for example, protein-coding regions and particularly protein-coding regions corresponding to catalytic activities, substrate/ligand binding, or other functional activities of a protein.

[0244] The SNP described herein are also useful for designing RNA interference reagents that specifically target nucleic acid molecules having a particular SNP variant. RNA interference (RNAi), also referred to as gene silencing, is based on using double-stranded RNA (dsRNA) molecules to turn genes off. When introduced into a cell, dsRNAs are processed by the cell into short fragments (generally about 21, 22, or 23 nucleotides in length) known as small interfering RNAs (siRNAs) which the cell uses in a sequence-specific manner to recognize and destroy complementary RNAs (Thompson, *Drug Discovery Today*, 7 (17): 912-917 (2002)).

[0245] Described herein are isolated nucleic acid molecules that are about 18-26 nucleotides in length, preferably 19-25 nucleotides in length, and more preferably 20, 21, 22, or 23 nucleotides in length, and the use of these nucleic acid molecules for RNAi. Because RNAi molecules, including siRNAs, act in a sequence-specific manner, the SNP described herein can be used to design RNAi reagents that recognize and destroy nucleic acid molecules having specific SNP alleles/nucleotides (such as deleterious alleles that lead to the production of defective proteins), while not affecting nucleic acid molecules having alternative SNP alleles (such as alleles that encode proteins having normal function). As with antisense reagents, RNAi reagents may be directly useful as therapeutic agents (e.g., for turning off defective, disease-causing genes), and are also useful for characterizing and validating gene function (e.g., in gene knock-out or knock-down experiments).

[0246] The following references provide a further review of RNAi: Reynolds et al., "Rational siRNA design for RNA interference", *Nat Biotechnol.* 2004 Mar;22(3):326-30. Epub 2004 Feb 01; Chi et al., "Genomewide view of gene silencing by small interfering RNAs", *PNAS* 100(11):6343-6346, 2003; Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents", *J. Biol. Chem.* 278: 7108-7118, 2003; Agami, "RNAi and related mechanisms and their potential use for therapy", *Curr Opin Chem Biol.* 2002 Dec;6(6):829-34; Lavery et al., "Antisense and RNAi: powerful tools in drug target discovery and validation", *Curr Opin Drug Discov Devel.* 2003 Jul;6(4):561-9; Shi, "Mammalian RNAi for the masses", *Trends Genet* 2003 Jan;19(1):9-12; Shuey et al., "RNAi: gene-silencing in therapeutic intervention", *Drug Discovery Today* 2002 Oct;7(20):1040-1046; McManus et al., *Nat Rev Genet* 2002 Oct;3(10):737-47; Xia et al., *Nat Biotechnol* 2002 Oct;20(10):1006-10; Plasterk et al., *Curr Opin Genet Dev* 2000 Oct;10(5):562-7; Bosher et al., *Nat Cell Biol* 2000 Feb;2(2):E31-6; and Hunter, *Curr Biol* 1999 Jun 17;9(12):R440-2).

[0247] A subject suffering from a pathological condition, such as a cardiovascular disorder, ascribed to a SNP may be treated so as to correct the genetic defect (see Kren et al., *Proc. Natl. Acad. Sci. USA* 96:10349-10354 (1999)). Such a subject can be identified by any method that can detect the polymorphism in a biological sample drawn from the subject. Such a genetic defect may be permanently corrected by administering to such a subject a nucleic acid fragment incorporating a repair sequence that supplies the normal/wild-type nucleotide at the position of the SNP. This site-specific repair sequence can encompass an RNA/DNA oligonucleotide that operates to promote endogenous repair of a subject's genomic DNA. The site-specific repair sequence is administered in an appropriate vehicle, such as a complex with polyethylenimine, encapsulated in anionic liposomes, a viral vector such as an adenovirus, or other pharmaceutical composition that promotes intracellular uptake of the administered nucleic acid. A genetic defect leading to an inborn pathology may then be overcome, as the chimeric oligonucleotides induce incorporation of the normal sequence into the subject's genome. Upon incorporation, the normal gene product is expressed, and the replacement is propagated, thereby engendering a permanent repair and therapeutic enhancement of the clinical condition of the subject.

[0248] In cases in which a cSNP results in a variant protein that is ascribed to be the cause of, or a contributing factor to, a pathological condition, a method of treating such a condition can include administering to a subject experiencing the pathology the wild-type/normal cognate of the variant protein. Once administered in an effective dosing regimen, the wild-type cognate provides complementation or remediation of the pathological condition.

[0249] Also described herein is a method for identifying a compound or agent that can be used to treat cardiovascular

disorders. The SNP disclosed herein is useful as targets for the identification and/or development of therapeutic agents. A method for identifying a therapeutic agent or compound typically includes assaying the ability of the agent or compound to modulate the activity and/or expression of a SNP-containing nucleic acid or the encoded product and thus identifying an agent or a compound that can be used to treat a disorder characterized by undesired activity or expression of the SNP-containing nucleic acid or the encoded product. The assays can be performed in cell-based and cell-free systems. Cell-based assays can include cells naturally expressing the nucleic acid molecules of interest or recombinant cells genetically engineered to express certain nucleic acid molecules.

[0250] Variant gene expression in a patient having a cardiovascular disorder or undergoing statin treatment can include, for example, either expression of a SNP-containing nucleic acid sequence (for instance, a gene that contains a SNP can be transcribed into an mRNA transcript molecule containing the SNP, which can in turn be translated into a variant protein) or altered expression of a normal/wild-type nucleic acid sequence due to one or more SNPs (for instance, a regulatory/control region can contain a SNP that affects the level or pattern of expression of a normal transcript).

[0251] Assays for variant gene expression can involve direct assays of nucleic acid levels (e.g., mRNA levels), expressed protein levels, or of collateral compounds involved in a signal pathway. Further, the expression of genes that are up- or down-regulated in response to the signal pathway can also be assayed. In this embodiment, the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

[0252] Modulators of variant gene expression can be identified in a method wherein, for example, a cell is contacted with a candidate compound/agent and the expression of mRNA determined. The level of expression of mRNA in the presence of the candidate compound is compared to the level of expression of mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of variant gene expression based on this comparison and be used to treat a disorder such as a cardiovascular disorder that is characterized by variant gene expression (e.g., either expression of a SNP-containing nucleic acid or altered expression of a normal/wild-type nucleic acid molecule due to one or more SNPs that affect expression of the nucleic acid molecule) due to a SNP described herein. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

[0253] Also, described herein is the use of a SNP or associated nucleic acid domain (e.g., catalytic domain, ligand/substrate-binding domain, regulatory/control region, etc.) or gene, or the encoded mRNA transcript, as a target, for preparing a compound for treating myocardial infarction, comprising using a compound identified through drug screening as a gene modulator to modulate variant nucleic acid expression. Modulation can include either up-regulation (i.e., activation or agonization) or down-regulation (i.e., suppression or antagonization) of nucleic acid expression.

[0254] Expression of mRNA transcripts and encoded proteins, either wild type or variant, may be altered in individuals with a particular SNP allele in a regulatory/control element, such as a promoter or transcription factor binding domain, that regulates expression. In this situation, methods of treatment and compounds can be identified, as discussed herein, that regulate or overcome the variant regulatory/control element, thereby generating normal, or healthy, expression levels of either the wild type or variant protein.

[0255] The SNP-containing nucleic acid molecule for use in the method of the present invention are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of a variant gene, or encoded product, in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as an indicator for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance, as well as an indicator for toxicities. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

[0256] Also, described herein is a pharmaceutical pack comprising a HMG-CoA reductase inhibitor and a set of instructions for administration of the HMG-CoA reductase inhibitor to humans diagnostically tested for the SNP at position 101 of SEQ ID NO:5 in the individual's nucleic acids. The SNP/haplotype for use in the method of the present invention is also useful for improving many different aspects of the drug development process. For instance, an aspect includes selecting individuals for clinical trials based on their SNP genotype. For example, individuals with SNP genotypes that indicate that they are likely to positively respond to a drug can be included in the trials, whereas those individuals whose SNP genotypes indicate that they are less likely to or would not respond to the drug, or who are at risk for suffering toxic effects or other adverse reactions, can be excluded from the clinical trials. This not only can improve the safety of clinical trials, but also can enhance the chances that the trial will demonstrate statistically significant efficacy. Furthermore, the SNP disclosed herein may explain why certain previously developed drugs performed poorly in clinical trials and may help identify a subset of the population that would benefit from a drug that had previously performed poorly in clinical trials, thereby "rescuing" previously developed drugs, and enabling the drug to be made available to a particular patient

population that can benefit from it.

[0257] SNPs have many important uses in drug discovery, screening, and development. A high probability exists that, for any gene/protein selected as a potential drug target, variants of that gene/protein will exist in a patient population. Thus, determining the impact of gene/protein variants on the selection and delivery of a therapeutic agent should be an integral aspect of the drug discovery and development process. (Jazwinska, *A Trends Guide to Genetic Variation and Genomic Medicine*, 2002 Mar; S30-S36).

[0258] Knowledge of variants (e.g., SNPs and any corresponding amino acid polymorphisms) of a particular therapeutic target (e.g., a gene, mRNA transcript, or protein) enables parallel screening of the variants in order to identify therapeutic candidates (e.g., small molecule compounds, antibodies, antisense or RNAi nucleic acid compounds, etc.) that demonstrate efficacy across variants (Rothberg, *Nat Biotechnol* 2001 Mar; 19(3):209-11). Such therapeutic candidates would be expected to show equal efficacy across a larger segment of the patient population, thereby leading to a larger potential market for the therapeutic candidate.

[0259] Furthermore, identifying variants of a potential therapeutic target enables the most common form of the target to be used for selection of therapeutic candidates, thereby helping to ensure that the experimental activity that is observed for the selected candidates reflects the real activity expected in the largest proportion of a patient population (Jazwinska, *A Trends Guide to Genetic Variation and Genomic Medicine*, 2002 Mar; S30-S36).

[0260] Additionally, screening therapeutic candidates against all known variants of a target can enable the early identification of potential toxicities and adverse reactions relating to particular variants. For example, variability in drug absorption, distribution, metabolism and excretion (ADME) caused by, for example, SNPs in therapeutic targets or drug metabolizing genes, can be identified, and this information can be utilized during the drug development process to minimize variability in drug disposition and develop therapeutic agents that are safer across a wider range of a patient population. The SNP disclosed herein including the variant proteins and encoding polymorphic nucleic acid molecules provided in Tables 1-2, are useful in conjunction with a variety of toxicology methods established in the art, such as those set forth in *Current Protocols in Toxicology*, John Wiley & Sons, Inc., N.Y.

[0261] Furthermore, therapeutic agents that target any art-known proteins (or nucleic acid molecules, either RNA or DNA) may cross-react with the variant proteins (or polymorphic nucleic acid molecules) disclosed in Table 1, thereby significantly affecting the pharmacokinetic properties of the drug. Consequently, the protein variants and the SNP-containing nucleic acid molecules disclosed in Tables 1-2 are useful in developing, screening, and evaluating therapeutic agents that target corresponding art-known protein forms (or nucleic acid molecules). Additionally, as discussed above, knowledge of all polymorphic forms of a particular drug target enables the design of therapeutic agents that are effective against most or all such polymorphic forms of the drug target.

PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION THEREOF

[0262] For reference only, any of the cardiovascular disease and/or statin response-associated proteins, and encoding nucleic acid molecules, disclosed herein can be used as therapeutic targets (or directly used themselves as therapeutic compounds) for the preparation of the pharmaceutical composition for treating cardiovascular disorder and related pathologies, and the present disclosure enables therapeutic compounds (e.g., small molecules, antibodies, therapeutic proteins, RNAi and antisense molecules, etc.) to be developed that target (or are comprised of) any of these therapeutic targets.

[0263] In general, a therapeutic compound will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The actual amount of the therapeutic compound described herein, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors.

[0264] Therapeutically effective amounts of therapeutic compounds may range from, for example, approximately 0.01-50 mg per kilogram body weight of the recipient per day; preferably about 0.1-20 mg/kg/day. Thus, as an example, for administration to a 70 kg person, the dosage range would most preferably be about 7 mg to 1.4 g per day.

[0265] In general, therapeutic compounds will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal, or by suppository), or parenteral (e.g., intramuscular, intravenous, or subcutaneous) administration. The preferred manner of administration is oral or parenteral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Oral compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.

[0266] The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills, or capsules are preferred) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area, i.e., decreasing particle

size. For example, U.S. Patent No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a cross-linked matrix of macromolecules. U.S. Patent No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.

[0267] Pharmaceutical compositions are comprised of, in general, a therapeutic compound in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are nontoxic, aid administration, and do not adversely affect the therapeutic benefit of the therapeutic compound. Such excipients may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one skilled in the art.

[0268] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.

[0269] Compressed gases may be used to disperse a compound described herein in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.

[0270] Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).

[0271] The amount of the therapeutic compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of the therapeutic compound based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80 wt %.

[0272] Therapeutic compounds can be administered alone or in combination with other therapeutic compounds or in combination with one or more other active ingredient(s). For example, an inhibitor or stimulator of a cardiovascular disorder-associated protein can be administered in combination with another agent that inhibits or stimulates the activity of the same or a different cardiovascular disorder-associated protein to thereby counteract the affects of a cardiovascular disorder.

[0273] For further information regarding pharmacology, see *Current Protocols in Pharmacology*, John Wiley & Sons, Inc., N.Y.

HUMAN IDENTIFICATION APPLICATIONS

[0274] For reference only, in addition to their diagnostic and therapeutic uses in myocardial infarction and HMG-CoA reductase inhibitor treatment of myocardial infarction, the SNP described herein is also useful as human identification markers for such applications as forensics, paternity testing, and biometrics (see, e.g., Gill, "An assessment of the utility of single nucleotide polymorphisms (SNPs) for forensic purposes", *Int J Legal Med.* 2001;114(4-5):204-10). Genetic variations in the nucleic acid sequences between individuals can be used as genetic markers to identify individuals and to associate a biological sample with an individual. Determination of which nucleotides occupy a set of SNP positions in an individual identifies a set of SNP markers that distinguishes the individual. The more SNP positions that are analyzed, the lower the probability that the set of SNPs in one individual is the same as that in an unrelated individual. Preferably, if multiple sites are analyzed, the sites are unlinked (i.e., inherited independently). Thus, preferred sets of SNPs can be selected from among the SNPs disclosed herein, which may include SNPs on different chromosomes, SNPs on different chromosome arms, and/or SNPs that are dispersed over substantial distances along the same chromosome arm.

[0275] Furthermore, among the SNPs disclosed herein, preferred SNPs for use in certain forensic/human identification applications include SNPs located at degenerate codon positions (i.e., the third position in certain codons which can be one of two or more alternative nucleotides and still encode the same amino acid), since these SNPs do not affect the encoded protein. SNPs that do not affect the encoded protein are expected to be under less selective pressure and are therefore expected to be more polymorphic in a population, which is typically an advantage for forensic/human identification applications. However, for certain forensics/human identification applications, such as predicting phenotypic characteristics (e.g., inferring ancestry or inferring one or more physical characteristics of an individual) from a DNA sample, it may be desirable to utilize SNPs that affect the encoded protein.

[0276] For many of the SNPs disclosed in Tables 1-2 (which are identified as "Applera" SNP source), Tables 1-2 provide SNP allele frequencies obtained by re-sequencing the DNA of chromosomes from 39 individuals (Tables 1-2 also provide allele frequency information for "Celera" source SNPs and, where available, public SNPs from dbEST, HGBASE, and/or HGMD). The allele frequencies provided in Tables 1-2 enable these SNPs to be readily used for human identification applications. Although any SNP disclosed in Table 1 and/or Table 2 could be used for human identification, the closer that the frequency of the minor allele at a particular SNP site is to 50%, the greater the ability of that SNP to

discriminate between different individuals in a population since it becomes increasingly likely that two randomly selected individuals would have different alleles at that SNP site. Using the SNP allele frequencies provided in Tables 1-2, one of ordinary skill in the art could readily select a subset of SNPs for which the frequency of the minor allele is, for example, at least 1%, 2%, 5%, 10%, 20%, 25%, 30%, 40%, 45%, or 50%, or any other frequency in-between. Thus, since Tables 1-2 provide allele frequencies based on the re-sequencing of the chromosomes from 39 individuals, a subset of SNPs could readily be selected for human identification in which the total allele count of the minor allele at a particular SNP site is, for example, at least 1, 2, 4, 8, 10, 16, 20, 24, 30, 32, 36, 38, 39, 40, or any other number in-between.

[0277] Furthermore, Tables 1-2 also provide population group (interchangeably referred to herein as ethnic or racial groups) information coupled with the extensive allele frequency information. For example, the group of 39 individuals whose DNA was re-sequenced was made-up of 20 Caucasians and 19 African-Americans. This population group information enables further refinement of SNP selection for human identification. For example, preferred SNPs for human identification can be selected from Tables 1-2 that have similar allele frequencies in both the Caucasian and African-American populations; thus, for example, SNPs can be selected that have equally high discriminatory power in both populations. Alternatively, SNPs can be selected for which there is a statistically significant difference in allele frequencies between the Caucasian and African-American populations (as an extreme example, a particular allele may be observed only in either the Caucasian or the African-American population group but not observed in the other population group); such SNPs are useful, for example, for predicting the race/ethnicity of an unknown perpetrator from a biological sample such as a hair or blood stain recovered at a crime scene. For a discussion of using SNPs to predict ancestry from a DNA sample, including statistical methods, see Frudakis et al., "A Classifier for the SNP-Based Inference of Ancestry", *Journal of Forensic Sciences* 2003; 48(4):771-782.

[0278] SNPs have numerous advantages over other types of polymorphic markers, such as short tandem repeats (STRs). For example, SNPs can be easily scored and are amenable to automation, making SNPs the markers of choice for large-scale forensic databases. SNPs are found in much greater abundance throughout the genome than repeat polymorphisms. Population frequencies of two polymorphic forms can usually be determined with greater accuracy than those of multiple polymorphic forms at multi-allelic loci. SNPs are mutationally more stable than repeat polymorphisms. SNPs are not susceptible to artefacts such as stutter bands that can hinder analysis. Stutter bands are frequently encountered when analyzing repeat polymorphisms, and are particularly troublesome when analyzing samples such as crime scene samples that may contain mixtures of DNA from multiple sources. Another significant advantage of SNP markers over STR markers is the much shorter length of nucleic acid needed to score a SNP. For example, STR markers are generally several hundred base pairs in length. A SNP, on the other hand, comprises a single nucleotide, and generally a short conserved region on either side of the SNP position for primer and/or probe binding. This makes SNPs more amenable to typing in highly degraded or aged biological samples that are frequently encountered in forensic casework in which DNA may be fragmented into short pieces.

[0279] SNPs also are not subject to microvariant and "off-ladder" alleles frequently encountered when analyzing STR loci. Microvariants are deletions or insertions within a repeat unit that change the size of the amplified DNA product so that the amplified product does not migrate at the same rate as reference alleles with normal sized repeat units. When separated by size, such as by electrophoresis on a polyacrylamide gel, microvariants do not align with a reference allelic ladder of standard sized repeat units, but rather migrate between the reference alleles. The reference allelic ladder is used for precise sizing of alleles for allele classification; therefore alleles that do not align with the reference allelic ladder lead to substantial analysis problems. Furthermore, when analyzing multi-allelic repeat polymorphisms, occasionally an allele is found that consists of more or less repeat units than has been previously seen in the population, or more or less repeat alleles than are included in a reference allelic ladder. These alleles will migrate outside the size range of known alleles in a reference allelic ladder, and therefore are referred to as "off-ladder" alleles. In extreme cases, the allele may contain so few or so many repeats that it migrates well out of the range of the reference allelic ladder. In this situation, the allele may not even be observed, or, with multiplex analysis, it may migrate within or close to the size range for another locus, further confounding analysis.

[0280] SNP analysis avoids the problems of microvariants and off-ladder alleles encountered in STR analysis. Importantly, microvariants and off-ladder alleles may provide significant problems, and may be completely missed, when using analysis methods such as oligonucleotide hybridization arrays, which utilize oligonucleotide probes specific for certain known alleles. Furthermore, off-ladder alleles and microvariants encountered with STR analysis, even when correctly typed, may lead to improper statistical analysis, since their frequencies in the population are generally unknown or poorly characterized, and therefore the statistical significance of a matching genotype may be questionable. All these advantages of SNP analysis are considerable in light of the consequences of most DNA identification cases, which may lead to life imprisonment for an individual, or reassociation of remains to the family of a deceased individual.

[0281] DNA can be isolated from biological samples such as blood, bone, hair, saliva, or semen, and compared with the DNA from a reference source at particular SNP positions. Multiple SNP markers can be assayed simultaneously in order to increase the power of discrimination and the statistical significance of a matching genotype. For example, oligonucleotide arrays can be used to genotype a large number of SNPs simultaneously. The SNP: described herein

can be assayed in combination with other polymorphic genetic markers, such as other SNPs known in the art or STRs, in order to identify an individual or to associate an individual with a particular biological sample.

[0282] Furthermore, the SNP described herein can be genotyped for inclusion in a database of DNA genotypes, for example, a criminal DNA databank such as the FBI's Combined DNA Index System (CODIS) database. A genotype obtained from a biological sample of unknown source can then be queried against the database to find a matching genotype, with the SNP described herein providing nucleotide positions at which to compare the known and unknown DNA sequences for identity. For reference only, described herein is a database comprising novel SNPs or SNP allele: described herein (e.g., the database can comprise information indicating which alleles are possessed by individual members of a population at a SNP site described herein), such as for use in forensics, biometrics, or other human identification applications. Such a database typically comprises a computer-based system in which the SNPs or SNP allele described herein are recorded on a computer readable medium (see the section of the present specification entitled "Computer-Related Embodiments"). For reference only, the SNP described herein can also be assayed for use in paternity testing. The object of paternity testing is usually to determine whether a male is the father of a child. In most cases, the mother of the child is known and thus, the mother's contribution to the child's genotype can be traced. Paternity testing investigates whether the part of the child's genotype not attributable to the mother is consistent with that of the putative father. Paternity testing can be performed by analyzing sets of polymorphisms in the putative father and the child, with the SNP described herein providing nucleotide positions at which to compare the putative father's and child's DNA sequences for identity. If the set of polymorphisms in the child attributable to the father does not match the set of polymorphisms of the putative father, it can be concluded, barring experimental error, that the putative father is not the father of the child. If the set of polymorphisms in the child attributable to the father match the set of polymorphisms of the putative father, a statistical calculation can be performed to determine the probability of coincidental match, and a conclusion drawn as to the likelihood that the putative father is the true biological father of the child.

[0283] In addition to paternity testing, SNPs are also useful for other types of kinship testing, such as for verifying familial relationships for immigration purposes, or for cases in which an individual alleges to be related to a deceased individual in order to claim an inheritance from the deceased individual, etc. For further information regarding the utility of SNPs for paternity testing and other types of kinship testing, including methods for statistical analysis, see Krawczak, "Informativity assessment for biallelic single nucleotide polymorphisms", *Electrophoresis* 1999 Jun;20(8):1676-81.

[0284] For reference only, the use of the SNP described herein for human identification further extends to various authentication systems, commonly referred to as biometric systems, which typically convert physical characteristics of humans (or other organisms) into digital data. Biometric systems include various technological devices that measure such unique anatomical or physiological characteristics as finger, thumb, or palm prints; hand geometry; vein patterning on the back of the hand; blood vessel patterning of the retina and color and texture of the iris; facial characteristics; voice patterns; signature and typing dynamics; and DNA. Such physiological measurements can be used to verify identity and, for example, restrict or allow access based on the identification. Examples of applications for biometrics include physical area security, computer and network security, aircraft passenger check-in and boarding, financial transactions, medical records access, government benefit distribution, voting, law enforcement, passports, visas and immigration, prisons, various military applications, and for restricting access to expensive or dangerous items, such as automobiles or guns (see, for example, O'Connor, *Stanford Technology Law Review* and U.S. Patent No. 6,119,096).

[0285] Groups of SNPs can be typed to uniquely identify an individual for biometric applications such as those described above. Such SNP typing can readily be accomplished using, for example, DNA chips/arrays. Preferably, a minimally invasive means for obtaining a DNA sample is utilized. For example, PCR amplification enables sufficient quantities of DNA for analysis to be obtained from buccal swabs or fingerprints, which contain DNA-containing skin cells and oils that are naturally transferred during contact.

[0286] Further information regarding techniques for using SNPs in forensic/human identification applications can be found in, for example, *Current Protocols in Human Genetics*, John Wiley & Sons, N.Y. (2002), 14.1-14.7.

VARIANT PROTEINS, ANTIBODIES, VECTORS & HOST CELLS, & USES THEREOF

Variant Proteins Encoded by SNP-Containing Nucleic Acid Molecules

[0287] The present invention provides the use of SNP-containing nucleic acid molecules, many of which encode proteins having variant amino acid sequences as compared to the art-known (i.e., wild-type) proteins. Amino acid sequences encoded by the polymorphic nucleic acid molecules described herein are identified as SEQ ID NO:2 in Table 1 and provided in the Sequence Listing. These variants will generally be referred to herein as variant proteins/peptides/polypeptides, or polymorphic proteins/peptides/polypeptides. The terms "protein", "peptide", and "polypeptide" are used herein interchangeably.

[0288] A variant protein may be encoded by, for example, a nonsynonymous nucleotide substitution at any one of the cSNP positions disclosed herein. In addition, variant proteins may also include proteins whose expression, structure,

and/or function is altered by a SNP disclosed herein, such as a SNP that creates or destroys a stop codon, a SNP that affects splicing, and a SNP in control/regulatory elements, e.g. promoters, enhancers, or transcription factor binding domains.

[0289] As used herein, a protein or peptide is said to be "isolated" or "purified" when it is substantially free of cellular material or chemical precursors or other chemicals. The variant proteins described herein can be purified to homogeneity or other lower degrees of purity. The level of purification will be based on the intended use. The key feature is that the preparation allows for the desired function of the variant protein, even if in the presence of considerable amounts of other components.

[0290] As used herein, "substantially free of cellular material" includes preparations of the variant protein having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the variant protein is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

[0291] The language "substantially free of chemical precursors or other chemicals" includes preparations of the variant protein in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the variant protein having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

[0292] An isolated variant protein may be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant host cells), or synthesized using known protein synthesis methods. For example, a nucleic acid molecule containing SNP(s) encoding the variant protein can be cloned into an expression vector, the expression vector introduced into a host cell, and the variant protein expressed in the host cell. The variant protein can then be isolated from the cells by any appropriate purification scheme using standard protein purification techniques. Examples of these techniques are described in detail below (Sambrook and Russell, 2000, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

[0293] Described herein are isolated variant proteins that comprise, consist of or consist essentially of an amino acid sequence that contains a variant amino acid encoded by a codon which contains the SNP described herein.

[0294] The variant proteins consist of amino acid sequences that contain the amino acid polymorphism (or truncations or extensions due to creation or destruction of a stop codon, respectively) encoded by the SNP used in the present invention provided in Table 1 and/or Table 2. A protein consists of an amino acid sequence when the amino acid sequence is the entire amino acid sequence of the protein.

[0295] The variant proteins further consist essentially of amino acid sequences that contain the amino acid polymorphisms (or truncations or extensions due to creation or destruction of a stop codon, respectively) encoded by the SNP used in the method of the present invention provided in Table 1 and/or Table 2. A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues in the final protein.

[0296] The variant proteins further comprise amino acid sequences that contain the amino acid polymorphisms (or truncations or extensions due to creation or destruction of a stop codon, respectively) encoded by the SNP used in the method of the present invention provided in Table 1 and/or Table 2. A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein may contain only the variant amino acid sequence or have additional amino acid residues, such as a contiguous encoded sequence that is naturally associated with it or heterologous amino acid residues. Such a protein can have a few additional amino acid residues or can comprise many more additional amino acids. A brief description of how various types of these proteins can be made and isolated is provided below.

[0297] The variant protein described herein can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a variant protein operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the variant protein. "Operatively linked" indicates that the coding sequences for the variant protein and the heterologous protein are ligated in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the variant protein. In another embodiment, the fusion protein is encoded by a fusion polynucleotide that is synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A variant protein-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the variant protein.

[0298] In many uses, the fusion protein does not affect the activity of the variant protein. The fusion protein can include,

but is not limited to, enzymatic fusion proteins, for example, beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate their purification following recombinant expression. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence. Fusion proteins are further described

in, for example, Terpe, "Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems", Appl Microbiol Biotechnol. 2003 Jan;60(5):523-33. Epub 2002 Nov 07; Graddis et al., "Designing proteins that work using recombinant technologies", Curr Pharm Biotechnol. 2002 Dec;3(4):285-97; and Nilsson et al., "Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins", Protein Expr Purif. 1997 Oct;11(1):1-16. **[0299]** For reference only, described herein are obvious variants of the variant polypeptides described herein, such as naturally-occurring mature forms (e.g., allelic variants), non-naturally occurring recombinantly-derived variants, and orthologs and paralogs of such proteins that share sequence homology. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants described herein exclude those known in the prior art before the present disclosure. For reference only, further variants of the variant polypeptides disclosed in Table 1 can comprise an amino acid sequence that shares at least 70-80%, 80-85%, 85-90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with an amino acid sequence indicated in Table 1 (or a fragment thereof) and that includes an amino acid residue (allele) disclosed in Table 1 (which is encoded by a SNP allele). Thus, described herein are polypeptides that have a certain degree of sequence variation compared with the polypeptide sequence indicated in Table 1, but that contain an amino acid residue (allele) encoded by a SNP allele disclosed herein. In other words, as long as a polypeptide contains amino acid residue disclosed herein, other portions of the polypeptide that flank the amino acid residue can vary to some degree from the polypeptide sequence shown in Table 1. For reference only, full-length pre-processed forms, as well as mature processed forms, of proteins that comprise the amino acid sequences disclosed herein can readily be identified as having complete sequence identity to one of the variant proteins described herein as well as being encoded by the same genetic locus as the variant protein described herein.

[0300] Orthologs of a variant peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of a variant peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from non-human mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs can be encoded by a nucleic acid sequence that hybridizes to a variant peptide-encoding nucleic acid molecule under moderate to stringent conditions depending on the degree of relatedness of the two organisms yielding the homologous proteins. For reference only, variant proteins include, but are not limited to, proteins containing deletions, additions and substitutions in the amino acid sequence caused by the SNP described herein. One class of substitutions is conserved amino acid substitutions in which a given amino acid in a polypeptide is substituted for another amino acid of like characteristics. Typical conservative substitutions are replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in, for example, Bowie et al., Science 247:1306-1310 (1990).

[0301] Variant proteins can be fully functional or can lack function in one or more activities, e.g. ability to bind another molecule, ability to catalyze a substrate, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variations or variations in non-critical residues or in non-critical regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree. Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, truncations or extensions, or a substitution, insertion, inversion, or deletion of a critical residue or in a critical region.

[0302] Amino acids that are essential for function of a protein can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham et al., Science 244:1081-1085 (1989)), particularly using the amino acid sequence and polymorphism information provided in Table 1. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as enzyme activity or in assays such as an *in vitro* proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., J. Mol. Biol. 224:899-904 (1992); de Vos et al. Science 255:306-312 (1992)).

[0303] Polypeptides can contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Accordingly, the variant proteins of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included,

in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (e.g., polyethylene glycol), or in which additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence for purification of the mature polypeptide or a pro-protein sequence.

[0304] Known protein modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

[0305] Such protein modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins - Structure and Molecular Properties*, 2nd Ed., T.E. Creighton, W. H. Freeman and Company, New York (1993); Wold, F., *Posttranslational Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter et al., *Meth. Enzymol.* 182: 626-646 (1990); and Rattan et al., *Ann. N.Y. Acad. Sci.* 663:48-62 (1992).

[0306] Described herein are fragments of the variant proteins in which the fragments contain one or more amino acid sequence variations (e.g., substitutions, or truncations or extensions due to creation or destruction of a stop codon) encoded by the SNP disclosed herein. The fragments, however, are not to be construed as encompassing fragments that have been disclosed in the prior art before the present invention.

[0307] As used herein, a fragment may comprise at least about 4, 8, 10, 12, 14, 16, 18, 20, 25, 30, 50, 100 (or any other number in-between) or more contiguous amino acid residues from a variant protein, wherein at least one amino acid residue is affected by a SNP described herein, e.g., a variant amino acid residue encoded by a nonsynonymous nucleotide substitution at a cSNP position described herein. The variant amino acid encoded by a cSNP may occupy any residue position along the sequence of the fragment. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the variant protein or the ability to perform a function, e.g., act as an immunogen. Particularly important fragments are biologically active fragments. Such fragments will typically comprise a domain or motif of a variant protein of the present invention, e.g., active site, transmembrane domain, or ligand/substrate binding domain. Other fragments include, but are not limited to, domain or motif-containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known to those of skill in the art (e.g., PROSITE analysis) (*Current Protocols in Protein Science*, John Wiley & Sons, N.Y. (2002)).

Uses of Variant Proteins

[0308] The variant protein described herein can be used in a variety of ways, including but not limited to, in assays to determine the biological activity of a variant protein, such as in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another type of immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the variant protein (or its binding partner) in biological fluids; as a marker for cells or tissues in which it is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); as a target for screening for a therapeutic agent; and as a direct therapeutic agent to be administered into a human subject. Any of the variant proteins disclosed herein may be developed into reagent grade or kit format for commercialization as research products. Methods for performing the uses listed above are well known to those skilled in the art (see, e.g., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Sambrook and Russell, 2000, and *Methods in Enzymology: Guide to Molecular Cloning Techniques*, Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987).

[0309] In a specific embodiment of the invention, the methods of the present invention include detection of a variant protein of amino acid sequence SEQ ID NO:2. Variant protein is disclosed in Table 1 and in the Sequence Listing (SEQ ID NO: 2). Detection of such proteins can be accomplished using, for example, antibodies, small molecule compounds, aptamers, ligands/substrates, other proteins or protein fragments, or other protein-binding agents. Preferably, protein protection agent used in the method of the present invention is specific for a variant protein of amino acid sequence SEQ ID NO:2 and can therefore discriminate between a variant protein having R at position 170 of SEQ ID NO:2 and the wild-type protein or another variant form e.g. having W at position 170 of SEQ ID NO:2.

[0310] This can generally be accomplished by, for example, selecting or designing detection agents that bind to the region of a protein that differs between the variant and wild-type protein, such as a region of a protein that contains one or more amino acid substitutions that is/are encoded by a non-synonymous cSNP described herein or a region of a protein that follows a nonsense mutation-type SNP that creates a stop codon thereby leading to a shorter polypeptide,

or a region of a protein that follows a read-through mutation-type SNP that destroys a stop codon thereby leading to a longer polypeptide in which a portion of the polypeptide is present in one version of the polypeptide but not the other.

[0311] In another specific aspect, the variant protein used in the method of the present invention is used as targets for evaluating an individual's predisposition to developing myocardial infarction, or stroke, for treating and/or preventing myocardial infarction, or for predicting an individual's response to HMG-CoA reductase inhibitor treatment for reducing risk of having myocardial infarction. Accordingly, the invention provides methods for detecting the presence of, or levels of, a variant protein of SEQ ID NO:2 in a cell, tissue, or organism. Such methods typically involve contacting a test sample with an agent (e.g., an antibody, small molecule compound, or peptide) capable of interacting with the variant protein such that specific binding of the agent to the variant protein can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an array, for example, an antibody or aptamer array (arrays for protein detection may also be referred to as "protein chips"). The variant protein of interest can be isolated from a test sample and assayed for the presence of a variant amino acid sequence encoded by a SNP disclosed herein. The SNP may cause changes to the protein and the corresponding protein function/activity, such as through non-synonymous substitutions in protein coding regions that can lead to amino acid substitutions, deletions, insertions, and/or rearrangements; formation or destruction of stop codons; or alteration of control elements such as promoters. SNPs may also cause inappropriate post-translational modifications.

[0312] One preferred agent for detecting a variant protein in a sample is an antibody capable of selectively binding to a variant form of the protein (antibodies are described in greater detail in the next section). Such samples include, for example, tissues, cells, and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

[0313] *In vitro* methods for detection of the variant protein associated with myocardial infarction cardiovascular disorders and/or HMG-CoA reductase inhibitor response that are disclosed herein and fragments thereof include, but are not limited to, enzyme linked immunosorbent assays (ELISAs), radioimmunoassays (RIA), Western blots, immunoprecipitations, immunofluorescence, and protein arrays/chips (e.g., arrays of antibodies or aptamers). For further information regarding immunoassays and related protein detection methods, see Current Protocols in Immunology, John Wiley & Sons, N.Y., and Hage, "Immunoassays", Anal Chem. 1999 Jun 15;71(12):294R-304R.

[0314] Additional analytic methods of detecting amino acid variants include, but are not limited to, altered electrophoretic mobility, altered tryptic peptide digest, altered protein activity in cell-based or cell-free assay, alteration in ligand or antibody-binding pattern, altered isoelectric point, and direct amino acid sequencing.

[0315] For reference only, variant proteins can be detected *in vivo* in a subject by introducing into the subject a labeled antibody (or other type of detection reagent) specific for a variant protein. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

[0316] Other uses of the variant peptides described herein are based on the class or action of the protein. For example, proteins isolated from humans and their mammalian orthologs serve as targets for identifying agents (e.g., small molecule drugs or antibodies) for use in therapeutic applications, particularly for modulating a biological or pathological response in a cell or tissue that expresses the protein. Pharmaceutical agents can be developed that modulate protein activity.

[0317] As an alternative to modulating gene expression, therapeutic compounds can be developed that modulate protein function. For example, many SNPs affect the amino acid sequence of the encoded protein (e.g., non-synonymous cSNPs and nonsense mutation-type SNPs). Such alterations in the encoded amino acid sequence may affect protein function, particularly if such amino acid sequence variations occur in functional protein domains, such as catalytic domains, ATP-binding domains, or ligand/substrate binding domains. It is well established in the art that variant proteins having amino acid sequence variations in functional domains can cause or influence pathological conditions. In such instances, compounds (e.g., small molecule drugs or antibodies) can be developed that target the variant protein and modulate (e.g., up- or down-regulate) protein function/activity. The variant protein described herein is useful as a target of compounds for therapeutic purposes.

[0318] Variant proteins can be targeted using, for example, small molecule compounds, antibodies, aptamers, ligands/substrates, other proteins, or other protein-binding agents. Additionally, the skilled artisan will recognize that the novel protein variants (and polymorphic nucleic acid molecules) disclosed in Table 1 may themselves be directly used as therapeutic agents by acting as competitive inhibitors of corresponding art-known proteins (or nucleic acid molecules such as mRNA molecules).

[0319] The variant proteins described herein are particularly useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can utilize cells that naturally express the protein, a biopsy specimen, or cell cultures. In one embodiment, cell-based assays involve recombinant host cells expressing the variant protein. Cell-free assays can be used to detect the ability of a compound to directly bind to a variant protein or to the corresponding SNP-containing nucleic acid fragment that encodes the variant protein.

[0320] A variant protein described herein as well as appropriate fragments thereof, can be used in high-throughput screening assays to test candidate compounds for the ability to bind and/or modulate the activity of the variant protein. These candidate compounds can be further screened against a protein having normal function (e.g., a wild-type/non-

variant protein) to further determine the effect of the compound on the protein activity. Furthermore, these compounds can be tested in animal or invertebrate systems to determine *in vivo* activity/effectiveness. Compounds can be identified that activate (agonists) or inactivate (antagonists) the variant protein, and different compounds can be identified that cause various degrees of activation or inactivation of the variant protein.

[0321] Further, the variant proteins can be used to screen a compound for the ability to stimulate or inhibit interaction between the variant protein and a target molecule that normally interacts with the protein. The target can be a ligand, a substrate or a binding partner that the protein normally interacts with (for example, epinephrine or norepinephrine). Such assays typically include the steps of combining the variant protein with a candidate compound under conditions that allow the variant protein, or fragment thereof, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the variant protein and the target, such as any of the associated effects of signal transduction.

[0322] Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam et al., Nature 354:82-84 (1991); Houghten et al., Nature 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang et al., Cell 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

[0323] One candidate compound is a soluble fragment of the variant protein that competes for ligand binding. Other candidate compounds include mutant proteins or appropriate fragments containing mutations that affect variant protein function and thus compete for ligand.

[0324] Described herein is a fragment that competes for ligand, for example with a higher affinity, or a fragment that binds ligand but does not allow release.

[0325] Described herein are other end point assays to identify compounds that modulate (stimulate or inhibit) variant protein activity. The assays typically involve an assay of events in the signal transduction pathway that indicate protein activity. Thus, the expression of genes that are up or down-regulated in response to the variant protein dependent signal cascade can be assayed. In one embodiment, the regulatory region of such genes can be operably linked to a marker that is easily detectable, such as luciferase. Alternatively, phosphorylation of the variant protein, or a variant protein target, could also be measured. Any of the biological or biochemical functions mediated by the variant protein can be used as an endpoint assay. These include all of the biochemical or biological events described herein, in the references cited herein, for these endpoint assay targets, and other functions known to those of ordinary skill in the art.

[0326] Binding and/or activating compounds can also be screened by using chimeric variant proteins in which an amino terminal extracellular domain or parts thereof, an entire transmembrane domain or subregions, and/or the carboxyl terminal intracellular domain or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate than that which is normally recognized by a variant protein. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the variant protein is derived.

[0327] The variant proteins are also useful in competition binding assays in methods designed to discover compounds that interact with the variant protein. Thus, a compound can be exposed to a variant protein under conditions that allow the compound to bind or to otherwise interact with the variant protein. A binding partner, such as ligand, that normally interacts with the variant protein is also added to the mixture. If the test compound interacts with the variant protein or its binding partner, it decreases the amount of complex formed or activity from the variant protein. This type of assay is particularly useful in screening for compounds that interact with specific regions of the variant protein (Hodgson, Bio/technology, 1992, Sept 10(9), 973-80).

[0328] To perform cell-free drug screening assays, it is sometimes desirable to immobilize either the variant protein or a fragment thereof, or its target molecule, to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Any method for immobilizing proteins on matrices can be used in drug screening assays. In one embodiment, a fusion protein containing an added domain allows the protein to be bound to a matrix. For example, glutathione-S-transferase/¹²⁵I fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ³⁵S-labeled) and a candidate compound, such as a drug candidate, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads can be washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of bound material found in the bead fraction quantitated from the gel using standard electrophoretic techniques.

[0329] Either the variant protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Alternatively, antibodies reactive with the variant protein but which do not interfere with binding of the variant protein to its target molecule can be derivatized to the wells of the plate, and the variant protein trapped in the wells by antibody conjugation. Preparations of the target molecule and a candidate compound are incubated in the variant protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the protein target molecule, or which are reactive with variant protein and compete with the target molecule, and enzyme-linked assays that rely on detecting an enzymatic activity associated with the target molecule.

[0330] Modulators of variant protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the protein pathway, such as cardiovascular disease. These methods of treatment typically include the steps of administering the modulators of protein activity in a pharmaceutical composition to a subject in need of such treatment.

[0331] The variant proteins, or fragments thereof, disclosed herein can themselves be directly used to treat a disorder characterized by an absence of, inappropriate, or unwanted expression or activity of the variant protein.

[0332] In yet another aspect described herein variant proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8: 1693-1696; and Brent WO94/10300) to identify other proteins that bind to or interact with the variant protein and are involved in variant protein activity. Such variant protein-binding proteins are also likely to be involved in the propagation of signals by the variant proteins or variant protein targets as, for example, elements of a protein-mediated signaling pathway. Alternatively, such variant protein-binding proteins are inhibitors of the variant protein.

[0333] The two-hybrid system is based on the modular nature of most transcription factors, which typically consist of separable DNA-binding and activation domains. Briefly, the assay typically utilizes two different DNA constructs. In one construct, the gene that codes for a variant protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a variant protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein that interacts with the variant protein.

Antibodies Directed to Variant Proteins

[0334] The present invention also provides the use of an antibody that selectively binds to the variant protein of amino acid sequence SEQ ID NO: 2 and fragments thereof. The antibody may be used to quantitatively or qualitatively detect the variant protein of amino acid sequence SEQ ID NO:2. As used herein, an antibody selectively binds a target variant protein when it binds the variant protein and does not significantly bind to non-variant proteins, i.e., the antibody does not significantly bind to normal, wild-type, or art-known proteins that do not contain a variant amino acid sequence a SNP in position 170 of SEQ ID NO:2 (variant amino acid sequences may be due to, for example, nonsynonymous cSNPs, nonsense SNPs that create a stop codon, thereby causing a truncation of a polypeptide or SNPs that cause read-through mutations resulting in an extension of a polypeptide).

[0335] As used herein, an antibody is defined in terms consistent with that recognized in the art: they are multi-subunit proteins produced by an organism in response to an antigen challenge. The antibody used in the method of the present invention includes both monoclonal antibodies and polyclonal antibodies, as well as antigen-reactive proteolytic fragments of such antibodies, such as Fab, F(ab)₂, and Fv fragments. In addition, an antibody for use in the method of the present invention further includes any of a variety of engineered antigen-binding molecules such as a chimeric antibody (U.S. Patent Nos. 4,816,567 and 4,816,397; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851, 1984; Neuberger et al., Nature 312:604, 1984), a humanized antibody (U.S. Patent Nos. 5,693,762; 5,585,089; and 5,565,332), a single-chain Fv (U.S. Patent No. 4,946,778; Ward et al., Nature 334:544, 1989), a bispecific antibody with two binding specificities (Segal et al., J. Immunol. Methods 248:1, 2001; Carter, J. Immunol. Methods 248:7, 2001), a diabody, a triabody, and a tetrabody (Todorovska et al., J. Immunol. Methods, 248:47, 2001), as well as a Fab conjugate (dimer or trimer), and a minibody.

[0336] Many methods are known in the art for generating and/or identifying antibodies to a given target antigen (Harlow, Antibodies, Cold Spring Harbor Press, (1989)). In general, an isolated peptide (e.g., a variant protein described herein) is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit, hamster or mouse. Either

a full-length protein, an antigenic peptide fragment (e.g., a peptide fragment containing a region that varies between a variant protein and a corresponding wild-type protein), or a fusion protein can be used. A protein used as an immunogen may be naturally-occurring, synthetic or recombinantly produced, and may be administered in combination with an adjuvant, including but not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substance such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and the like.

[0337] Monoclonal antibodies can be produced by hybridoma technology (Kohler and Milstein, Nature, 256:495, 1975), which immortalizes cells secreting a specific monoclonal antibody. The immortalized cell lines can be created *in vitro* by fusing two different cell types, typically lymphocytes, and tumor cells. The hybridoma cells may be cultivated *in vitro* or *in vivo*. Additionally, fully human antibodies can be generated by transgenic animals (He et al., J. Immunol., 169:595, 2002). Fd phage and Fd phagemid technologies may be used to generate and select recombinant antibodies *in vitro* (Hoogenboom and Chames, Immunol. Today 21:371, 2000; Liu et al., J. Mol. Biol. 315:1063, 2002). The complementarity-determining regions of an antibody can be identified, and synthetic peptides corresponding to such regions may be used to mediate antigen binding (U.S. Patent No. 5,637,677).

[0338] Antibodies are preferably prepared against regions or discrete fragments of a variant protein containing a variant amino acid sequence as compared to the corresponding wild-type protein (e.g., a region of a variant protein that includes an amino acid encoded by a nonsynonymous cSNP, a region affected by truncation caused by a nonsense SNP that creates a stop codon, or a region resulting from the destruction of a stop codon due to read-through mutation caused by a SNP). Furthermore, preferred regions will include those involved in function/activity and/or protein/binding partner interaction. Such fragments can be selected on a physical property, such as fragments corresponding to regions that are located on the surface of the protein, e.g., hydrophilic regions, or can be selected based on sequence uniqueness, or based on the position of the variant amino acid residue(s) encoded by the SNP described herein. An antigenic fragment will typically comprise at least about 8-10 contiguous amino acid residues in which at least one of the amino acid residues is an amino acid affected by a SNP disclosed herein. The antigenic peptide can comprise, however, at least 12, 14, 16, 20, 25, 50, 100 (or any other number in-between) or more amino acid residues, provided that at least one amino acid is affected by a SNP disclosed herein. Detection of an antibody for use in the method of the present invention can be facilitated by coupling (i.e., physically linking) the antibody or an antigen-reactive fragment thereof to a detectable substance. Detectable substances include, but are not limited to, various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

[0339] Antibodies, particularly the use of antibodies as therapeutic agents, are reviewed in: Morgan, "Antibody therapy for Alzheimer's disease", Expert Rev Vaccines. 2003 Feb;2(1):53-9; Ross et al., "Anticancer antibodies", Am J Clin Pathol. 2003 Apr;119(4):472-85; Goldenberg, "Advancing role of radiolabeled antibodies in the therapy of cancer". Cancer Immunol Immunother. 2003 May;52(5):281-96. Epub 2003 Mar 11; Ross et al., "Antibody-based therapeutics in oncology", Expert Rev Anticancer Ther. 2003 Feb;3(1):107-21; Cao et al., "Bispecific antibody conjugates in therapeutics", Adv Drug Deliv Rev. 2003 Feb 10;55(2):171-97; von Mehren et al., "Monoclonal antibody therapy for cancer", Annu Rev Med. 2003;54:343-69. Epub 2001 Dec 03; Hudson et al., "Engineered antibodies", Nat Med. 2003 Jan;9(1):129-34; Brekke et al., "Therapeutic antibodies for human diseases at the dawn of the twenty-first century", Nat Rev Drug Discov. 2003 Jan;2(1):52-62 (Erratum in: Nat Rev Drug Discov. 2003 Mar;2(3):240); Houdebine, "Antibody manufacture in transgenic animals and comparisons with other systems", Curr Opin Biotechnol. 2002 Dec;13(6):625-9; Andreaskos et al., "Monoclonal antibodies in immune and inflammatory diseases", Curr Opin Biotechnol. 2002 Dec;13(6):615-20; Kellermann et al., "Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics", Curr Opin Biotechnol. 2002 Dec;13(6):593-7; Pini et al., "Phage display and colony filter screening for high-throughput selection of antibody libraries", Comb Chem High Throughput Screen. 2002 Nov;5(7):503-10; Batra et al., "Pharmacokinetics and biodistribution of genetically engineered antibodies", Curr Opin Biotechnol. 2002 Dec;13(6):603-8; and Tangri et al., "Rationally engineered proteins or antibodies with absent or reduced immunogenicity", Curr Med Chem. 2002 Dec;9(24):2191-9.

Uses of Antibodies

[0340] Antibodies can be used to isolate the variant protein described herein from a natural cell source or from recombinant host cells by standard techniques, such as affinity chromatography or immunoprecipitation. In addition, antibodies are useful for detecting the presence of a variant protein of amino acid sequence SEQ ID NO:2 in cells or tissues to determine the pattern of expression of the variant protein among various tissues in an organism and over the course of

normal development or disease progression. Further, antibodies can be used to detect variant protein *in vitro*, in a bodily fluid, or in a cell lysate or supernatant in order to evaluate the amount and pattern of expression. Also, antibodies can be used to assess abnormal tissue distribution, abnormal expression during development, or expression in an abnormal condition, such as in myocardial infarction or during HMG-CoA reductase inhibitor treatment. Additionally, antibody detection of circulating fragments of the full-length variant protein can be used to identify turnover. An antibody to the variant protein for use in the method of the present invention is also useful in pharmacogenomic analysis. Thus, antibodies against variant proteins encoded by alternative SNP alleles can be used to identify individuals that require modified treatment modalities.

[0341] Further, antibodies can be used to assess expression of the variant protein in disease states such as in active stages of the disease or in an individual with a predisposition to a disease related to the protein's function, such as myocardial infarction, or during the course of a treatment regime, such as during HMG-CoA reductase inhibitor treatment. Antibodies specific for a variant protein encoded by a SNP-containing nucleic acid molecule of amino acid sequence SEQ ID NO:2 can be used in the method of the present invention to assay for the presence of a variant protein, such as to predict an individual's response to HMG-CoA reductase inhibitor treatment or predisposition/ susceptibility to myocardial infarction as indicated by the presence of the variant protein.

[0342] Antibodies are also useful as diagnostic tools for evaluating the variant proteins in conjunction with analysis by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays well known in the art.

[0343] Antibodies are also useful for tissue typing. Thus, where a specific variant protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

[0344] Antibodies can also be used to assess aberrant subcellular localization of a variant protein in cells in various tissues. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting the expression level or the presence of variant protein or aberrant tissue distribution or developmental expression of a variant protein, antibodies directed against the variant protein or relevant fragments can be used to monitor therapeutic efficacy.

[0345] The antibodies are also useful for inhibiting variant protein function, for example, by blocking the binding of a variant protein to a binding partner. These uses can also be applied in a therapeutic context in which treatment involves inhibiting a variant protein's function. An antibody can be used, for example, to block or competitively inhibit binding, thus modulating (agonizing or antagonizing) the activity of a variant protein. Antibodies can be prepared against specific variant protein fragments containing sites required for function or against an intact variant protein that is associated with a cell or cell membrane. For *in vivo* administration, an antibody may be linked with an additional therapeutic payload such as a radionuclide, an enzyme, an immunogenic epitope, or a cytotoxic agent. Suitable cytotoxic agents include, but are not limited to, bacterial toxin such as diphtheria, and plant toxin such as ricin. The *in vivo* half-life of an antibody or a fragment thereof may be lengthened by pegylation through conjugation to polyethylene glycol (Leong *et al.*, *Cytokine* 16:106, 200 1).

[0346] The invention also encompasses kits for using antibodies, such as kits for detecting the presence of a variant protein in a test sample. An exemplary kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting variant proteins in a biological sample; means for determining the amount, or presence/absence of variant protein in the sample; means for comparing the amount of variant protein in the sample with a standard; and instructions for use.

Vectors and Host Cells

[0347] Described herein are vectors containing the SNP-containing nucleic acid molecules described herein. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport a SNP-containing nucleic acid molecule. When the vector is a nucleic acid molecule, the SNP-containing nucleic acid molecule can be covalently linked to the vector nucleic acid. Such vectors include, but are not limited to, a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, or MAC.

[0348] A vector can be maintained in a host cell as an extrachromosomal element where it replicates and produces additional copies of the SNP-containing nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the SNP-containing nucleic acid molecules when the host cell replicates.

[0349] Further, disclosed herein are vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the SNP-containing nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

[0350] Expression vectors typically contain cis-acting regulatory regions that are operably linked in the vector to the SNP-containing nucleic acid molecules such that transcription of the SNP-containing nucleic acid molecules is allowed in a host cell. The SNP-containing nucleic acid molecules can also be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the SNP-containing nucleic acid molecules

from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however; that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

[0351] The regulatory sequences to which the SNP-containing nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

[0352] In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

[0353] In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region, a ribosome-binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. A person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors (see, e.g., Sambrook and Russell, 2000, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

[0354] A variety of expression vectors can be used to express a SNP-containing nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example, vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors can also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g., cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook and Russell, 2000, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

[0355] The regulatory sequence in a vector may provide constitutive expression in one or more host cells (e.g., tissue specific expression) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor, e.g., a hormone or other ligand. A variety of vectors that provide constitutive or inducible expression of a nucleic acid sequence in prokaryotic and eukaryotic host cells are well known to those of ordinary skill in the art.

[0356] A SNP-containing nucleic acid molecule can be inserted into the vector by methodology well-known in the art. Generally, the SNP-containing nucleic acid molecule that will ultimately be expressed is joined to an expression vector by cleaving the SNP-containing nucleic acid molecule and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

[0357] The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial host cells include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic host cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

[0358] As described herein, it may be desirable to express the variant peptide as a fusion protein. Accordingly, described herein are fusion vectors that allow for the production of the variant peptides. Fusion vectors can, for example, increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting, for example, as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired variant peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes suitable for such use include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith et al., *Gene* 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann et al., *Gene* 69:301-315 (1988)) and pET 11d (Studier et al., *Gene Expression Technology: Methods in Enzymology* 185:60-89 (1990)).

[0359] Recombinant protein expression can be maximized in a bacterial host by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Alternatively, the sequence of the SNP-containing nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example, *E. coli* (Wada et al., *Nucleic Acids Res.* 20:2111-2118 (1992)).

[0360] The SNP-containing nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast (e.g., *S. cerevisiae*) include pYepSec1 (Baldari, et al., *EMBO J.* 6:229-234 (1987)), pMFa (Kurjan et al., *Cell* 30:933-943(1982)), pJRY88 (Schultz et al., *Gene* 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, CA).

[0361] The SNP-containing nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al., Mol. Cell Biol. 3:2156-2165 (1983)) and the pVL series (Lucklow et al., Virology 170: 31-39 (1989)).

[0362] In certain embodiments, the SNP-containing nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. Nature 329:840(1987)) and pMT2PC (Kaufman et al., EMBO J. 6:187-195 (1987)).

[0363] Described herein are vectors in which the SNP-containing nucleic acid molecules described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to the SNP-containing nucleic acid sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

[0364] Described herein are also recombinant host cells containing the vectors described herein. Host cells therefore include, for example, prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

[0365] The recombinant host cells can be prepared by introducing the vector constructs described herein into the cells by techniques readily available to persons of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those described in Sambrook and Russell, 2000, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

[0366] Host cells can contain more than one vector. Thus, different SNP-containing nucleotide sequences can be introduced in different vectors into the same cell. Similarly, the SNP-containing nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the SNP-containing nucleic acid molecules, such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced, or joined to the nucleic acid molecule vector.

[0367] In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication can occur in host cells that provide functions that complement the defects.

[0368] Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be inserted in the same vector that contains the SNP-containing nucleic acid molecules described herein or may be in a separate vector. Markers include, for example, tetracycline or ampicillin-resistance genes for prokaryotic host cells, and dihydrofolate reductase or neomycin resistance genes for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait can be effective.

[0369] While the mature variant proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these variant proteins using RNA derived from the DNA constructs described herein.

[0370] Where secretion of the variant protein is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as G-protein-coupled receptors (GPCRs), appropriate secretion signals can be incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

[0371] Where the variant protein is not secreted into the medium, the protein can be isolated from the host cell by standard disruption procedures, including freeze/thaw, sonication, mechanical disruption, use of lysing agents, and the like. The variant protein can then be recovered and purified by well-known purification methods including, for example, ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

[0372] It is also understood that, depending upon the host cell in which recombinant production of the variant proteins described herein occurs, they can have various glycosylation patterns, or may be non-glycosylated, as when produced in bacteria. In addition, the variant proteins may include an initial modified methionine in some cases as a result of a host-mediated process.

[0373] For further information regarding vectors and host cells, see Current Protocols in Molecular Biology, John Wiley & Sons, N.Y.

Uses of Vectors and Host Cells, and Transgenic Animals

[0374] Recombinant host cells that express the variant proteins described herein have a variety of uses. For example,

the cells are useful for producing a variant protein that can be further purified into a preparation of desired amounts of the variant protein or fragments thereof. Thus, host cells containing expression vectors are useful for variant protein production.

[0375] Host cells are also useful for conducting cell-based assays involving the variant protein or variant protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a variant protein is useful for assaying compounds that stimulate or inhibit variant protein function. Such an ability of a compound to modulate variant protein function may not be apparent from assays of the compound on the native/wild-type protein, or from cell-free assays of the compound. Recombinant host cells are also useful for assaying functional alterations in the variant proteins as compared with a known function.

[0376] Genetically-engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a non-human mammal, for example, a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA containing a SNP described herein which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more of its cell types or tissues. Such animals are useful for studying the function of a variant protein *in vivo*, and identifying and evaluating modulators of variant protein activity. Other examples of transgenic animals include, but are not limited to, non-human primates, sheep, dogs, cows, goats, chickens, and amphibians. Transgenic non-human mammals such as cows and goats can be used to produce variant proteins which can be secreted in the animal's milk and then recovered.

[0377] A transgenic animal can be produced by introducing a SNP-containing nucleic acid molecule into the male pronuclei of a fertilized oocyte, e.g., by microinjection or retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any nucleic acid molecules that contain the SNP described herein can potentially be introduced as a transgene into the genome of a non-human animal.

[0378] Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the variant protein in particular cells or tissues.

[0379] Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described in, for example, U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Patent No. 4,873,191 by Wagner et al., and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes a non-human animal in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

[0380] In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1 (Lakso et al. PNAS 89:6232-6236 (1992)). Another example of a recombinase system is the FLP recombinase system of *S. cerevisiae*, (O'Gorman et al. Science 251:1351-1355 (1991)). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are generally needed. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected variant protein and the other containing a transgene encoding a recombinase.

[0381] Clones of the non-human transgenic animals described herein can also be produced according to the methods described in, for example, Wilmut, I. et al. Nature 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell (e.g., a somatic cell) is isolated.

[0382] Transgenic animals containing recombinant cells that express the variant proteins described herein are useful for conducting the assays described herein in an *in vivo* context. Accordingly, the various physiological factors that are present *in vivo* and that could influence ligand or substrate binding, variant protein activation, signal transduction, or other processes or interactions, may not be evident from *in vitro* cell-free or cell-based assays. Thus, non-human transgenic animals may be used to assay *in vivo* variant protein function as well as the activities of a therapeutic agent or compound that modulates variant protein function/activity or expression. Such animals are also suitable for assessing the effects of null mutations (i.e., mutations that substantially or completely eliminate one or more variant protein func-

tions).

[0383] For further information regarding transgenic animals, see Houdebine, "Antibody manufacture in transgenic animals and comparisons with other systems", *Curr Opin Biotechnol.* 2002 Dec;13(6):625-9; Petters et al., "Transgenic animals as models for human disease", *Transgenic Res.* 2000;9(4-5):347-51; discussion 345-6; Wolf et al., "Use of transgenic animals in understanding molecular mechanisms of toxicity", *J Pharm Pharmacol.* 1998 Jun;50(6):567-74; Echelard, "Recombinant protein production in transgenic animals", *Curr Opin Biotechnol.* 1996 Oct;7(5):536-40; Houdebine, "Transgenic animal bioreactors", *Transgenic Res.* 2000;9(4-5):305-20; Purity et al., "Embryonic stem cells, creating transgenic animals", *Methods Cell Biol.* 1998;57:279-93; and Robl et al., "Artificial chromosome vectors and expression of complex proteins in transgenic animals", *Theriogenology.* 2003 Jan 1;59(1):107-13.

COMPUTER-RELATED EMBODIMENTS

[0384] For reference only, the SNP described herein may be "provided" in a variety of mediums to facilitate use thereof. As used in this section, "provided" refers to a manufacture, other than an isolated nucleic acid molecule, that contains SNP information described herein. Such a manufacture provides the SNP information in a form that allows a skilled artisan to examine the manufacture using means not directly applicable to examining the SNPs or a subset thereof as they exist in nature or in purified form. The SNP information that may be provided in such a form includes any of the SNP information provided by the present description such as, for example, polymorphic nucleic acid and/or amino acid sequence information of the Sequence Listing SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:3 and SEQ ID NO:5; information about observed SNP alleles, alternative codons, populations, allele frequencies, SNP types, and/or affected proteins; or any other information provided in Tables 1-2 and/or the Sequence Listing.

[0385] For reference only, the SNP: described herein can be recorded on a computer readable medium. As used herein, "computer readable medium" refers to any medium that can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. A skilled artisan can readily appreciate how any of the presently known computer readable media can be used to create a manufacture comprising computer readable medium having recorded thereon a nucleotide sequence.

[0386] As used herein, "recorded" refers to a process for storing information on computer readable medium. A skilled artisan can readily adopt any of the presently Known methods for recording information on computer readable medium to generate manufactures comprising the SNP information disclosed herein.

[0387] A variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon a nucleotide or amino acid sequence disclosed herein.

[0388] The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the nucleotide/amino acid sequence information on computer readable medium. For example, the sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, represented in the form of an ASCII file, or stored in a database application, such as OB2, Sybase, Oracle, or the like. A skilled artisan can readily adapt any number of data processor structuring formats (e.g., text file or database) in order to obtain computer readable medium having recorded thereon the SNP information described herein. For reference only, by providing the SNP described herein in computer readable form, a skilled artisan can routinely access the SNP information for a variety of purposes. Computer software is publicly available which allows a skilled artisan to access sequence information provided in a computer readable medium. Examples of publicly available computer software include BLAST (Altschul et al, *J. Mol. Biol.* 215:403-410 (1990)) and BLAZE (Brutlag et al, *Comp. Chem.* 17:203-207 (1993)) search algorithms.

[0389] For reference only, described herein are systems, particularly computer-based systems, which contain the SNP information described herein. Such systems may be designed to store and/or analyze information on, for example, a large number of SNP positions, or information on SNP genotypes from a large number of individuals. The SNP information described herein represents a valuable information source. For reference only, the SNP information described herein stored/analyzed in a computer-based system may be used for such computer-intensive applications as determining or analyzing SNP allele frequencies in a population, mapping disease genes, genotype-phenotype association studies, grouping SNPs into haplotypes, correlating SNP haplotypes with response to particular drugs, or for various other bioinformatic, pharmacogenomic, drug development, or human identification/forensic applications.

[0390] As used herein, "a computer-based system" refers to the hardware means, software means, and data storage means used to analyze the SNP information described herein. For reference only, the minimum hardware means of the computer-based systems typically comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently available computer-based systems are suitable for such use. Such a system can be changed into a system described herein by utilizing the SNP information

provided in the tables and Sequence Listing disclosed herein or a subset thereof, without any experimentation.

[0391] For reference only, the computer-based systems comprise a data storage means having stored therein SNP information described herein and the necessary hardware means and software means for supporting and implementing a search means. As used herein, "data storage means" refers to memory which can store SNP information, or a memory access means which can access manufactures having recorded thereon the SNP information.

[0392] As used herein, "search means" refers to one or more programs or algorithms that are implemented on the computer-based system to identify or analyze SNPs in a target sequence based on the SNP information stored within the data storage means. Search means can be used to determine which nucleotide is present at a particular SNP position in the target sequence. As used herein, a "target sequence" can be any DNA sequence containing the SNP position(s) to be searched or queried.

[0393] As used herein, "a target structural motif," or "target motif," refers to any rationally selected sequence or combination of sequences containing a SNP position in which the sequence(s) is chosen based on a three-dimensional configuration that is formed upon the folding of the target motif.

[0394] There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzymatic active sites and signal sequences. Nucleic acid target motifs include, but are not limited to, promoter sequences, hairpin structures, and inducible expression elements (protein binding sequences).

[0395] A variety of structural formats for the input and output means can be used to input and output the information in the computer-based systems. An exemplary format for an output means is a display that depicts the presence or absence of specified nucleotides (alleles) at particular SNP positions of interest. Such presentation can provide a rapid, binary scoring system for many SNPs simultaneously. For reference only, one exemplary embodiment of a computer-based system comprising SNP information described herein is provided in Figure 1. Figure 1 provides a block diagram of a computer system 102 that can be used to implement the embodiment. The computer system 102 includes a processor 106 connected to a bus 104. Also connected to the bus 104 are a main memory 108 (preferably implemented as random access memory, RAM) and a variety of secondary storage devices 110, such as a hard drive 112 and a removable medium storage device 114. The removable medium storage device 114 may represent, for example, a floppy disk drive, a CD-ROM drive, a magnetic tape drive, etc. A removable storage medium 116 (such as a floppy disk, a compact disk, a magnetic tape, etc.) containing control logic and/or data recorded therein may be inserted into the removable medium storage device 114. The computer system 102 includes appropriate software for reading the control logic and/or the data from the removable storage medium 116 once inserted in the removable medium storage device 114.

[0396] The SNP information described herein may be stored in a well-known manner in the main memory 108, any of the secondary storage devices 110, and/or a removable storage medium 116. Software for accessing and processing the SNP information (such as SNP scoring tools, search tools, comparing tools, etc.) preferably resides in main memory 108 during execution.

EXAMPLES: GENETIC POLYMORPHISMS ASSOCIATED WITH MI AND STATIN RESPONSE

[0397] The following examples are offered to illustrate, but not to limit the claimed invention.

STUDY DESIGNS

[0398] In order to identify genetic markers associated with acute coronary events (e.g. MI, stroke, unstable angina, congestive heart failure, etc.) or response to statin treatment for the prevention of coronary events, samples were genotyped in two clinical trials: the Cholesterol and Recurrent Events (CARE) study (a randomized multicenter double-blinded trial on secondary prevention of acute coronary events with pravastatin; Sacks et al., Am. J. Cardiol. 68: 1436-1446 [1991]), and the West of Scotland Coronary Prevention Study (WOSCOPS) study (Shepherd et al., N Eng J Med 333 (20), pp. 1301-7, Nov. 16, 1995; Packard et al., NEngJMed 343 (16), pp. 1148-55, Oct. 19, 2000).

[0399] A well-documented myocardial infarction (MI) was one of the enrollment criteria for entry into the CARE study. Patients were enrolled in the CARE trial from 80 participating study centers. Men and post-menopausal women were eligible for the trial if they had had an acute MI between 3 and 20 months prior to randomization, were 21 to 75 years of age, and had plasma total cholesterol levels of less than 240 mg/deciliter, LDL cholesterol levels of 115 to 174 mgs/deciliter, fasting triglyceride levels of less than 350 mgs/deciliter, fasting glucose levels of no more than 220 mgs/deciliter, left ventricular ejection fractions of no less than 25 %, and no symptomatic congestive heart failure. Patients were randomized to receive either 40 mg of pravastatin once daily or a matching placebo. The primary endpoint of the trial was death from coronary heart disease and the median duration of follow-up was 5.0 years (range, 4.0 to 6.2 years). All individuals included in the study had signed informed consent forms and the study protocol was approved by the respective Institutional Review Boards (IRBs).

[0400] For genotyping SNPs in CARE patient samples, DNA was extracted from blood samples using conventional DNA extraction methods such as the QIAamp kit from Qiagen. Genotypes were obtained by a method similar to that

described by Lannone (M.A. Lannone et al., *Cyrometry* 39(2):131-140 [Feb. 1, 2000]; also described in section "SNP DETECTION REAGENTS," *supra*). Briefly, target DNA was amplified by multiplex PCR, the amplified product was submitted to a multiplex oligo ligation assay (OLA), the specific ligated products were hybridized to unique universal "ZIP code" oligomer sequences covalently attached to Luminex xMAP® Multi-Analyte COOH Microspheres, and these hybridization products/microspheres were detected in a rapid automated multiplex system using the Luminex 100 instrument. Alternatively, allele specific primers were designed for detecting each SNP and genotypes were obtained on an ABI PRISM® 7900HT Sequence Detection PCR system (Applied Biosystems) by allele-specific PCR, similar to the method described by Germer et al (Germer S., Holland M.J., Higuchi R. 2000, *Genome Res.* 10: 258-266).

[0401] Genetic markers identified as associated with acute coronary events or response to statin treatment for the prevention of coronary events in the CARE samples were also genotyped in a second sample set, the West of Scotland Coronary Prevention Study (WOSCOPS). The design of the original WOSCOPS cohort and the nested case-control study have been described (Shepherd et al., *N Eng J Med* 333 (20), pp. 1301-7, Nov. 16, 1995; Packard et al., *N Eng J Med* 343 (16), pp. 1148-55, Oct. 19, 2000). The objective of the WOSCOPS trial was to assess pravastatin efficacy at reducing risk of primary MI or coronary death among Scottish men with hypercholesterolemia (fasting LDL cholesterol > 155 mg/dl). Participants in the WOSCOPS study were 45-64 years of age and followed for an average of 4.9 years for coronary events. The nested case-control study included as cases all WOSCOPS patients who experienced a coronary event (confirmed nonfatal MI, death from coronary heart disease, or a revascularization procedure; N=580). Controls were age- and smoking-matched unaffected patients. All individuals included in the study had signed informed consent forms and the study protocol was approved by the IRBs. DNA was extracted and genotyped as described above.

EXAMPLE 1: GENETIC POLYMORPHISM hCV3054799 ASSOCIATED WITH RISK OF MI/RMI AND RESPONSE TO STATIN TREATMENT

[0402] The association of hCV3054799 with risk of MI in patients was tested in two clinical trials, CARE and WOSCOPS, with patients receiving treatment with either pravastatin- or placebo. CARE was a secondary prevention trial (i.e., recurrent MI as endpoint) and WOSCOPS was a primary prevention trial. SNP genotype frequencies in a group of 244 patients who had a second MI during the five years of CARE follow-up (cases) were compared with the frequencies in the group of 2471 CARE patients who did not experience a second MI (controls). To replicate this finding, SNP genotype frequencies in a group of 483 patients who had an MI within the five years of the WOSCOPS follow-up (cases) were compared with the frequencies in the group of 1094 WOSCOPS patients who did not experience MI (controls). The analysis in WOSCOPS (a nested case-control study) was performed using the MI as an endpoint.

[0403] Tables 5-7 list the counts of total patients studied, as well as the number of patients in each treatment arm (study strata). Also presented are the counts of specific genotypes observed following the genotyping assays, their frequencies and the frequencies of the two alleles for this SNP. The counts represent the total number of valid genotyping assay results obtained, which in some instances is slightly less than the total number of patients enrolled in the study.

[0404] The statistics in Table 8 demonstrate the association of hCV3054799 with MI/RMI. In both the CARE and WOSCOPS studies, an association analysis was performed for each of the two modes of inheritance, dominant and recessive. Additionally, a genotypic test (heterozygote v. major homozygote) and an allelic test of association were performed using Fisher's exact method. Estimates of odds ratios and corresponding ninety-five percent confidence intervals were calculated. The significance of the disease association for hCV3054799 with the overall (unstratified) population, and with the placebo- or pravastatin-treated patients are indicated in Table 8. Analysis of these statistics shows that the association of hCV3054799 with MI risk is especially significant, and is replicated in both CARE and WOSCOPS studies. In patients that are heterozygous carriers of the minor allele, the odds ratio for risk of MI relative to patients with no minor allele is 1.7, with a P value below 0.01 both studies. The odds ratio is approximately the same (1.6-1.7) when calculated for the dominant mode of inheritance (a genotype with one or two minor alleles vs. none), with a P value less than or equal to 0.01 in both studies.

[0405] A logistic regression method was used to adjust for major epidemiologic risk factors in the CARE and WOSCOPS study samples (Table 8). In the CARE samples, this method adjusted for the risk factors associated with sex, family history, smoking status, body mass index and hypertension. In the WOSCOPS set, logistic regression was performed to adjust for the risk factors of family history and hypertension. No adjustments were made for sex or smoker status in the WOSCOPS set because all patients were male, and the cases and controls were matched as to smoker status. The odds ratios shown in Table 9 for heterozygous samples clearly confirm the association of hCV3054799 with MI risk, independent of and uninfluenced by other conventional risk factors. As in Table 8, the OR for risk of MI in a heterozygous carrier is approximately 1.7, with P values below 0.01 in both studies.

[0406] Also analyzed was whether hCV3054799 is associated with response to statin treatment (specifically, a decreased risk of MI as a result of treatment with pravastatin). Table 10 presents these risk association results. The number of heterozygous patients in the pravastatin treatment group who had a second MI during the five-year followup (cases) were compared with the number of heterozygous individuals who did not experience a second MI (controls). Heterozygous

carriers in the placebo treatment group were used as a reference in determining the odds ratios. Results in the columns under the heading "Risk Reduction by Statin" demonstrate the strong association of hCV3054799 with response to pravastatin treatment: an odds ratio of approximately 0.5 for carriers treated with pravastatin, with P values in both studies well below 0.01. These data indicate that carriers of this allele had a reduced risk of having an MI if they received statin treatment and particularly pravastatin treatment. For comparison, the odds ratio for association of this SNP with MI risk in placebo-treated carriers is also presented, under the heading "MI/RMI risk estimation" (data from Table 8; again, heterozygous carriers).

[0407] See also Tables 17 and 18 for additional data supporting the conclusion that individuals carrying certain hCV3054799 alleles had an increased risk of developing MI/RMI, and that they responded well to statin treatment. Data in Tables 17 and 18 were derived as follows:

[0408] In analyzing the CARE patients, statistical analysis was performed with SAS version 9. Cox proportional hazard models (Wald tests) were used in CARE to assess the association of genotype with both the risk of incident MI in the placebo arm and the effect of on MI pravastatin compared to placebo in subgroups defined by genotypes. In analyzing the WOSCOPS patients, a conditional logistic regression model was used in WOSCOPS given that the controls had been previously matched to the cases. The column entitled "On-trial MI" lists the number of patients who suffered an RMI during the clinical trial period.

[0409] In Table 18, p interaction values were calculated. An interaction (or effect modification) is formed when a third variable modifies the relation between an exposure and outcome. A p interaction <0.05 indicates that a third variable (genotype) modifies the relation between an exposure (statin treatment) and outcome (MI). Genotype and drug interaction is present when the incidence rate of disease in the presence of different genotypes under placebo and statin treatment differs from the incidence rate expected to result from their individual effects. HR stands for Hazard Ratio, which is a concept similar to Odds Ratio (OR). The hazard ratio in survival analysis is the effect of an explanatory variable on the hazard or risk of an event. It describes the likelihood of developing MI based on comparison of event rate between patient treated with pravastatin and placebo. The hCV3054799 risk allele predicted risk of MI in CARE and was associated with odds of CHD in WOSCOPS. In both trials, carriers of this risk allele (about 60% of population) benefited from pravastatin treatment.

EXAMPLE 2: OTHER GENETIC POLYMORPHISMS ASSOCIATED WITH RISK OF MI/RMI AND RESPONSE TO STATIN TREATMENT

[0410] An additional 175 markers were analyzed in samples from the CARE study (secondary MI prevention trial). All patients in CARE had an MI within ten months prior to enrollment in the trial. During the five years of follow-up, 264 patients experienced a recurrent MI (cases) and 2649 patients did not (controls). Of the cases, 150 received placebo treatment and 114 received pravastatin; of the controls, 1290 received placebo and 1359 received pravastatin.

[0411] Tables 11-13 show the total counts of case and control samples for each SNP, and a breakdown of cases and controls by genotype: major and minor homozygous individuals, and heterozygous individuals. Table 11 shows the data for the placebo-treatment arm of the study, Table 12, the pravastatin-treatment arm, and Table 13, data for all samples unstratified by treatment.

[0412] The genotypes for each SNP were tested for association with RMI. This genotypic test of association (i.e., minor homozygote genotype vs. major, and heterozygote vs. major) was performed separately for placebo-treated patients and for all patients unstratified by treatment group, using the Fisher's exact method. Table 14 shows the odds ratios obtained from the genotypic analysis of the placebo-treatment arm (under the headings "Homozygous Minor" and "Heterozygous Carriers"). The reliability of the OR for each particular SNP is confirmed by its respective 95% confidence interval (CI) and P value, also shown. From Table 14 one can see the association of several SNPs with MI risk when they are present in a Homozygous Minor genotype (association based on an OR > 1, the lower limit of the 95% CI > 1 and a P value < 0.05). These SNPs include but are not limited to: hCV11433557, hCV16054991, hCV25472673, and hCV7514870. In the Heterozygous Carriers genotype, SNPs associated with an increased risk of RMI in Table 14 are: hCV11450617, hCV16189747, hCV25963691, hCV3054799 and hCV465412.

[0413] The Dominant and Recessive modes of inheritance for each SNP were also tested for association with MI risk (i.e., Dominant = one or two minor alleles vs. none; Recessive = two minor alleles vs. one or none), in placebo-treated and unstratified sample groups. Table 14 shows modal results for the placebo-treated patients. According to the OR's, P values and confidence intervals listed, all of the SNPs mentioned above as associated with MI risk in Heterozygous Carriers are also associated with increased risk for MI in the Dominant inheritance mode, excepting hCV25963691 and with the addition of hCV1801149 (OR 2.14, P value 0.04). Likewise, all of the SNPs listed above as associated with risk in Homozygous Minor patients are also associated with increased risk for MI in the Recessive inheritance mode.

[0414] Table 15 shows results of the genotypic and modal tests of association performed on all patients unstratified by treatment arm; i.e., including statin-treated patients. In this analysis (again according to OR, 95% CI and P value), SNP's significantly associated with MI when present in the Homozygous Minor genotype include: hCV16203383,

hCV2146578 and hCV25936375. In the Heterozygous Carriers genotype, MI-risk SNP's include: hCV11450617, hCV16189747, hCV25624196, hCV25963691 and hCV3054799.

[0415] The Dominant and Recessive modal results of Table 15 (patients unstratified by treatment arm) indicate that in the Dominant mode, SNP's associated with an increased risk of RMI include: hCV11450617, hCV16189747, hCV25624196, hCV25741584 and hCV3054799. In the Recessive mode, SNP's associated with an increases risk of RMI include: hCV16054991, hCV16203383 and hCV25936375.

[0416] The statistical results in Table 16 demonstrate the SNPs predictive of response to statin treatment in the prevention of RMI. All of these SNPs show a significant difference in risk association between their respective placebo- and statin-treated patient groups, as evidenced by Breslow Day P value for each SNP (<0.05). For all SNPs in Table 16, the minor homozygous individuals showed statistically different associations with statin response (OR of placebo vs. pravastatin treatment) when compared to heterozygous and major homozygous individuals. That is, these SNPs, when present in a genotype of one and/or two alleles, are associated with a response to statin treatment such that risk of MI is reduced. Here the Breslow-Day statistics tests whether the odds ratios for MI are different between carriers and non-carriers. A Breslow-Day p value <0.05 means that the association between treatment group and MI is not homogenous across genotypes, therefore, this SNP may be associated with variability in statin response.

[0417] As shown in Tables 19 and 20, certain individuals carrying SNPs who were identified in Table 14 as being associated with an increased risk of developing MI/RMI can benefit from being treated with statin because statin reduced their risk of developing MI/RMI, as compared those who did not undergo statin treatment. For example, in the case of hCV11450617, individuals with Heterozygous genotype and the Dominant genotype have their risk of developing MI reduced by statin treatment.

EXAMPLE 3: ADDITIONAL SNPS IN LD WITH SNPS THAT ARE ASSOCIATED WITH RISK OF MI/RMI AND RESPONSE TO STATIN TREATMENT

[0418] An investigation was conducted to identify SNP markers in linkage disequilibrium (LD) with SNPs which have been found to be associated with risk of MI/RMI and response to statin treatment, such as those shown in Tables 1-20. Briefly, the power threshold (T) was set at 51% for detecting disease association using LD markers. This power threshold is based on equation (31) above, which incorporates allele frequency data from previous disease association studies, the predicted error rate for not detecting truly disease-associated markers, and a significance level of 0.05. Using this power calculation and the sample size, for each interrogated SNP a threshold level of LD, or r^2 value, was derived (r_T^2 ,

equations (32) and (33)). The threshold value r_T^2 is the minimum value of linkage disequilibrium between the interrogated SNP and its LD SNPs possible such that the non-interrogated SNP still retains a power greater or equal to T for detecting disease-association.

[0419] Based on the methodology described above, LD SNPs were discovered for the interrogated SNPs shown in Tables 5-20. Table 21 shows a listing of some of the LD SNPs, each of which is associated with its respective interrogated SNP. Also shown are the public SNP IDs (rs numbers) for interrogated and LD SNPs, the threshold r^2 value and the power used to determine this, and the r^2 value of linkage disequilibrium between the interrogated SNP and its matching LD SNP. As an example in Table LD SNP, MI/RMI-associated SNP hCV1450617 was calculated to be in LD with hCV27846382 at an r^2 value of 0.73586, based on a 51% power calculation. Thus, hCV27846382 would also be a MI/RMI-associated SNP due to its being in LD with the interrogated SNP hCV11450617.

Table 1

Gene Number: 6 / Celera Gene: hCG1647070 - 84000313730920 / Celera Transcript: hCT1647197 - 84000313730921 / Public Transcript Accession: / Celera Protein: hCP1617236 - 197000069366336 / Public Protein Accession: / Gene Symbol: KJF6 / Protein Name: / Celera Genomic Axis: GA_x5YUV32W6W6(12311520..12426711) / Chromosome: 6 / OMIM NUMBER: / OMIM Information: // Transcript Sequence (SEQ ID NO:1): // Protein Sequence (SEQ ID NO: 2): // SNP Information // Context (SEQ ID NO:3): / Celera SNP ID: hCV3054799 / Public SNP ID: rs20455 / SNP in Transcript Sequence SEQ ID NO:1 SNP Position Transcript: 694 / SNP Source: ABI_Val;Celera;HGBASE;HapMap; dbSNP / Population(A allele,Count): no_pop(T,-|C,-) / SNP Type: Missense Mutation / Protein Coding: SEQ ID NO:2, at position 170,(W,TGG) (R,CGG)

EP 1 926 491 B1

Table 2:

Gene Number : 6 / Celera Gene: hCG1647070 - 84000313730920 / Gene Symbol: KIF6 / Protein Name: / Celera
 Genomic Axis: GA_x5YUV32W6W6(12311520..12426711)/Chromosome: 6 / OMIM NUMBER: / OMIM Information:
 // Genomic Sequence (SEQ ID NO:4): // SNP Information // Context (SEQ ID NO:5): / Celera SNP ID: hCV3054799
 / Public SNP ID: rs20455 / SNP in Genomic Sequence: SEQ ID NO:4 / SNP Position Genomic: 31149 / SNP Source:
 ABI_Val;Applera;Celera;HGBASE;HapMap;dbSNP / Population(A, -|G, -) / SNP Type:
 MISSENSE MUTATION

Table 5: Allelic counts for hCV3054799.

Study	Stratum	All Count	Case Count	Cont Count	Major Allele			Minor Allele		
					Allele	Case Freq	Cont Freq	Allele	Case Freq	Cont Freq
CARE	Unstratified	2714	244	2470	A	0.60	0.64	G	0.40	0.36
	Placebo	1334	142	1192	A	0.60	0.65	G	0.40	0.35
	Pravastatin	1380	102	1278	A	0.60	0.64	G	0.40	0.36
WOSCOPS	Unstratified	1548	478	1070	A	0.63	0.66	G	0.37	0.34
	Placebo	808	286	522	A	0.62	0.69	G	0.38	0.31
	Pravastatin	740	192	548	A	0.65	0.63	G	0.35	0.37

Table 6:

Genotypic counts for hCV3054799.																		
Study	Major homozygous						Minor homozygous						Heterozygous					
	Genot	Case Count	Cont Count	Case Freq	Cont Freq		Genot	Case Count	Cont Count	Case Freq	Cont Freq		Genot	Case Count	Cont Count	Case Freq	Cont Freq	
CARE	AA	82	1030	0.34	0.42		GG	35	314	0.14	0.13		GA	127	1126	0.52	0.46	
	AA	44	502	0.31	0.42		GG	17	143	0.12	0.12		GA	81	547	0.57	0.46	
	AA	38	528	0.37	0.41		GG	18	171	0.18	0.13		GA	46	579	0.45	0.45	
WOSCOPS	AA	189	475	0.40	0.44		GG	67	132	0.14	0.12		GA	222	463	0.46	0.43	
	AA	105	259	0.37	0.50		GG	39	58	0.14	0.11		GA	142	205	0.50	0.39	
	AA	84	216	0.44	0.39		GG	28	74	0.15	0.14		GA	80	258	0.42	0.47	

Table 7: Combined counts for hCV3054799

Study	Maj hom + Het		Het + Min hom	
	Case Count	Cont Count	Case Count	Cont Count
CARE	209	2156	162	1440
	125	1049	98	690
	84	1107	64	750
WOSCOPS	411	938	289	595
	247	464	181	263
	164	474	108	332

Table 8: Association of genetic polymorphism hCV3054799 with MI/RMI risk- estimates unadjusted.

Study	Stratum	Heterozygous Carriers (Het vs. Maj hom)			Dominant ([Het + Min hom] vs. Maj hom)			Recessive (Min hom vs. [Maj hom + Het])			Allelic		
		OR	95% CI	P value*	OR	95% CI	P value*	OR	95% CI	P value*	OR	95% CI	P value*
CARE	Unstratified	1.42	1.06-1.89	0.0201	1.41	1.07-1.86	0.0141	1.15	0.79-1.68	0.4825	1.23	1.02-1.49	0.0336
	Placebo	1.69	1.15-2.49	0.0078	1.62	1.12-2.35	0.0114	1.00	0.58-1.71	1.0000	1.27	0.98-1.63	0.0666
	Pravastatin	1.10	0.71-1.72	0.7342	1.19	0.78-1.80	0.4647	1.39	0.81-2.37	0.2314	1.19	0.89-1.60	0.2570
WOSCOPS	Unstratified	1.21	0.96-1.52	0.1241	1.22	0.98-1.52	0.0756	1.16	0.84-1.59	0.3667	1.15	0.98-1.35	0.0796
	Placebo	1.71	1.25-2.33	0.0009	1.70	1.26-2.28	0.0005	1.26	0.82-1.95	0.3091	1.41	1.14-1.74	0.0020
	Pravastatin	0.80	0.56-1.14	0.2381	0.84	0.60-1.17	0.3061	1.09	0.68-1.75	0.7159	0.93	0.73-1.19	0.5800
*Fisher's exact P value.													

Table 9: Association of genetic polymorphism hCV3054799 with MI/RMI risk- estimates adjusted by logistic regression.

Study	Genotype	Risk Freq*	OR**	95% CI	P value***
CARE	Min hom	0.12	1.36	0.75-2.44	0.321
	Het	0.47	1.69	1.14-2.49	0.008
WOSCOPS	Min hom	0.12	1.62	1.01-2.60	0.043
	Het	0.43	1.65	1.21-2.25	0.002
*Chi-square test for frequency of risk genotype. **Odds ratio derived from patients in Placebo treatment arm. ***Fisher's exact P value.					

Table 10: Association of genetic polymorphism hCV3054799 with MI/RMI risk and response to statin treatment.

study	MI/RMI risk estimation (Het vs. Maj hom)* Placebo stratum			Risk Reduction by Statin (Pravastatin vs. Placebo) Heterozygous carriers		
	OR	95% CI	P value**	OR	95% CI	P value**
CARE	1.69	1.15-2.49	0.0078	0.54	0.36-0.78	0.00139
WOSCOPS	1.71	1.25-2.33	0.0009	0.45	0.32-0.62	0.0000014
*Data also presented in Table 9, Heterozygous carriers. **Fisher's exact P value.						

Marker	Case		Cont		Major homozygous				Minor homozygous				Heterozygous			
	Count	Count	Genotype	Case Count	Cont Count	Genotype	Case Count	Cont Count	Genotype	Case Count	Cont Count	Genotype	Case Count	Cont Count		
hCV11433557	102	943	CC	57	592	CC	57	592	GG	9	41	GC	36	310		
hCV11450617	145	1220	GG	61	633	GG	61	633	AA	13	101	AG	71	486		
hCV12107274	104	942	CC	54	423	CC	54	423	TT	8	122	TC	42	397		
hCV15965459	133	1157	TT	95	843	TT	95	843	AA	1	20	AT	37	294		
hCV15973230	124	1023	GG	91	657	GG	91	657	AA	3	61	AG	30	305		
hCV15974589	101	938	CC	31	238	CC	31	238	TT	21	220	TC	49	480		
hCV1603656	104	947	CC	82	818	CC	82	818	TT	2	6	TC	20	123		
hCV16054991	132	1145	GG	60	599	GG	60	599	AA	17	81	AG	55	465		
hCV16189747	138	1174	CC	61	641	CC	61	641	AA	9	75	AC	68	458		
hCV1801149	50	403	GG	36	341	GG	36	341	AA	1	2	AG	13	60		
hCV22275215	103	947	CC	79	632	CC	79	632	TT	2	39	TC	22	276		
hCV2476746	123	1016	CC	55	405	CC	55	405	TT	9	138	TC	59	473		
hCV25472673	104	947	TT	29	338	TT	29	338	CC	22	133	CT	53	476		
hCV25623506	104	947	CC	101	894	CC	101	894	TT	0	2	TC	3	51		
hCV25745415	145	1217	GG	91	718	GG	91	718	TT	2	63	TG	52	436		
hCV25749177	145	1217	GG	89	704	GG	89	704	AA	4	75	AG	52	438		
hCV25963691	145	1217	CC	84	793	CC	84	793	GG	3	52	GC	58	372		
hCV2741051	104	947	TT	66	494	TT	66	494	CC	3	67	CT	35	386		
hCV3054799	104	945	AA	29	398	AA	29	398	GG	13	116	GA	62	431		
hCV465412	133	1157	CC	88	881	CC	88	881	AA	2	27	AC	43	249		
hCV7514870	103	936	CC	41	436	CC	41	436	AA	17	90	AC	45	410		
hCV881283	145	1219	GG	130	1129	GG	130	1129	CC	0	2	CG	15	88		

Table 12: Genotypic counts for genetic polymorphisms in CARE study - Pravastatin treatment arm.

Marker	Case Count	Cont Count	Genotype	Case Count	Cont Count	Genotype	Case Count	Cont Count	Genotype	Case Count	Cont Count
hCV12107274	84	1040	CC	34	481	TC	37	446	TT	13	113
hCV15965459	99	1231	TT	85	918	AT	13	292	AA	1	21
hCV15974589	85	1036	CC	16	286	TC	35	514	TT	34	236
hCV1603656	85	1047	CC	76	873	TC	9	166	TT	0	8
hCV16054991	95	1216	GG	58	661	AG	29	467	AA	8	88
hCV25472673	85	1046	TT	38	392	CT	33	482	CC	14	172
hCV25623506	85	1046	CC	72	984	TC	12	62	TT	1	0
hCV25745415	107	1302	GG	57	798	TG	39	445	TT	11	59
hCV25749177	107	1300	GG	56	776	AG	39	444	AA	12	80
hCV2741051	85	1046	TT	39	533	CT	40	433	CC	6	80
hCV881283	107	1303	GG	103	1179	CG	4	122	CC	0	2

Table 13: Genotypic counts for genetic polymorphisms in CARE study - Unstratified by treatment arm.

Marker	Case Count	Cont Count	Genot	Case Count	Cont Count	Genot	Case Count	Cont Count	Genot	Case Count	Cont Count
hCV11450617	252	2523	AA	22	204	AG	120	1034	GG	110	1285
hCV15973230	216	2135	AA	5	118	AG	62	664	GG	149	1353
hCV16054991	227	2361	AA	25	169	AG	84	932	GG	118	1260
hCV16189747	241	2428	AA	15	153	AC	120	909	CC	106	1366
hCV16203383	248	2513	TT	35	253	TC	114	1077	CC	99	1183
hCV1690777	213	2104	GG	0	4	GA	7	147	AA	206	1953
hCV2146578	215	2127	TT	49	372	TC	103	1033	CC	63	722
hCV22275215	188	1994	TT	4	76	TC	41	592	CC	143	1326
hCV2476746	215	2117	TT	18	283	TC	96	967	CC	101	867
hCV25624196	213	2101	AA	5	52	AG	62	471	GG	146	1578
hCV25741584	232	2390	CC	0	0	CG	8	35	GG	224	2355
hCV25936375	233	2402	AA	12	64	AG	62	649	GG	159	1689
hCV25963691	251	2521	GG	5	100	GC	99	793	CC	147	1628
hCV3054799	189	1990	GG	29	259	GA	100	898	AA	60	833
hCV3200162	189	1993	GG	16	234	GA	75	885	AA	98	874
hCV945276	243	2421	TT	34	459	TG	121	1181	GG	88	781
hCV9879153	188	1992	TT	36	436	TC	85	986	CC	67	570

Table 14: RMI risk association of genetic polymorphisms in CARE study - Placebo treatment arm.

Marker	Minor Homozygous (Min hom vs. Maj hom)			Heterozygous Carriers (Het vs. Maj hom)			Dominant ([Het + Min hom]) vs. Maj hom			Recessive Min hom vs. ([Het+Maj hom])		
	OR	95% CI	P value*	OR	95% CI	P value*	OR	95% CI	P value*	OR	95% CI	P value*
hCV11433557	2.28	1.05-4.93	0.0425	1.21	0.78-1.87	0.4242	1.33	0.88-2.01	0.1972	2.13	1.00-4.52	0.0519
hCV11450617	1.34	0.71-2.52	0.3807	1.52	1.06-2.18	0.0262	1.48	1.05-2.10	0.0280	1.09	0.60-2.00	0.7512
hCV15973230	0.36	0.11-1.16	0.0999	0.71	0.46-1.10	0.1437	0.65	0.43-0.99	0.0459	0.39	0.12-1.27	0.1437
hCV16054991	2.10	1.17-3.77	0.0186	1.18	0.80-1.74	0.4295	1.32	0.92-1.89	0.1419	1.94	1.11-3.39	0.0240
hCV16189747	1.26	0.60-2.64	0.5424	1.56	1.08-2.25	0.0186	1.52	1.06-2.17	0.0239	1.02	0.50-2.09	0.8559
hCV1801149	4.74	0.42-53.53	0.2652	2.05	1.03-4.10	0.0616	2.14	1.09-4.20	0.0422	4.09	0.36-45.96	0.2965
hCV22275215	0.41	0.10-1.73	0.3005	0.64	0.39-1.04	0.0842	0.61	0.38-0.98	0.0454	0.46	0.11-1.94	0.4208
hCV2476746	0.48	0.23-1.00	0.0456	0.92	0.62-1.36	0.6905	0.82	0.56-1.19	0.3307	0.50	0.25-1.01	0.0627
hCV25472673	1.93	1.07-3.48	0.0352	1.30	0.81-2.08	0.2918	1.44	0.92-2.25	0.1292	1.64	0.99-2.72	0.0584
hCV25745415	0.25	0.06-1.04	0.0362	0.94	0.66-1.35	0.7841	0.85	0.60-1.22	0.4211	0.26	0.06-1.06	0.0389
hCV25963691	0.54	0.17-1.78	0.4709	1.47	1.03-2.10	0.0373	1.36	0.96-1.93	0.0984	0.47	0.15-1.54	0.2657
hCV2741051	0.34	0.10-1.10	0.0664	0.68	0.44-1.04	0.0892	0.63	0.41-0.95	0.0299	0.39	0.12-1.26	0.1435
hCV3054799	1.54	0.77-3.05	0.2528	1.97	1.24-3.13	0.0038	1.88	1.20-2.94	0.0060	1.02	0.55-1.88	0.8762
hCV465412	0.74	0.17-3.17	1.0000	1.73	1.17-2.56	0.0083	1.63	1.11-2.40	0.0147	0.64	0.15-2.72	0.7608
hCV7514870	2.01	1.09-3.69	0.0308	1.17	0.75-1.82	0.4996	1.32	0.87-2.00	0.2117	1.86	1.06-3.27	0.0389

For hCV15973230, hCV22275215 and hCV2741051, major homozygotes were associated with RMI using heterozygotes and minor homozygotes as reference.

For hCV2476746 and hCV25745415, major homozygotes were associated with RMI using minor homozygotes as reference.

Table 15: RMI risk association of genetic polymorphisms in CARE study - Unstratified by treatment arm.

Marker	Minor Homozygous (Min hom vs. Maj hom)			Heterozygous carriers (Het vs. Maj hom)			Dominant ([Het+Min hom]) vs. Maj hom			Recessive Min hom vs. (Het+ Maj hom)]		
	OR	95% CI	P value*	OR	95% CI	P value*	OR	95% CI	P value*	OR	95% CI	P value*
hCV11450617	1.26	0.78-2.04	0.3583	1.36	1.03-1.78	0.0312	1.34	1.03-1.74	0.0292	1.09	0.69-1.72	0.7169
hCV15973230	0.38	0.15-0.96	0.0357	0.85	0.62-1.16	0.3162	0.78	0.58-1.05	0.1183	0.41	0.16-1.00	0.0520
hCV16054991	1.58	1.00-2.50	0.0609	0.96	0.72-1.29	0.8237	1.06	0.80-1.39	0.7278	1.61	1.03-2.50	0.0464
hCV16189747	1.26	0.72-2.22	0.4347	1.70	1.29-2.24	0.0002	1.64	1.25-2.14	0.0003	0.99	0.57-1.71	1.0000
hCV16203383	1.65	1.10-2.49	0.0192	1.26	0.95-1.68	0.1144	1.34	1.03-1.75	0.0327	1.47	1.00-2.15	0.0502
hCV1690777	0.00	0.00-0.00	1.0000	0.45	0.21-0.98	0.0420	0.44	0.20-0.95	0.0314	0.00	0.00-0.00	1.0000
hCV2146578	1.51	1.02-2.24	0.0476	1.14	0.82-1.59	0.4577	1.24	0.91-1.69	0.1734	1.39	0.99-1.95	0.0619
hCV22275215	0.49	0.18-1.35	0.2361	0.64	0.45-0.92	0.0147	0.62	0.44-0.88	0.0072	0.55	0.20-1.52	0.3109
hCV2476746	0.55	0.32-0.92	0.0230	0.85	0.64-1.14	0.2941	0.78	0.59-1.04	0.0948	0.59	0.36-0.97	0.0418
hCV25624196	1.04	0.41-2.64	0.8114	1.42	1.04-1.95	0.0320	1.38	1.02-1.88	0.0392	0.95	0.37-2.40	1.0000
hCV25741584	0.00	0.00-0.00	1.0000	2.40	1.10-5.24	0.0498	2.40	1.10-5.24	0.0498	0.00	0.00-0.00	1.0000
hCV25936375	1.99	1.05-3.77	0.0390	1.01	0.75-1.38	0.9374	1.10	0.83-1.47	0.5008	1.98	1.05-3.73	0.0391
hCV25963691	0.55	0.22-1.38	0.2671	1.38	1.06-1.81	0.0193	1.29	0.99-1.68	0.0626	0.49	0.20-1.22	0.1623
hCV3054799	1.55	0.98-2.47	0.0718	1.55	1.11-2.16	0.0103	1.55	1.13-2.13	0.0067	1.21	0.80-1.84	0.3687
hCV3200162	0.61	0.35-1.05	0.0872	0.76	0.55-1.04	0.0940	0.73	0.54-0.98	0.0386	0.70	0.41-1.18	0.1904
hCV945276	0.66	0.44-0.99	0.0483	0.91	0.68-1.21	0.5526	0.84	0.64-1.10	0.2225	0.70	0.48-1.01	0.0570
hCV9879153	0.70	0.46-1.07	0.1164	0.73	0.52-1.03	0.0787	0.72	0.53-0.99	0.0445	0.85	0.58-1.23	0.4061

Table 16: Association of genetic polymorphisms with response to statin treatment in CARE study. Risk of RMI in placebo- vs. pravastatin-treated patients.

Marker	Major homozygous			Minor homozygous			Heterozygous			BD P value**
	OR	95% CI	P value*	OR	95% CI	P value*	OR	95% CI	P value*	
hCV12107274	0.55	0.35-0.87	0.0100	1.75	0.70-4.39	0.2598	0.78	0.49-1.24	0.3462	0.0255
hCV15965459	0.82	0.60-1.12	0.2115	0.95	0.06-16.28	1.0000	0.35	0.18-0.68	0.0011	0.0408
hCV15974589	0.43	0.23-0.80	0.0090	1.51	0.85-2.68	0.1979	0.67	0.42-1.05	0.0881	0.0018
hCV1603656	0.87	0.63-1.20	0.4064	0.00	0.00-0.00	0.4667	0.33	0.15-0.76	0.0099	0.0097
hCV16054991	0.88	0.60-1.28	0.5015	0.43	0.18-1.06	0.0854	0.53	0.33-0.84	0.0063	0.0463
hCV25472673	1.13	0.68-1.87	0.7014	0.49	0.24-1.00	0.0524	0.61	0.39-0.97	0.0422	0.0382
hCV25623506	0.65	0.47-0.89	0.0069	0.00	0.00-0.00	0.3333	3.29	0.88-12.30	0.0939	0.0035
hCV25745415	0.56	0.40-0.80	0.0010	5.87	1.25-27.61	0.0176	0.73	0.48-1.14	0.1865	0.0073
hCV25749177	0.57	0.40-0.81	0.0017	2.81	0.87-9.10	0.1124	0.74	0.48-1.14	0.1873	0.0169
hCV2741051	0.55	0.36-0.83	0.0041	1.68	0.40-6.95	0.7321	1.02	0.63-1.64	1.0000	0.0307
hCV881383	0.76	0.58-0.99	0.0464	0.00	0.00-0.00	1.0000	0.19	0.06-0.60	0.0029	0.0185
*Fisher's exact P value.										
**Breslow-Day P value.										

Table 17: Association of *KIF6* hCV3054799 with MI and CHD in the placebo arm of CARE and WOSCOPS

Study	Genotype	On-trial MI*	Total*	Unadjusted			Adjusted†		
				HR	95%CI	p Value	HR	95%CI	p Value
CARE	GG	16	155	1.33	0.75-2.35	0.33	1.33	0.75-2.36	0.33
	GA	82	636	1.63	1.13-2.35	0.009	1.54	1.07-2.23	0.02
	GG+GA	98	791	1.57	1.10-2.25	0.013	1.50	1.05-2.15	0.03
	AA	44	542	1.00	ref		1.00	ref	
Study	Genotype	Case*	Control*	Matched‡			Adjusted†‡		
				OR	95%CI	p Value	OR	95%CI	p Value
WOSCOPS	GG	35	59	1.49	0.92-2.40	0.10	1.48	0.91-2.41	0.11
	GA	137	204	1.61	1.18-2.21	0.003	1.56	1.14-2.15	0.006
	GG+GA	172	263	1.59	1.18-2.14	0.003	1.55	1.14-2.09	0.005
	AA	104	256	1.00	ref		1.00	ref	

*Data for patients presented as number of patients

†Adjusted for age (continuous), sex, smoking (current versus non-current) (except in WOSCOPS, where no adjustments for age and smoking were made because cases and controls were matched), history of hypertension, history of diabetes, BMI (continuous), baseline LDL-C level (continuous), and baseline HDL-C level (continuous).

‡Cases and controls were matched for age (in two-year age groups) and smoking (current versus non-current), all were men.

Table 18: Effect of pravastatin on MI and CHD in *KIF6* hCV3054799 subgroups: CARE and WOSCOPS

Study	Genotype	Treatment	On-trial MI*	Total*	Unadjusted			Adjusted†		
					HR	95% CI	p Value	HR	95% CI	p Value
CARE	GG + GA	Pravastatin	64	810	0.63	0.46-0.86	0.004	0.63	0.46-0.87	0.005
		Placebo	98	791	1.00	ref		1.00	ref	
	AA	Pravastatin	39	554	0.86	0.56-1.33	0.50	0.80	0.52-1.24	0.32
		Placebo	44	542	1.00	ref		1.00	ref	
					p interaction 0.25§			p interaction 0.39§		
Study	Genotype	Treatment	Case*	Control*	Matched††			Adjusted††		
					OR†	95% CI†	p Value	OR†	95% CI	p Value
WOSCOPS	GG + GA	Pravastatin	108	330	0.50	0.38-0.67	<0.0001	0.50	0.38-0.67	<0.0001
		Placebo	172	263	1.00	ref		1.00	ref	
	AA	Pravastatin	81	213	0.94	0.67-1.33	0.73	0.91	0.64-1.28	0.58
		Placebo	104	256	1.00	ref		1.00	ref	
					p interaction 0.006§			p interaction 0.011§		

data for patients presented as number of patients

†Adjusted for age (continuous), smoking (current versus non-current) (except in WOSCOPS, where no adjustment for age and smoking were made because cases and controls were matched), history of hypertension, history of diabetes, BMI (continuous), baseline LDL-C level (continuous), and baseline HDL-C level (continuous). †Cases and controls were matched for age (in two-year age groups) and smoking (current versus non-current), all were men.

§Likelihood ratio test of interaction between *KIF6* hCV3054799 genotype and treatment.

Table 19: Genotypic counts for genetic polymorphisms in CARE study - Placebo arm and statin arm

	Marker	Treatment	Genot	case cnt	control cnt	Genot	case cnt	control cnt	Genot	case cnt	control cnt
5	hCV11450617	placebo	A A	13	101	A G	71	486	GG	61	633
	hCV11450617	statin	AA	9	103	A G	49	548	GG	49	652
	hCV15973230	placebo	A A	3	61	A G	30	305	GG	91	657
	hCV15973230	statin	A A	2	57	A G	32	359	GG	58	696
10	hCV25745415	placebo	T T	2	63	T G	52	436	GG	91	718
	hCV25745415	statin	T T	11	59	T G	39	445	GG	57	798
	hCV25963691	placebo	G G	3	52	G C	58	372	CC	84	793
	hCT25963691	statin	G G	2	48	G C	41	421	CC	63	835
15	hCV2741051	placebo	C C	3	67	C T	35	386	TT	66	494
	hCV2741051	statin	CC	6	80	CT	40	433	TT	39	533
	hCV3054799	placebo	G G	13	116	G A	62	431	AA	29	398
	hCV3054799	statin	G G	16	143	G A	38	467	AA	31	435
	hCV465412	placebo	A A	2	27	A C	43	249	CC	88	881
20	hCV465412	statin	A A	2	20	A C	24	298	CC	73	910
	hCV7514870	placebo	A A	17	90	A C	45	410	CC	41	436
	hCV7514870	statin	A A	9	130	A C	40	439	CC	35	466

25

30

35

40

45

50

55

Table 20: Risk reduction by pravastatin in CARE patients stratified by genotypes of the SNPs associated with MI (table 14) Risk of RMI in placebo- vs. pravastatin-treated patients.

Marker	Minor Homozygous			Heterozygous			Major Homozygous			Dominant		
	OR_min	95%CI	P value*	OR_het	95%CI	P value*	OR_maj	95%CI	P value*	OR_dom	95%CI	P value*
hCV11450617	0.68	0.28-1.66	0.502	0.61	0.42-0.9	0.012	0.78	0.53-1.16	0.234	0.62	0.44-0.89	0.010
hCV11450617												
hCV15973230	0.71	0.12-4.43	1.000	0.91	0.54-1.53	0.790	0.60	0.43-0.86	0.004	0.91	0.56-1.5	0.704
hCV15973230												
hCV25745415	5.87	1.25-27.62	0.018	0.73	0.48-1.14	0.187	0.56	0.4-0.8	0.001	0.92	0.62-1.38	0.682
hCV25745415												
hCV25963691	0.72	0.12-4.52	1.000	0.62	0.41-0.96	0.033	0.71	0.51-1.01	0.058	0.64	0.43-0.97	0.038
hCV25963691												
hCV2741051	1.68	0.41-6.96	0.732	1.02	0.64-1.64	1.000	0.55	0.37-0.83	0.004	1.07	0.69-1.68	0.820
hCV2741051												
hCV3054799	1.00	0.47-2.17	1.000	0.57	0.37-0.87	0.008	0.98	0.58-1.66	1.000	0.65	0.45-0.94	0.020
hCV3054799												
hCV465412	1.35	0.18-10.42	1.000	0.47	0.28-0.79	0.004	0.80	0.59-1.12	0.189	0.50	0.31-0.84	0.008
hCV465412												
hCV7514870	0.37	0.16-0.86	0.021	0.83	0.54-1.3	0.428	0.80	0.5-1.28	0.403	0.69	0.47-1.03	0.073
hCV514870												
*Fisher's exact P value.												

Table 21: LD SNPs associated with MI/RMI risks and statin response

	Interrogated SNP	Interrogated SNP RS	LD SNP	LD SNP RS	Power	Threshold r_T^2	r^2
5	hCV11450617	rs1944270	hCV27846382	rs7234924	0.51	0.58	0.73586
	hCV15973230	rs2304024	hCV25639371	rs3734051	0.51	0.39	0.60534
	hCV15973230	rs2304024	hCV25951598	rs3734049	0.51	0.39	0.8599
	hCV15973230	rs2304024	hCV25953895	rs3734047	0.51	0.39	0.86466
10	hCV15973230	rs2304024	hCV31985917	rs6870052	0.51	0.39	0.86466
	hCV15974589	rs4875	hCV1238304	rs8455	0.51	0.93	0.9329
	hCV15974589	rs4875	hCV2004219	rs891464	0.51	0.93	1
	hCV15974589	rs4875	hCV29114176	rs6804259	0.51	0.93	0.96148
15	hCV15974589	rs4875	hCV29114183	rs7621897	0.51	0.93	1
	hCV15974589	rs4875	hCV29114184	rs6772483	0.51	0.93	1
	hCV15974589	rs4875	hCV29593475	rs9819567	0.51	0.93	1
	hCV15974589	rs4875	hCV29864539	rs6803047	0.51	0.93	1
20	hCV15974589	rs4875	hCV3175476	rs6800914	0.51	0.93	0.96448
	hCV16189747	rs2298566	hCV1067003	rs735094	0.51	0.24	0.32038
	hCV16189747	rs2298566	hCV11345437	rs7937411	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV11345444	rs7937166	0.51	0.24	0.84361
25	hCV16189747	rs2298566	hCV25626063	rs3751039	0.51	0.24	0.3836
	hCV16189747	rs2298566	hCV25626077	rs4414223	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV25626089	rs4586174	0.51	0.24	0.9631
	hCV16189747	rs2298566	hCV25626101	rs6590537	0.51	0.24	0.84541
30	hCV16189747	rs2298566	hCV25759522	rs3751037	0.51	0.24	0.96383
	hCV16189747	rs2298566	hCV25767057	rs12421950	0.51	0.24	0.24257
	hCV16189747	rs2298566	hCV26490015	rs7942621	0.51	0.24	0.41952
	hCV16189747	rs2298566	hCV26490026	rs7924461	0.51	0.24	0.86498
35	hCV16189747	rs2298566	hCV26490027	rs7937782	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV26490028	rs7924736	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV26490038	rs6590523	0.51	0.24	0.85859
	hCV16189747	rs2298566	hCV26490043	rs6421609	0.51	0.24	0.86498
40	hCV16189747	rs2298566	hCV26490055	rs3794143	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV26490056	rs3794140	0.51	0.24	0.67868
	hCV16189747	rs2298566	hCV26490057	rs7925664	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV26490064	rs3829270	0.51	0.24	0.86498
45	hCV16189747	rs2298566	hCV26490066	rs3794132	0.51	0.24	0.89643
	hCV16189747	rs2298566	hCV26490121	rs2875322	0.51	0.24	0.47739
	hCV16189747	rs2298566	hCV27467549	rs3190331	0.51	0.24	0.41054
	hCV16189747	rs2298566	hCV27497392	rs3829271	0.51	0.24	0.34599
50	hCV16189747	rs2298566	hCV27502173	rs3794139	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV27868997	rs4622274	0.51	0.24	0.29087
	hCV16189747	rs2298566	hCV27868998	rs4936121	0.51	0.24	0.38654
	hCV16189747	rs2298566	hCV27869000	rs4436551	0.51	0.24	0.41054
55	hCV16189747	rs2298566	hCV27869001	rs4264159	0.51	0.24	0.40152
	hCV16189747	rs2298566	hCV27931232	rs4456262	0.51	0.24	0.41054
	hCV16189747	rs2298566	hCV27996234	rs4457753	0.51	0.24	0.41296
	hCV16189747	rs2298566	hCV29138817	rs4936120	0.51	0.24	0.31397
55	hCV16189747	rs2298566	hCV29138819	rs7116068	0.51	0.24	0.36418
	hCV16189747	rs2298566	hCV29138820	rs7119425	0.51	0.24	0.39687
	hCV16189747	rs2298566	hCV29138822	rs6590518	0.51	0.24	0.39687
	hCV16189747	rs2298566	hCV29138826	rs4936123	0.51	0.24	0.41054

EP 1 926 491 B1

(continued)							
	Interrogated SNP	Interrogated SNP RS	LD SNP	LD SNP RS	Power	Threshold r_T^2	r^2
5	hCV16189747	rs2298566	hCV29138827	rs6590520	0.51	0.24	0.40531
	hCV16189747	rs2298566	hCV29138833	rs6590532	0.51	0.24	0.75456
	hCV16189747	rs2298566	hCV29138834	rs6590533	0.51	0.24	0.84765
	hCV16189747	rs2298566	hCV29138837	rs7110968	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV29138841	rs7933747	0.51	0.24	0.84826
10	hCV16189747	rs2298566	hCV29138842	rs7933767	0.51	0.24	0.86378
	hCV16189747	rs2298566	hCV29138843	rs7930661	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV29138844	rs7943935	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV29138848	rs7110591	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV29138854	rs7949722	0.51	0.24	0.85299
15	hCV16189747	rs2298566	hCV3108695	rs4937582	0.51	0.24	1
	hCV16189747	rs2298566	hCV3108709	rs948085	0.51	0.24	1
	hCV16189747	rs2298566	hCV3108767	rs3198419	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV31258077	rs6590515	0.51	0.24	0.39687
	hCV16189747	rs2298566	hCV31258078	rs6590517	0.51	0.24	0.39687
20	hCV16189747	rs2298566	hCV31258101	rs4459316	0.51	0.24	0.41952
	hCV16189747	rs2298566	hCV31258105	rs7106973	0.51	0.24	0.36538
	hCV16189747	rs2298566	hCV31258108	rs7107595	0.51	0.24	0.41054
	hCV16189747	rs2298566	hCV31258111	rs7937514	0.51	0.24	0.86498
	hCV16189747	rs2298566	hCV31258124	rs3794136	0.51	0.24	0.86252
25	hCV16189747	rs2298566	hCV3251044	rs7114655	0.51	0.24	0.3931
	hCV16189747	rs2298566	hCV3251060	rs7943757	0.51	0.24	0.29892
	hCV16189747	rs2298566	hCV3251061	rs4366492	0.51	0.24	0.43166
	hCV16189747	rs2298566	hCV3251063	rs6590512	0.51	0.24	0.3731
	hCV16189747	rs2298566	hCV3251074	rs7106373	0.51	0.24	0.96341
30	hCV16189747	rs2298566	hCV3251078	rs4601795	0.51	0.24	0.42463
	hCV16189747	rs2298566	hDV71141362	rs876641	0.51	0.24	0.40253
	hCV16189747	rs2298566	hDV71218734	rs7110949	0.51	0.24	0.86498
	hCV1801149	rs4750685	hCV11276365	rs4750935	0.51	0.73	0.88081
	hCV1801149	rs4750685	hCV1801142	rs9787436	0.51	0.73	1
35	hCV1801149	rs4750685	hCV1801143	rs7100645	0.51	0.73	1^
	hCV1801149	rs4750685	hCV1801150	rs7918199	0.51	0.73	1
	hCV1801149	rs4750685	hCV1801168	rs3781301	0.51	0.73	0.88095
	hCV1801149	rs4750685	hCV218623	rs12261926	0.51	0.73	0.75008
	hCV1801149	rs4750685	hCV31968274	rs11016063	0.51	0.73	0.75008
40	hCV1801149	rs4750685	hCV31968275	rs11016062	0.51	0.73	0.74272
	hCV1801149	rs4750685	hCV374877	rs12252890	0.51	0.73	0.75008
	hCV1801149	rs4750685	hCV8903188	rs997983	0.51	0.73	1
	hCV22275215	rs3826543	hCV25610955	rs7221716	0.51	0.24	0.64584
	hCV22275215	rs3826543	hCV25610955	rs7221716	0.51	0.560671413	0.64584
45	hCV22275215	rs3826543	hCV26960050	rs7221547	0.51	0.24	0.64511
	hCV22275215	rs3826543	hCV26960050	rs7221547	0.51	0.560671413	0.64511
	hCV22275215	rs3826543	hCV27915850	rs4792722	0.51	0.24	0.50871
	hCV22275215	rs3826543	hCV29573094	rs8079361	0.51	0.24	0.4
	hCV22275215	rs3826543	hCV30294410	rs9899432	0.51	0.24	0.61158
50	hCV22275215	rs3826543	hCV30294410	rs9899432	0.51	0.560671413	0.61158
	hCV22275215	rs3826543	hCV30957093	rs7225429	0.51	0.24	0.81833
	hCV22275215	rs3826543	hCV30957093	rs7225429	0.51	0.560671413	0.81833
	hCV22275215	rs3826543	hCV30957101	rs6503096	0.51	0.24	0.81833
	hCV22275215	rs3826543	hCV30957101	rs6503096	0.51	0.24	0.81833

EP 1 926 491 B1

(continued)

	Interrogated SNP	Interrogated SNP RS	LD SNP	LD SNP RS	Power	Threshold r_T^2	r^2
5	hCV22275215	rs3826543	hCV30957101	rs6503096	0.51	0.560671413	0.81833
	hCV22275215	rs3826543	hCV30957112	rs7208297	0.51	0.24	0.48325
	hCV22275215	rs3826543	hCV31793593	rs4792590	0.51	0.24	0.59064
	hCV22275215	rs3826543	hCV31793593	rs4792590	0.51	0.560671413	0.59064
	hCV22275215	rs3826543	hCV7453127	rs8531	0.51	0.24	0.25349
10	hCV22275215	rs3826543	hDV71102112	rs869773	0.51	0.24	0.26288
	hCV3200162	rs10455	hCV27053832	rs2542939	0.51	0.67	0.95761
	hCV3200162	rs10455	hCV31898499	rs11675373	0.51	0.67	0.95787
	hCV3200162	rs10455	hCV3200161	rs2542941	0.51	0.67	1
15	hCV3200162	rs10455	hDV71152540	rs950163	0.51	0.67	1

SEQUENCE LISTING

[0420]

20	<110> Celera Corporation
	<120> GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RE- SPONSE, METHODS OF DETECTION AND USES THEREOF
25	<130> C101719PCEPT
	<140> EP 06815404.6
	<141> 2006-09-25
30	<150> 60/720,274
	<151> 2005-09-23
	<150> 11/526,137
35	<151> 2006-09-22
	<160> 5
	<170> FastSEQ for Windows Version 4.0
40	<210> 1
	<211> 1356
	<212> DNA
	<213> Homo Sapiens
45	<400> 1

50

55

5	tggaagggcc	tcctcagcag	gtgtcagcc	agctggaaga	gcctggggcc	acctgtctgg	60
	tcagagtctc	tctgctgtgg	gccctcttgg	gccagggctg	gttttgtggg	ctgactgaag	120
	tgacaatgaa	attaatagga	tcctgatgct	gtgactgagg	ccatttcctt	gtgtctccaa	180
	acaggaatga	gagaggaaat	gtcattagga	tgccaggagg	cttttgaaat	cttcaagagg	240
	gaccacgctg	acagcgttac	catcgatgac	aacaacaga	tcttgaaa	gagattttct	300
10	gaagccaagg	ccctgggaga	aagtataaat	gaagcaagaa	gtaaaattgg	tcacctgaag	360
	gaagaaatca	cccagcggca	tatacagcaa	gtagccctag	gaatctcgg	aaacatggcc	420
	gtgcctctga	tgccagacca	gcaggaggag	aagctgcat	cacaactgga	ggaagaaaag	480
	agaagggtata	aaacaaatgtt	cactcgccctg	aaagccctga	aggtggagat	cgagcacttg	540
	cagctgctca	tggacaaagc	caagggtgaag	ctacagaag	agtttgaagt	ctggctgggca	600
15	gaggaggcca	agacactgca	ggtaaatctt	ccagcagtga	attcactcga	tcacacgaag	660
	ccatttctcc	ccaacatctga	ctcccagcat	gaatggctcc	aactcctctc	taacaaaagt	720
	tctggagggt	gggaagtcca	agatcaaggc	actggcagat	tcgatgtctg	tgatgtgaat	780
	gccaggaaaa	tcctgcccct	gccttgcccc	agtccacaca	gccagaaaca	gagcagcacc	840
	agcacccac	tggaagacag	catccccaag	aggccagtgt	cgtccatccc	tctcaccgga	900
20	gacagccaga	cggactcgg	catcatcgcc	ttcatcaagg	ccagacagag	cattctgcag	960
	aagcaatgtt	tgggaagcaa	ttgaatttcc	aggaaatatt	catccatgaa	ttatgccagc	1020
	aagaatgaag	cacagatgaa	ggcagcgccc	ctcacttgct	ctggcttcag	aagtgaacta	1080
	tgggctgctg	ggagcaacta	gtgactttga	ttcccatgga	ggggactgtg	tttctttaag	1140
	gatgctgacc	tggaggccac	cgagaggctg	gggctggggc	tgaccacaac	atccttctctg	1200
20	tgttgctgg	agctgctggc	agggccaggc	aaggccagag	tgctaggggc	aggggtgaagg	1260
	cttcagctca	ctgttgtagt	gacgttttgt	gtagatcttt	ataagctttt	gagaatgtga	1320
	aatagcacca	tcaaaaatata	atgtcagagg	atgtctc			1356

<210> 2
<211> 265
<212> PRT
<213> Homo Sapiens

<400> 2

30	Met 1	Arg	Glu	Glu	Met 5	Ser	Leu	Gly	Cys	Gln 10	Glu	Ala	Phe	Glu	Ile 15	Phe
	Lys	Arg	Asp	His 20	Ala	Asp	Ser	Val	Thr 25	Ile	Asp	Asp	Asn	Lys 30	Gln	Ile
	Leu	Lys	Gln 35	Arg	Phe	Ser	Glu	Ala 40	Lys	Ala	Leu	Gly	Glu 45	Ser	Ile	Asn
35	Glu 50	Ala	Arg	Ser	Lys	Ile	Gly 55	His	Leu	Lys	Glu	Glu 60	Ile	Thr	Gln	Arg
	His 65	Ile	Gln	Gln	Val	Ala 70	Leu	Gly	Ile	Ser	Glu 75	Asn	Met	Ala	Val	Pro 80
	Leu	Met	Pro	Asp	Gln 85	Gln	Glu	Glu	Lys	Leu 90	Arg	Ser	Gln	Leu	Glu 95	Glu
40	Glu	Lys	Arg	Arg 100	Tyr	Lys	Thr	Met	Phe 105	Thr	Arg	Leu	Lys	Ala 110	Leu	Lys
	Val	Glu	Ile 115	Glu	His	Leu	Gln	Leu 120	Leu	Met	Asp	Lys	Ala 125	Lys	Val	Lys
	Leu	Gln 130	Lys	Glu	Phe	Glu	Val 135	Trp	Trp	Ala	Glu	Glu 140	Ala	Thr	Asn	Leu
45	Gln 145	Val	Asn	Ser	Pro	Ala 150	Val	Asn	Ser	Leu	Asp 155	His	Thr	Lys	Pro	Phe 160
	Leu	Gln	Thr	Ser	Asp 165	Ser	Gln	His	Glu	Trp 170	Ser	Gln	Leu	Leu	Ser 175	Asn
	Lys	Ser	Ser	Gly 180	Gly	Trp	Glu	Val	Gln 185	Asp	Gln	Gly	Thr	Gly 190	Arg	Phe
50	Asp	Val	Cys 195	Asp	Val	Asn	Ala	Arg 200	Lys	Ile	Leu	Pro	Ser 205	Pro	Cys	Pro
	Ser	Pro 210	His	Ser	Gln	Lys	Gln 215	Ser	Ser	Thr	Ser	Thr 220	Pro	Leu	Glu	Asp
	Ser 225	Ile	Pro	Lys	Arg	Pro 230	Val	Ser	Ser	Ile	Pro 235	Leu	Thr	Gly	Asp	Ser 240
55	Gln	Thr	Asp	Ser	Asp 245	Ile	Ile	Ala	Phe	Ile 250	Lys	Ala	Arg	Gln	Ser 255	Ile
	Leu	Gln	Lys	Gln 260	Cys	Leu	Gly	Ser	Asn 265							

EP 1 926 491 B1

<210> 3
 <211> 201
 <212> DNA
 <213> Homo Sapiens

5

<400> 3

10

gtgggcagag	gaggccacca	acctgcaggt	aaattctcca	gcagtgaatt	cactcgatca	60
cacgaagcca	tttctccaga	catctgactc	ccagcatgaa	yggccccaac	tcctctctaa	120
caaaagttct	ggaggctggg	aagtccaaga	tcaaggcact	ggcagattcg	atgtctgtga	180
tgtgaatgcc	aggaaaatcc	t				201

<210> 4
 <211> 10000
 <212> DNA
 <213> Homo Sapiens

15

<400> 4

20

25

agctctctcg	tgtatcactt	agaaagctca	tccgtggatg	tctgcagggc	ttcaggcagg	60
actgagtaac	tctgtagcac	tgagtatctt	tgagcagctt	ggacacagtc	cacaggtaat	120
gacggttggt	ctaaggggga	cggaaacgaa	ggaaaagaga	atggactatc	tgcattgggag	180
aaggggatga	acgtagtggg	ccacagggac	gtctgagatg	ggctggggta	gagggaggga	240
tgaatcagcc	atcaagggtgc	cctccctccc	tcagggtcctg	ggcagggaagt	gtaccaggct	300
cactgtgggc	agacactcca	ttcattttatg	aatgatctgt	tgggaaccta	ctgtgcgctg	360
gggctatctg	ttgagactct	accatgttct	gggaaagtca	gccagcacag	cttcctcctg	420

30

35

40

45

50

55

ccttttcttg ctttttctct cactgctgc ctctctactc ttttctggtc acaccctcac 480
 atctccctct tacatcagtt tttcacaac caccacagcc caataagact tcacctggct 540
 ggggttttag atagagtctt tctcagaagc atgttcagtt taatggggga cttctgaaaa 600
 ccctagggcc acaaaagcca cagaaaagggc aacataatgg tggacttttg gggagatctc 660
 agctcaagag gcccacagac tgtgctgtag gaactgggga gcagccaggt ttctggagcc 720
 tcctagcttt ccaccagtag cctggcctga ccactctcta ctgccccag gtgcttccc 780
 tctgcccgtt ctctgccttg gggctccact cctggctgac ctctggcat ctggctagat 840
 ccatgcccgt tgcctctgct ttttttatct tggatctct tggcttaaat cttttatgga 900
 tggactaagt gcccacagat gcctttttcat ggtggctact ctacaggtgt ctgggtgggct 960
 gaggatggcc cagccttgga tcaaacagcc ccctcagctg acctgcccc gcccagggga 1020
 tgggggcac acacatatag gtaccacctg gaaggcactc gccgtggcag atacgggtggc 1080
 ctttctgtcc aggacaagca acaattgttt ttgtaataag gaggagagaa caaaagagag 1140
 actgagagag agagagggag agcgagagag agaaagagag agagagagag agagcttgta 1200
 gaagataaaa gctctctgca ccagagagga tgttcccatc ctgcctccct cgcttccctg 1260
 cttaactcat tctacacaca ctgactgagc gcctcccatg ttctgggacc tgattcagct 1320
 actcttccca gtccactgtg gtcttgtgag gtcagcgtt ggtcaagatt aggagaaaa 1380
 ctgcagggtc gcagagacct ctctgtccaa catctcccta cgtgggact actctgctgt 1440
 gagctctggg tggacaccag gcatgattta caatcccttt caggggaatta ttgctgctaa 1500
 tgggcagagc caatttatgc ttccaaggg ggagggcaaa atcaattaat ggagagcctg 1560
 acatggccag gcctgatgac agagtgtggc ctgacatccg gaggtgataa gggactttct 1620
 gaggctgaac taataaggag attggggaaa aagaagaaaa acaacacccc ctccccatct 1680
 gcccacatga tttgggtgac aatgggcaga gaattcagag taaacagagc agtggggcac 1740
 gagcctcttt ccatctgaac gagcctggag ataaggactg gacaggccgc ccatcccacc 1800
 atcaacatag gtattcgcta tggagcccct caatagacat atccatatgg gtgaaaaagg 1860
 acactttcca aaccagaaca caggggagaa gataaggccc acctgcccc ggtgtgtgct 1920
 ttgtagtaga aagggcaagt ggagacagag agcactgggt ttagatgcca gctccctaac 1980
 tgtgcccccc agatagtttg caccacgtgg ctggagcggc aagctttcga tgtggggagc 2040
 tgggtcccg gagtctcccc cacagcgtcc tacgtggagg cggcgggtggc gcgggtttgt 2100
 aggggtcttt gtgtgtcctc gtgagtatga tctcagaggt gggccagctc gtgctgtgac 2160
 cagcagacag accagggaaa gctgaagggt gattcaaggt aaagccttga aacagacaaa 2220
 caaacacacc tgttactaat tttgtctaga aactgcactt ttcttttttt taaggagcag 2280
 gattctctct ccatatgaaa tctttcccag agccccaatc tgaagcctag taaagagtgg 2340
 agctctgggt gaagtgggg cagagggctc ccatttccac cagcccagag agtgtgattt 2400
 caagagccct taccgtaat tctgaaatgg atgcccttgt ctaagtggga cttccctcag 2460
 cgcaggtccc aagacacaat gcgggtgtgc gtggttcac tgggacctga tccaggatgc 2520
 gcaagcaggg gagtggggaa cagaaggcag tcgattcagg gtgtgttttc gcacaggtga 2580
 ctgttgcggg caactggggc cccatcccgc tgggacctc tgggagactg tgcagaacac 2640
 actgtagagt tgttccacag agtggcaagg aagctggggg gtttatctac caactcttgt 2700
 cccttgttaa ttgaagattg ctctggggga ggtaactcc tgcactgcca gcctgccctg 2760
 cctgtgggct gagagcactc ctgcccagag agagtccctg tgggtagaaa gatgcaggtg 2820
 cttaggacag aatgtctact gtatagatgg aggcctttcca caagtgtgct atgtgacctc 2880
 caggcgggct ggggggatct ggcagagtac tgacactgtc tgtcacaggc tctagttctc 2940
 cactcctttg tctgggtcac tgtgttttg tcatctctgc agggaaattg ctcttctgtg 3000
 aaccttaatg aaggggtggc cagcttgtcc tggcatatta ggccgggtgcc cttggaagca 3060
 tgacaagagt gggaagacca taccctcatc tcttgatggc cactcaaatt gaaaaagaa 3120
 attgttttta ttgatttat tattttgaga tggagtctca ctctgtcgcc caggctggag 3180
 tgcagtggcg cgatctcagc tcactgcaac ctctgcctcc cgggttcaag cagttctctg 3240
 ccttagcctc ccaagtagct gggattatag gcagccgcca ccatgcctgg ctaatttttg 3300
 tattttaagt agagatgggg ttccaccatc ttgtccaggc tggctttgaa ctctgacct 3360
 catgatccac cctcctcagc ctcccaaagt gctgggatta caggcgtgag ccactgtgcc 3420
 cggccatgaa agatattgtt aaaagatctg ctggccatcc cctgttaatg aatctcccta 3480
 catccctcca cctcttcaga ctataagaaa aacccatagc tttgagagtc attggagctg 3540
 cagcagcagc aagaagcctg ggctgtgtg agccaggatg tagatgagg gtgcccgtga 3600
 gacagggagg agcagagcgt cccagggcc tgggagagat actgagccca gaaaccagag 3660
 gagagacagg gccagctgct cttgggtgtg gagggctctg gcaaataatt ttttgggat 3720
 ggaccctgt gtgtataaac aatttgatga aaaaaactta gtaccaaatt catgagccca 3780
 tgtgaggtat aatgattgat ttgtgtagat ttagaataat gacagagaag aggcacttag 3840
 gcatttgttt attgtctaatt tggttcacat gacgattctt tgtcctatga tgttaagagt 3900
 ccatcaaate agcatgttag cgcaggtctg gtggcccaat cccaggtagt gccataaaag 3960
 aaatgccaca ccagccagcg ggaatgatct cctcatcagg ctgctttcct ggaaccaggg 4020
 actgactagg aagccctaaa acagcttcat aggcataagt cctagagcac cttgggacat 4080
 ctggtcaacc ctatgcatgc actggagaac ttcctgaaag aagaaaaggg aactgagacc 4140
 cacatgagcc ctggactatg ttagggggtg cctgcattgga tgacgttgtt ggtcatggct 4200

5 ggtcccagca ccagagggag acttagaaa ttttagcaa agcatgtcaa agcacagggt 4260
 acccccaaaa catggggctg aaggcatggg gactgcttgc ctcagtctaa agacagtgat 4320
 ggaaaagaca aaccaggag atgtttcggg gaaaagaaaa caacaacatc ccacacctgg 4380
 ggccagaagg ggaggggtgc tggcctgggg aggggctgcc ctcctgagat caggagctga 4440
 gtgaatggag agggaagagt accagctggc atgctgcttg ctctttgctg agttccctct 4500
 cagtgtgggt gaaactggct cagccctgct ggctggcacg aggccatgga aaacccaaat 4560
 aaagcagtta actctgaaaa ggttgctgct tcttcctatt ccttgggaga tgcattcagg 4620
 gctacactca gaggccactt ttcgcaaggt gaggaggagc ttgtattcaa ggaaacactg 4680
 ctttttcctc ccacatttga cacatatgtt ttcaacatcc aacattcaca gccaacctct 4740
 ctacacctgc tctgcctcgg agccctggca gtccctggac acgtgttatg gaaggaacac 4800
 10 tgtctccccc acatgctcac atggcccaa tccccacaag tccccctttt gccaaagtcc 4860
 acgtcctttg cctcttccca tcacccaata cccaacctgc catcattgtc ctaagcttcc 4920
 ctctcctgct tctctctttg caccttgccg ggttctcaca ctcccacca ccttgatagt 4980
 gagtccaagc ccacctacc ccaccccaa ctcttcttc tttttctgag acagggtctt 5040
 gctctgtcat ccaggctgga gtgcagtggg gtgatcacag ctactgcag ccttaacctc 5100
 ctgggttcaa ggatcctccc acctcagcct cccgagtagc tgagactaca ggcgcttgct 5160
 15 accatgcccc gctaaccaca actccttctt aatcagattg tcttgcttac ttgtttattg 5220
 tccctctctt tttttttttt tcagagaagg agtctcgctc ttgttgccca ggttggagtg 5280
 cagtggcacg atctcagctc actgcaact ctgcctccag ggttcaagtg attgtcctgc 5340
 ctcagcctcc agagtagctg ggattacagg tgcgcaccac cacaccagc taatttttgt 5400
 atttttagta gcgatggggg ttcgccatgt tggccaggtt ggtctcaaac tctgcacctc 5460
 gtgatccgcc agcctcagtc tcccaaagtg ttgggattac aggcgtgagc caccatgcct 5520
 20 ggcttgtccc tctccttctg tagaaggttc caagaatgct ggcactttct ctgtctctgt 5580
 cacctctgac tctcagaac ttagcacaat ggatggcaca tccttgtaa aacaatgacc 5640
 agatgaatga gacatgctta tgtttaagga attacaagga gcattttttc tgcctagatt 5700
 tgaaacacac acccattgca ttttaaaaaa tgtttctgtc tatttactct atcaactgtg 5760
 ccatgcctgg ggctgtttct atttgttttt tctttttttt ttttttgaga cagagtttca 5820
 ctcttgttgc ccaagctgga gtgcaatggc acaatttcgg ctactgtaa cctctgcctc 5880
 25 ctgggctcaa gcaattctcc tgcctcagcc tctgagtagc tgggattaca ggtacgcaac 5940
 accatgcccc gctatttttt gtatttttag tagagacggg gtttcccat gttgaacagg 6000
 ctgttcttga actcctgacc tcagggtgat cctctgcctc ggcctcccaa agtgcaggga 6060
 ttataggagt gagccacc acccggcctc tatttctatt gatggtttt tctcctctca 6120
 tggcccatat ttctctgctt ctttgcattg ctgattattt tttaatggac accagacatt 6180
 gtggattcta tattgttggg tgcctggttc ttttggtttt gtttttcata ttcctttaga 6240
 30 tattttgaag ctttgttttg ggactcattg aagtacttg ttttttctata ttcctttaga 6300
 tgactccttt ggggctggct ttttaagctt tgttaggtgg gaccagagca atctatcatc 6360
 taggactaat ttggcccccac ttctgaggca gtacccttat tgtctctata caatgactgt 6420
 tttgggaggt ttctccactc tggctgttgg aaacatgaac tcttcccaac acagtgttat 6480
 ctcaggaaat tattccacct gcttctctct ggtggttctt tcccctgcct tgggtaattt 6540
 cttcacatgc agatgttgat cggtagttag ctgaagactc aagggttaacc ctctgaagat 6600
 35 ctccagagca tgcctctctc ctttctctct ttttttctc ctctctctct ccttctctct 6660
 ctctcatccc tgggactctg ccttgcaaat ttaagccact ttgtcctccc tggattccca 6720
 gctccatttc ctcaactcag ggaaaccact gggctctacc tggttcccc ttcctgggct 6780
 gcagcctgaa aactcactgc aggcagtaag ttggagcaat catagggtc cctcacttg 6840
 tttcccttct cttgcggatc aatcataccc tatattgctt gttatccaat ggctgaaaac 6900
 cattggtttg tatagaggat tttgtctcat ttttagtcat ttaaagcagg agggtaaatc 6960
 40 aggtccttgt tgcctcatca tggctgtagg tgggtgtcct gcttttccat atacaggatg 7020
 ctctcagtgc ctttccacag gctgcattga gagacaatga actctgcact gagaaatcct 7080
 agatccagtc atatactgtc tctgggttcc aatttctgtg ccagtctgct attgctacaa 7140
 ttaatgctat ataacaacc actctaaacc tcagtggttt atgacaagca gcatatattc 7200
 tcatgccaat aggtcttttg gtgagccata gttcagctga tctgggctgg gcttgcctgg 7260
 gaggtcctgc tccaggctgt agactgggct caggctctgt ctctggatgt tccaggctga 7320
 45 aggggcagca gctacccatg gcatgttcat cccaagagag atcactggag caagaggcaa 7380
 gctcaaccat gagagcaca ttcaagcctc tgcctggatc aggtttgcca acaccacatt 7440
 agtcaaagtg ggccatgaca aagctttgga tgtgtaattc tatactgggt gtagaagaatt 7500
 aaaatgatgt attcagtata ccacaatttc tctatctgct ttctaaaact ccttttttagc 7560
 aagatctggg caagctacat ttttaacttc ctccccaac ctccgtccac cctacttctt 7620
 gtcaagggat tggtagagcc agttgaattc tgcaggagac tgggctggag tccactggcta 7680
 50 ggctgctttc cagaaaaatg ttttgaaaat cccacatttt ggcctagagt gaactcagat 7740
 acttcttgtc atccgtggct ccactgatcc caggtggatt gctggaaagt cttttcaaaa 7800
 cattgcatca atttctccca tttgcagagg ccagtgaact ctgggaagg gactgctgt 7860
 caagcatgtg tccatatcaa aggtgggct tccattaggg gatgttcgga gcaaaaggcc 7920
 ccttggccag ttgctgcaca cactttgcat atgctctgga caccagtggc ccagatccc 7980

```

5  atgttggtgtg tttttctgtc ttcatttcct ttcctgtctt agtgattgcc ccaggaggct 8040
   gggtcacacc ccgcatgggg ccatgccaca catctctgtc agtaaggcct ttggatccag 8100
   gagatgatgt ctccagtggg gatctaattg tgaagagactc tggcagggtg tgtggctcat 8160
   gcctgcaatc ccagcacttt gggaggccaa ggcgggagca tcgcttaagg ccaggaattt 8220
   gagaccatcc tgagccacac agtgagaccc tgtctctaca aaaaatttaa aacgagctag 8280
   gtgtggtggt gcatgcctgt agttccagct actttggagg ctgagggtgag aggatcgctt 8340
   gagcccagga gttggaggct gagtatggct tgagcccagg agttggaggc tgactagtga 8400
   ggtatggctg caccactgca cccagcctg gctgacagag acccccccac tctcaaaaaa 8460
   taaataaaaag aaagtaaaaa taaaagaaaa taaaagttag tagactctac ccagctctag 8520
   agggctgagg gcactaaggc atgccaagaa tactgtgtgt gctacatagg ggactggggc 8580
10 aaatgccatg ccatcttcag ggctcttgag agtgtgtgtg tgtatgtgtg tgtgtgtgtg 8640
   cagttacatg tgtgttccat ggactcttgg ggaggcttct agaatcagaa tttggtcttc 8700
   ctctggttct acagacttta cagagggtct actatgttcc attgaactgt gagggccagg 8760
   agtggaccag agatgctggc ccctgtcccg atgggattca gtcagagcct gggggaagtc 8820
   agagtgacac cagcctgaga aacacatctg ggttctggct cgtctactca tgaactgaag 8880
   gaccgtttac tgaacagcga ctctgtgctt gggacacagc aatgagcaag acaaacagg 8940
15 ccctgttgca ttggagctct tagtattatg ggggggttgca ggtatttcaa aaataggcaa 9000
   gttcgggaagg ataacatgtc agatagtgat gcagaaaaaa tggtaatggg ataggggata 9060
   actagggggg gactcgagat ggagtgggtc ggggaagccc cctgaagagg ggacatttgt 9120
   cagtggcata gaacagcaag ctgaatctcc ccttcaactc ggcccttctaa ttatataaaa 9180
   taggggtgtg gattagaggg gctcgatggg cctgcctagc ttagaaatgt aatggtttaa 9240
   tcttctcctg catgatcctg ttaccagtc ctaaaaaacg aaaaagaaaa tcaagccaat 9300
20 tatactatat taccactctg ctccccctca gggctcatcag gtcctgtatt tataggacag 9360
   agacaccagg agcagtggac cagcactttt atccagttag ctctatttcc aggtgccact 9420
   cctgtctacc ctccgctgcc cctccctggc tgcagctggg ttggaacccc ctggcccagg 9480
   gggcagtctt tcaagaacct ccttgagggc tgcccactc cccttggag gtgcattgag 9540
   agggcccatg gagacaagac cccagggcag ctatgtttt ccctgtggaa gtggggagtg 9600
   tcagcccaaa tcctcccaag tggctgggtg aagggtgtga ggcccaagg acccacactg 9660
25 ccctctctca agctctcagc agagcccctg ggagctgccc actgttctct ggggtgctatg 9720
   atgtccttag accctgcagg gcagatggct ccctggagac acagctgttc aggcactgcc 9780
   tccaggtcat cctggccaag aggtgatgg tgaaagatgt ggtctgggag atcaggattg 9840
   gccttcagga tgccctgcat tccactgcct tgccgtggc tgggacatcc tgcctggacc 9900
   tgtcatggcc atttctgggc ttccaaacca gagcacgggc caagggagag agctggcaaa 9960
   tcgttaaaaa taaaaatatt cccccacat tccactggtg 10000

```

```

<210> 5
<211> 201
<212> DNA
<213> Homo Sapiens

```

```

<400> 5

```

```

acaggaatat gttaaacaga aaggtaggga gccttttctg ggaactctaa cacctccggt 60
gagttctcac cttacctttt gttagagagg agttgggacc rttcatgctg ggagtcagat 120
gtctggagaa atggcttcgt gtgatcgagt gaattcactg ctggagaatt tacctgttgg 180
ccccagaagg agtttcacag t

```

Claims

1. An in vitro method of identifying an individual having an altered risk for developing myocardial infarction (MI), comprising detecting the single nucleotide polymorphism (SNP) in the nucleotide sequence of SEQ ID NO: 5 in said individual's nucleic acids, wherein the individual has an increased risk for developing myocardial infarction due to the presence of G at position 101 of SEQ ID NO: 5 or the presence of C at position 101 of its complement.
2. An in vitro method of evaluating an individual's likelihood of responding to HMG-CoA reductase inhibitor treatment for reducing the individual's risk of having myocardial infarction, comprising detecting the single nucleotide polymorphism (SNP) in the nucleotide sequence of SEQ ID NO: 5 in said individual's nucleic acids, wherein the individual has a greater likelihood of responding to HMG-CoA reductase inhibitor treatment due to the presence of G at position 101 of SEQ ID NO: 5 or the presence of C at position 101 of its complement.
3. The method of claim 1 or 2, wherein said nucleic acid is a nucleic acid isolated from a biological sample from said individual.

4. The method of claim 1 or 2, in which the nucleic acids are prepared from blood cells, saliva or buccal swabs of the individual.
5. The method of any one of claims 1-4, wherein said detecting step comprises nucleic acid amplification.
6. The method of claim 5, wherein said nucleic acid amplification is carried out by polymerase chain reaction.
7. The method of any one of claims 1-6, comprising contacting the nucleic acids of the individual with a detection reagent, and determining which nucleotide is present or absent at position 101 of SEQ ID NO: 5.
8. The method of claim 7, in which the detection reagent is a polynucleotide probe.
9. The method of claim 8, in which the 3' end of the probe hybridizes to the SNP in the nucleic acid.
10. The method of claim 8, in which the probe is labeled with a reporter dye.
11. The method of any one of claims 1-6, wherein said detecting step is performed using allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5' nuclease digestion, molecular beacon assay, oligonucleotide ligation assay (OLA), size analysis, single-stranded conformation polymorphism analysis (SSCP), or denaturing gradient gel electrophoresis (DGGE).
12. Use of an amplified polynucleotide containing the single nucleotide polymorphism (SNP) at position 101 of SEQ ID NO: 5, or the complement thereof, in the method according to any one of claims 1-11, wherein the amplified polynucleotide is between about 16 and about 1,000 nucleotides in length.
13. Use of claim 12 in which the amplified polynucleotide comprises the nucleotide sequence of SEQ ID NO: 5.
14. Use of an isolated polynucleotide which specifically hybridizes to a nucleic acid molecule containing the single nucleotide polymorphism (SNP) at position 101 of SEQ ID NO: 5, or the complement thereof, in the method according to any one of claims 1-11.
15. Use of claim 14 wherein the isolated polynucleotide is 8-70 nucleotides in length.
16. Use of claim 14 wherein the isolated polynucleotide is an allele-specific probe.
17. Use of claim 14 wherein the isolated polynucleotide is an allele-specific primer.
18. Use of a test kit comprising the polynucleotide as defined in any one of claims 12-17, a buffer, and an enzyme in the method of any one of claims 1-11.
19. The method or use of any one of claims 1-18, wherein said individual is homozygous for said G or said C.
20. The method or use of any one of claims 1-18, wherein said individual is heterozygous for said G or said C.
21. An in vitro method of identifying an individual having an altered risk for developing myocardial infarction (MI), comprising detecting the presence of arginine (R) or tryptophan (W) at position 170 of the amino acid sequence of SEQ ID NO: 2, wherein the individual has an increased risk for developing MI due to the presence of R at position 170 of the amino acid sequence of SEQ ID NO: 2.
22. An in vitro method of evaluating an individual's likelihood of responding to HMG-CoA reductase inhibitor treatment for reducing the individual's risk of having myocardial infarction, comprising detecting the presence of arginine (R) or tryptophan (W) at position 170 of the amino acid sequence of SEQ ID NO: 2, wherein the individual has a greater likelihood of responding to HMG-CoA reductase inhibitor treatment due to the presence of R at position 170 of the amino acid sequence of SEQ ID NO: 2.
23. Use of a protein detection reagent in the method of claim 21 or 22, wherein said protein detection reagent selectively binds to a protein having R at position 170 of the amino acid sequence of SEQ ID NO: 2 as compared to a variant form of said protein having the amino acid sequence of SEQ ID NO: 2 with W at position 170.

24. Use according to claim 23, wherein said reagent is an antibody, an antibody fragment, an aptamer, a peptide, a ligand, or a small molecule compound.
25. Use according to claim 24, wherein said reagent is labeled with a reporter dye or an imaging agent.

5

Patentansprüche

- 10 1. In vitro-Verfahren zur Identifizierung eines Individuums, das ein verändertes Risiko besitzt Myokardinfarkt (MI) zu entwickeln, umfassend das Detektieren des Einzelnukleotidpolymorphismus (Single Nucleotide Polymorphism, SNP) in der Nukleotidsequenz von SEQ ID NO:5 in den Nukleinsäuren des Individuums, wobei das Individuum aufgrund des Vorliegens von G an Position 101 von SEQ ID NO:5 oder des Vorliegens von C an Position 101 ihrer komplementären Sequenz ein erhöhtes Risiko hat, Myokardinfarkt zu entwickeln.
- 15 2. In vitro-Verfahren zur Beurteilung der Wahrscheinlichkeit, ob ein Individuum auf HMG-CoA Reduktase-Inhibitor-Behandlung anspricht, um das Risiko des Individuums, einen Myokardinfarkt zu entwickeln, zu verringern, umfassend das Detektieren des Einzelnukleotidpolymorphismus in der Nukleotidsequenz von SEQ ID NO:5 in den Nukleinsäuren des Individuums, wobei das Individuum aufgrund des Vorliegens von G an Position 101 von SEQ ID NO:5 oder des Vorliegens von C an Position 101 ihrer komplementären Sequenz eine größere Wahrscheinlichkeit hat, auf die HMG-CoA Reduktase-Inhibitor Behandlung anzusprechen.
- 20 3. Verfahren nach Anspruch 1 oder 2, wobei die Nukleinsäure eine von einer biologischen Probe des Individuums isolierte Nukleinsäure ist.
- 25 4. Verfahren nach Anspruch 1 oder 2, bei dem die Nukleinsäuren aus Blutzellen, Speichel, oder Wangenabstrichen gewonnen werden.
5. Verfahren nach irgend einem der Ansprüche 1-4, bei dem der Detektierungsschritt Nukleinsäureamplifikation umfasst.
- 30 6. Verfahren nach Anspruch 5, wobei die Nukleinsäureamplifikation mittels Polymerase-Kettenreaktion (polymerase chain reaction) durchgeführt wird.
- 35 7. Verfahren nach irgend einem der Ansprüche 1-6, das das Inkontaktbringen der Nukleinsäuren des Individuums mit einem Detektionsreagenz und die Bestimmung, welches Nukleotid an Position 101 von SEQ ID NO:5 vorliegt oder nicht vorliegt, umfasst.
8. Verfahren nach Anspruch 7, bei dem das Detektionsreagenz eine Polynukleotidsonde ist.
- 40 9. Verfahren nach Anspruch 8, bei dem das 3' Ende der Sonde mit dem SNP in der Nukleinsäure hybridisiert.
10. Verfahren nach Anspruch 8, bei dem die Sonde mit einem Reporterfarbstoff markiert ist.
- 45 11. Verfahren nach irgend einem der Ansprüche 1-6, wobei der Detektierungsschritt unter Verwendung eines Verfahrens durchgeführt wird, das ausgewählt ist aus der Gruppe bestehend aus: Allel-spezifischer Sondenhybridisierung, Allel-spezifischer Primerextension, Allel-spezifischer Amplifikation, Sequenzierung, 5'-Nuklease-Verdau, Molecular-Beacon-Assay, Oligonukleotid-Ligationsassay (OLA), Größenanalyse, Einzelstrang-Konformationspolymorphismus (SSCP) oder denaturierender Gradientengelelektrophorese (DGGE).
- 50 12. Verwendung eines amplifizierten Polynukleotids, das den Einzelnukleotidpolymorphismus an Position 101 von SEQ ID NO:5 enthält, oder dessen Komplement davon, in dem Verfahren nach irgend einem der Ansprüche 1-11, wobei das amplifizierte Polynukleotid zwischen etwa 16 und etwa 1.000 Nukleotide lang ist.
13. Verwendung nach Anspruch 12, bei der das amplifizierte Polynukleotid die Nukleotidsequenz SEQ ID NO:5 umfasst.
- 55 14. Verwendung eines isolierten Polynukleotids, welches spezifisch mit einem Nukleinsäuremolekül, welches einen Einzelnukleotidpolymorphismus (SNP) an Position 101 von SEQ ID NO:5 enthält, oder dem Komplement davon hybridisiert, in dem Verfahren nach irgend einem der Ansprüche 1-11.

15. Verwendung nach Anspruch 14, bei der das isolierte Polynukleotid 8-70 Nukleotide lang ist.
16. Verwendung nach Anspruch 14, bei der das isolierte Polynukleotid eine Allelspezifische Sonde ist.
- 5 17. Verwendung nach Anspruch 14, bei der das isolierte Polynukleotid ein Allel-spezifischer Primer ist.
18. Verwendung eines Test-Kits, umfassend das Polynukleotid, wie es in irgend einem der Ansprüche 12-17 definiert ist, einen Puffer und ein Enzym, in dem Verfahren nach irgend einem der Ansprüche 1-11.
- 10 19. Verfahren oder Verwendung nach irgend einem der Ansprüche 1-18, wobei das Individuum homozygot für das G oder das C ist.
20. Verfahren oder Verwendung nach irgend einem der Ansprüche 1-18, wobei das Individuum heterozygot für das G oder das C ist.
- 15 21. In vitro-Verfahren zur Identifizierung eines Individuums, das ein verändertes Risiko besitzt, Myokardinfarkt (MI) zu entwickeln, umfassend das Detektieren des Vorliegens von Arginin (R) oder Tryptophan (W) an Position 170 der Aminosäuresequenz von SEQ ID NO:2, wobei das Individuum aufgrund des Vorliegens von R an Position 170 der Aminosäuresequenz von SEQ ID NO:2 ein erhöhtes Risiko hat, MI zu entwickeln.
- 20 22. In vitro-Verfahren zur Beurteilung der Wahrscheinlichkeit, ob ein Individuum auf HMG-CoA Reduktase-Inhibitor-Behandlung anspricht, um das Risiko des Individuums, einen Myokardinfarkt zu entwickeln, zu verringern, umfassend das Detektieren des Vorliegens von Arginin (R) oder Tryptophan (W) an Position 170 der Aminosäuresequenz von SEQ ID NO:2, wobei das Individuum aufgrund des Vorliegens von R an Position 170 der Aminosäuresequenz von SEQ ID NO:2 eine größere Wahrscheinlichkeit hat, auf die HMG-CoA Reduktase-Inhibitor Behandlung anzusprechen.
- 25 23. Verwendung eines Proteindetektionsreagenz in dem Verfahren nach Anspruch 21 oder 22, bei der das Proteindetektionsreagenz selektiv an ein Protein bindet, das R an Position 170 der Aminosäuresequenz von SEQ ID NO:2 hat, im Vergleich zu einer varianten Form des Proteins, das die Aminosäuresequenz von SEQ ID NO:2 mit W an Position 170 aufweist.
- 30 24. Verwendung nach Anspruch 23, bei der das Reagenz ein Antikörper, ein Antikörperfragment, ein Aptamer, ein Peptid, ein Ligand oder eine niedermolekulare Verbindung ist.
- 35 25. Verwendung nach Anspruch 24, wobei das Reagenz mit einem Reporterfarbstoff oder einem bildgebenden Agens (imaging agent) markiert ist.

Revendications

1. Procédé *in vitro* d'identification d'un individu ayant un risque modifié de faire un infarctus du myocarde (MI), comprenant la détection du polymorphisme d'un seul nucléotide (SNP) dans la séquence de nucléotides de la SEQ ID NO: 5 dans les acides nucléiques dudit individu, dans lequel l'individu a un risque accru de faire un infarctus du myocarde en raison de la présence de G à la position 101 de la SEQ ID NO: 5 ou de la présence de C à la position 101 de son complément.
- 45 2. Procédé *in vitro* d'évaluation de la probabilité chez un individu de répondre à un traitement inhibiteur de la HMG-CoA réductase permettant de réduire le risque pour l'individu d'avoir un infarctus du myocarde, comprenant la détection du polymorphisme d'un seul nucléotide (SNP) dans la séquence de nucléotides de la SEQ ID NO: 5 dans les acides nucléiques dudit individu, dans lequel l'individu a une plus grande probabilité de répondre à un traitement inhibiteur de la HMG-CoA réductase en raison de la présence de G à la position 101 de la SEQ ID NO: 5 ou de la présence de C à la position 101 de son complément.
- 50 3. Procédé selon la revendication 1 ou 2, dans lequel ledit acide nucléique est un acide nucléique isolé à partir d'un échantillon biologique provenant dudit individu.
- 55 4. Procédé selon la revendication 1 ou 2, dans lequel les acides nucléiques sont préparés à partir de globules sanguins,

de salive ou de prélèvements buccaux de l'individu.

- 5 5. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel ladite étape de détection comprend une amplification d'acide nucléique.
6. Procédé selon la revendication 5, dans lequel l'amplification d'acide nucléique est effectuée au moyen d'une réaction d'amplification en chaîne par polymérase.
- 10 7. Procédé selon l'une quelconque des revendications 1 à 6, comprenant la mise en contact des acides nucléiques de l'individu avec un réactif de détection, et la détermination du nucléotide présent ou absent à la position 101 de la SEQ ID NO: 5.
8. Procédé selon la revendication 7, dans lequel le réactif de détection est une sonde de polynucléotides.
- 15 9. Procédé selon la revendication 8, dans lequel l'extrémité 3' de la sonde s'hybride au SNP dans l'acide nucléique.
10. Procédé selon la revendication 8, dans lequel la sonde est marquée avec un colorant rapporteur.
- 20 11. Procédé selon l'une quelconque des revendications 1 à 6, dans lequel ladite étape de détection est effectuée en utilisant une hybridation par sonde spécifique d'un allèle, une extension d'amorce spécifique d'un allèle, une amplification spécifique d'un allèle, un séquençage, une digestion par une 5'-nucléase, une étude avec balise moléculaire, un test de ligature d'oligonucléotide (OLA), une analyse de taille, une analyse d'un polymorphisme de conformation à simple brin (SSCP) ou une électrophorèse sur gel en gradient dénaturant (DGGE).
- 25 12. Utilisation d'un polynucléotide amplifié contenant le polymorphisme d'un seul nucléotide (SNP) à la position 101 de la SEQ ID NO: 5, ou de son complément, dans le procédé selon l'une quelconque des revendications 1 à 11, dans laquelle le polynucléotide amplifié a une longueur comprise entre environ 16 et environ 1 000 nucléotides.
- 30 13. Utilisation selon la revendication 12, dans laquelle le polynucléotide amplifié comprend la séquence de nucléotides de la SEQ ID NO: 5.
- 35 14. Utilisation d'un polynucléotide isolé qui s'hybride spécifiquement à une molécule d'acide nucléique contenant le polymorphisme d'un seul nucléotide (SNP) à la position 101 de la SEQ ID NO: 5, ou de son complément, dans le procédé selon l'une quelconque des revendications 1 à 11.
- 40 15. Utilisation selon la revendication 14, dans laquelle le polynucléotide isolé a une longueur de 8 à 70 nucléotides.
16. Utilisation selon la revendication 14, dans laquelle le polynucléotide isolé est une sonde spécifique d'un allèle.
- 40 17. Utilisation selon la revendication 14, dans laquelle le polynucléotide isolé est une amorce spécifique d'un allèle.
18. Utilisation d'une trousse d'essai comprenant le polynucléotide tel que défini dans l'une quelconque des revendications 12 à 17, un tampon et une enzyme, dans le procédé selon l'une quelconque des revendications 1 à 11.
- 45 19. Procédé ou utilisation selon l'une quelconque des revendications 1 à 18, dans lequel ou laquelle ledit individu est homozygote pour ledit G ou ledit C.
20. Procédé ou utilisation selon l'une quelconque des revendications 1 à 18, dans lequel ou laquelle ledit individu est hétérozygote pour ledit G ou ledit C.
- 50 21. Procédé *in vitro* d'identification d'un individu ayant un risque modifié de faire un infarctus du myocarde (MI), comprenant la détection de la présence d'arginine (R) ou de tryptophane (W) à la position 170 de la séquence d'acides aminés de la SEQ ID NO: 2, dans lequel l'individu a un risque accru de faire un MI en raison de la présence de R à la position 170 de la séquence d'acides aminés de la SEQ ID NO: 2.
- 55 22. Procédé *in vitro* d'évaluation de la probabilité chez un individu de répondre à un traitement inhibiteur de la HMG-CoA réductase permettant de réduire le risque pour l'individu d'avoir un infarctus du myocarde, comprenant la détection de la présence d'arginine (R) ou de tryptophane (W) à la position 170 de la séquence d'acides aminés

de la SEQ ID NO: 2, dans lequel l'individu a une plus grande probabilité de répondre à un traitement inhibiteur de la HMG-CoA réductase en raison de la présence de R à la position 170 de la séquence d'acides aminés de la SEQ ID NO: 2.

- 5 **23.** Utilisation d'un réactif de détection de protéine dans le procédé de la revendication 21 ou 22, dans laquelle ledit réactif de détection de protéine se lie spécifiquement à une protéine ayant R à la position 170 de la séquence d'acides aminés de la SEQ ID NO: 2 comparée à une forme variante de ladite protéine ayant la séquence d'acides aminés de la SEQ ID NO: 2 avec W à la position 170.
- 10 **24.** Utilisation selon la revendication 23, dans laquelle ledit réactif est un anticorps, un fragment d'anticorps, un aptamère, un peptide, un ligand ou un composé petite molécule.
- 15 **25.** Utilisation selon la revendication 24, dans laquelle ledit réactif est marqué avec un colorant rapporteur ou un agent d'imagerie.

15

20

25

30

35

40

45

50

55




FIGURE 1

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 72027405 P [0001]
- WO 9740462 A [0039]
- US 4683195 A [0102]
- US 4683202 A [0102]
- US 5270184 A [0102]
- US 5422252 A [0102]
- US 5399491 A [0102]
- US 6027923 A [0102]
- US 5539082 A [0112]
- US 5527675 A [0112]
- US 5623049 A [0112]
- US 5714331 A [0112]
- WO 9604000 A [0113]
- US 4835263 A [0114]
- US 5801115 A [0114]
- EP 235726 A, Dattagupta [0129]
- WO 8911548 A, Saiki [0129]
- US 4988617 A [0133] [0170]
- US 4458066 A [0134]
- WO 9322456 A [0136]
- US 5210015 A [0139] [0168]
- US 5538848 A [0139] [0168]
- US 5118801 A [0139] [0170]
- US 5312728 A [0139] [0170]
- US 5866336 A [0139] [0170]
- US 6117635 A [0139] [0170]
- US 5837832 A [0145]
- WO 9511995 A, Chee [0145]
- US 5807522 A, Brown [0145]
- US 620332 A [0150]
- US 10620333 A [0150]
- US 6124478 A [0150]
- US 6107024 A [0150]
- US 5994073 A [0150]
- US 5981768 A [0150]
- US 5871938 A [0150]
- US 5843681 A [0150]
- US 5800999 A [0150]
- US 5773628 A [0150]
- US 20020110828 A [0150]
- WO 95251116 A [0152]
- US 5589136 A [0156]
- US 6153073 A, Dubrow [0156]
- US 6156181 A, Parce [0156]
- US 4988167 A [0166]
- US 6027889 A [0171]
- US 6268148 B [0171]
- US 5494810 A [0171]
- US 5830711 A [0171]
- US 6054564 A [0171]
- WO 9731256 A [0171]
- WO 0056927 A [0171]
- US 0117329 A [0171]
- US 09584905 B [0171]
- US 427818 P [0171]
- US 60445636 B [0171]
- US 60445494 B [0171]
- WO 9416101 A [0176]
- US 5498531 A [0178]
- US 4107288 A [0266]
- US 5145684 A [0266]
- US 6119096 A [0284]
- US 5283317 A [0332]
- WO 9410300 A, Brent [0332]
- US 4816567 A [0335]
- US 4816397 A [0335]
- US 5693762 A [0335]
- US 5585089 A [0335]
- US 5565332 A [0335]
- US 4946778 A [0335]
- US 5637677 A [0337]
- US 4736866 A [0379]
- US 4870009 A, Leder [0379]
- US 4873191 A, Wagner [0379]
- WO 9707668 A [0381]
- WO 9707669 A [0381]
- EP 06815404 A [0420]
- EP 60720274 A [0420]
- EP 11526137 A [0420]

Non-patent literature cited in the description

- **LLOYD-JONES DM.** *Lancet*, 1999, vol. 353, 89-92 [0009]
- **RR WILLIAMS.** *Am J Cardiology*, 2001, vol. 87, 129 [0013]
- **BROECKEL U.** *Nature Genetics*, 2002, vol. 30, 210 [0013]
- **HARRAP S.** *Arterioscler Thromb Vasc Biol*, 2002, vol. 22, 874-878 [0013]

- **SHEARMAN A.** *Human Molecular Genetics*, 2000, vol. 9 (9), 1315-1320 [0013]
- Heart and Stroke Statistical Update. American Heart Association, 2001 [0022]
- **WATERS, D.D.** What do the statin trials tell us?. *Clin Cardiol*, 2001, vol. 24 (8), III3-7 [0022]
- **SINGH, B.K. ; J.L. MEHTA.** Management of dyslipidemia in the primary prevention of coronary heart disease. *Curr Opin Cardiol*, 2002, vol. 17 (5), 503-11 [0022] [0028]
- **SHEPHERD, J. et al.** Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med*, 1995, vol. 333 (20), 1301-7 [0022]
- **DOWNS, J.R. et al.** Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *Jama*, 1998, vol. 279 (20), 1615-22 [0022]
- **SACKS, F.M. et al.** The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med*, 1996, vol. 335 (14), 1001-9 [0022]
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med*, 1998, vol. 339 (19), 1349-57 [0022]
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*, 1994, vol. 344 (8934), 1383-9 [0022]
- **PUDDU, P. ; G.M. PUDDU ; A. MUSCARI.** Current thinking in statin therapy. *Acta Cardiol*, 2001, vol. 56 (4), 225-31 [0023]
- **ALBERT, M.A. et al.** Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. *Jama*, 2001, vol. 286 (1), 64-70 [0023]
- **ROSENSON, R.S.** Non-lipid-lowering effects of statins on atherosclerosis. *Curr Cardiol Rep*, 1999, vol. 1 (3), 225-32 [0023]
- **DANGAS, G. et al.** pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. *Thromb Haemost*, 2000, vol. 83 (5), 688-92 [0023]
- **CRISBY, M.** Modulation of the inflammatory process by statins. *Drugs Today*, 2003, vol. 39 (2), 137-43 [0023]
- **LIAO, J.K.** Role of statin pleiotropism in acute coronary syndromes and stroke. *Int J Clin Pract*, 2003, 51-7 [0023]
- **DAVIDSON, M.H. et al.** The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. *Am J Cardiol*, 1997, vol. 79 (1), 38-42 [0024]
- **ZIEGLER, K. ; W. STUNKEL.** Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter. *Biochim Biophys Acta*, 1992, vol. 1139 (3), 203-9 [0025]
- **YAMAZAKI, M. et al.** Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. *Am J Physiol*, 1993, vol. 264, G36-44 [0025]
- **KOMAI, T. et al.** Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. *Biochem Pharmacol*, 1992, vol. 43 (4), 667-70 [0025]
- **HSIANG, B. et al.** A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. *J Biol Chem*, 1999, vol. 274 (52), 37161-8 [0025]
- **MASTERS, B.A. et al.** In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. *Toxicol Appl Pharmacol*, 1995, vol. 131 (1), 163-74 [0025]
- **NAKAHARA, K. et al.** Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. *Toxicol Appl Pharmacol*, 1998, vol. 152 (1), 99-106 [0025]
- **REIJNEVELD, J.C. et al.** Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. *Pediatr Res*, 1996, vol. 39 (6), 1028-35 [0025]
- **TUNSTALL-PEDOE, H. et al.** Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. *Lancet*, 2000, vol. 355 (9205), 688-700 [0026]
- **KUULASMAA, K. et al.** Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. *Lancet*, 2000, vol. 355 (9205), 675-87 [0026]
- **WONG, M.D. et al.** Contribution of major diseases to disparities in mortality. *N Engl J Med*, 2002, vol. 347 (20), 1585-92 [0026]
- **FLEGAL, K.M. et al.** Prevalence and trends in obesity among US adults, 1999-2000. *Jama*, 2002, vol. 288 (14), 1723-7 [0026]
- **BOYLE, J.P. et al.** Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. *Diabetes Care*, vol. 24 (11), 1936-40 [0026]

- **YUSUF, S. et al.** Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. *Circulation*, 2001, vol. 104 (23), 2855-64 [0026]
- **YUSUF, S. et al.** Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation*, 2001, vol. 104 (22), 2746-53 [0026]
- **CLARK, L.T.** Treating dyslipidemia with statins: the risk-benefit profile. *Am Heart J*, 2003, vol. 145 (3), 387-96 [0027]
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *Jama*, 2001, vol. 285 (19), 2486-97 [0028]
- **ROSES, A.D.** Pharmacogenetics and the practice of medicine. *Nature*, 2000, vol. 405 (6788), 857-65 [0029]
- **MOOSER, V. et al.** Cardiovascular pharmacogenetics in the SNP era. *J Thromb Haemost*, vol. 1 (7), 1398-1402 [0029]
- **HUMMA, L.M. ; S.G. TERRA.** Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. *Am. J. Health Syst Pharm*, 2002, vol. 59 (13), 1241-52 [0029]
- **KUIVENHOVEN, J.A. et al.** The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. *N Engl J Med*, 1998, vol. 338 (2), 86-93 [0029]
- **MAAT, M.P. et al.** -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern offibrinogen. REGRESS group. *Arterioscler Thromb Vasc Biol*, 1998, vol. 18 (2), 265-71 [0029]
- **ZAMBON, A. et al.** Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. *Circulation*, 2001, vol. 103 (6), 792-8 [0029]
- **JUKEMA, J.W. et al.** The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. *Circulation*, 1996, vol. 94 (8), 1913-8 [0029]
- **BRAY, P.F. et al.** The platelet PI(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. *Am J Cardiol*, 2001, vol. 88 (4), 347-52 [0029]
- **MAAT, M.P. et al.** Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. *Am J Cardiol*, 1999, vol. 83 (6), 852-6 [0029]
- **GERDES, L.U. et al.** The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. *Circulation*, 2000, vol. 101 (12), 1366-71 [0029]
- **PEDRO-BOTET, J. et al.** Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. *Atherosclerosis*, 2001, vol. 158 (1), 183-93 [0029]
- **GUSELLA.** *Ann. Rev. Biochem.*, 1986, vol. 55, 831-854 [0030]
- **WEBER et al.** Human diallelic insertion/deletion polymorphisms. *Am J Hum Genet*, October 2002, vol. 71 (4), 854-62 [0032]
- **STEPHENS et al.** *Science*, 20 July 2001, vol. 293, 489-493 [0034]
- **LINDER et al.** *Clinical Chemistry*, 1997, vol. 43, 254 [0039]
- **MARSHALL.** *Nature Biotechnology*, 1997, vol. 15, 1249 [0039]
- **SCHAFER et al.** *Nature Biotechnology*, 1998, vol. 16, 3 [0039]
- **SAMBROOK ; RUSSELL.** *Molecular Cloning: A Laboratory Manual.* Cold Spring Harbor Press, 2000 [0109] [0112] [0160]
- **COREY.** Peptide nucleic acids: expanding the scope of nucleic acid recognition. *Trends Biotechnol.*, June 1997, vol. 15, 224-9 [0112]
- **HYRUP et al.** Peptide nucleic acids (PNA): synthesis, properties and potential applications. *Bioorg Med Chem.*, January 1996, vol. 4 (1), 5-23 [0112]
- **LAGRIFFOUL et al.** *Bioorganic & Medicinal Chemistry Letters*, 1994, vol. 4, 1081-1082 [0113]
- **PETERSEN et al.** *Bioorganic & Medicinal Chemistry Letters*, 1996, vol. 6, 793-796 [0113]
- **KUMAR et al.** *Organic Letters*, 2001, vol. 3 (9), 1269-1272 [0113]
- *Current Protocols in Nucleic Acid Chemistry.* John Wiley & Sons, 2002 [0114]
- *Computational Molecular Biology.* Oxford University Press, 1988 [0119]
- *Biocomputing: Informatics and Genome Projects.* Academic Press, 1993 [0119]
- *Computer Analysis of Sequence Data.* Humana Press, 1994 [0119]
- **HEINJE, G.** *Sequence Analysis in Molecular Biology.* Academic Press, 1987 [0119]
- *Sequence Analysis Primer.* M Stockton Press, 1991 [0119]
- **NEEDLEMAN ; WUNSCH.** *J. Mol. Biol.*, 1970, (48), 444-453 [0119]
- **DEVEREUX, J. et al.** *Nucleic Acids Res.*, 1984, vol. 12 (1), 387 [0120]

- **E. MYERS ; W. MILLER.** *CABIOS*, 1989, vol. 4, 11-17 [0120]
- **ALTSCHUL et al.** *J. Mol. Biol.*, 1990, vol. 215, 403-10 [0121]
- **ALTSCHUL et al.** *Nucleic Acids Res.*, 1997, vol. 25 (17), 3389-3402 [0121]
- **PEARSON.** *Methods Mol. Biol.*, 1994, vol. 25, 365-389 [0121]
- **DUFRESNE et al.** *Nat Biotechnol*, December 2002, vol. 20 (12), 1269-71 [0121]
- Current Protocols in Bioinformatics. John Wiley & Sons, Inc, [0121]
- Mutation Detection A Practical Approach. Oxford University Press, 1998 [0129]
- **SAIKI et al.** *Nature*, 1986, vol. 324, 163-166 [0129]
- **NARANG et al.** *Methods in Enzymology*, 1979, vol. 68, 90 [0134]
- **BROWN et al.** *Methods in Enzymology*, 1979, vol. 68, 109 [0134]
- **BEAUCAGE et al.** *Tetrahedron Letters*, 1981, vol. 22, 1859 [0134]
- **GIBBS.** *Nucleic Acid Res.*, 1989, vol. 17, 2427-2448 [0136]
- **LIVAK et al.** *PCR Method Appl.*, 1995, vol. 4, 357-362 [0139]
- **TYAGI et al.** *Nature Biotechnology*, 1996, vol. 14, 303-308 [0139]
- **NAZARENKO et al.** *Nucl. Acids Res.*, 1997, vol. 25, 2516-2521 [0139]
- **LOCKHART, D. J. et al.** *Nat. Biotech.*, 1996, vol. 14, 1675-1680 [0145]
- **SCHENA, M. et al.** *Proc. Natl. Acad. Sci.*, 1996, vol. 93, 10614-10619 [0145]
- **ZAMMATTEO et al.** New chips for molecular biology and diagnostics. *Biotechnol Annu Rev.*, 2002, vol. 8, 85-101 [0146]
- **SOSNOWSKI et al.** Active microelectronic array system for DNA hybridization, genotyping and pharmacogenomic applications. *Psychiatr Genet.*, December 2002, vol. 12 (4), 181-92 [0146]
- **HELLER.** DNA microarray technology: devices, systems, and applications. *Annu Rev Biomed Eng.*, 22 March 2002, vol. 4, 129-53 [0146]
- **KOLCHINSKY et al.** Analysis of SNPs and other genomic variations using gel-based chips. *Hum Mutat.*, vol. 19 (4), 343-60 [0146]
- **MCGALL et al.** High-density genechip oligonucleotide probe arrays. *Adv Biochem Eng Biotechnol.*, 2002, vol. 77, 21-42 [0146]
- Current Protocols in Molecular Biology. John Wiley & Sons, 1989, 6.3.1-6.3.6 [0149]
- **WEIGL et al.** Lab-on-a-chip for drug development. *Adv Drug Deliv Rev.*, 24 February 2003, vol. 55 (3), 349-77 [0155]
- **CHEN et al.** Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput. *Pharmacogenomics J.*, 2003, vol. 3 (2), 77-96 [0166]
- **KWOK et al.** Detection of single nucleotide polymorphisms. *Curr Issues Mol Biol.*, April 2003, vol. 5 (2), 43-60 [0166]
- **SHI.** Technologies for individual genotyping: detection of genetic polymorphisms in drug targets and disease genes. *Am J Pharmacogenomics*, 2002, vol. 2 (3), 197-205 [0166]
- **KWOK.** Methods for genotyping single nucleotide polymorphisms. *Annu Rev Genomic Hum Genet*, vol. 2, 235-58 [0166]
- **MAMELLOS.** High-throughput SNP analysis for genetic association studies. *Curr Opin Drug Discov Devel.*, May 2003, vol. 6 (3), 317-21 [0166]
- **MYERS et al.** *Science*, 1985, vol. 230, 1242 [0167]
- **COTTON et al.** *PNAS*, 1988, vol. 85, 4397 [0167]
- **SALEEBA et al.** *Meth. Enzymol.*, 1992, vol. 217, 286-295 [0167]
- **ORITA et al.** *PNAS*, 1989, vol. 86, 2766 [0167]
- **COTTON et al.** *Mutat. Res.*, 1993, vol. 285, 125-144 [0167]
- **HAYASHI et al.** *Genet. Anal. Tech. Appl.*, 1992, vol. 9, 73-79 [0167]
- **MYERS et al.** *Nature*, vol. 313, 495 [0167]
- **WISE et al.** A standard protocol for single nucleotide primer extension in the human genome using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Rapid Commun Mass Spectrom.*, 2003, vol. 17 (11), 1195-202 [0174]
- **BOCKER.** SNP and mutation discovery using base-specific cleavage and MALDI-TOF mass spectrometry. *Bioinformatics*, July 2003, vol. 19, 144-153 [0175]
- **STORM et al.** MALDI-TOF mass spectrometry-based SNP genotyping. *Methods Mol Biol.*, 2003, vol. 212, 241-62 [0175]
- **JURINKE et al.** The use of MassARRAY technology for high throughput genotyping. *Adv Biochem Eng Biotechnol.*, 2002, vol. 77, 57-74 [0175]
- **JURINKE et al.** Automated genotyping using the DNA MassArray technology. *Methods Mol Biol.*, 2002, vol. 187, 179-92 [0175]
- *Biotechniques*, 1995, vol. 19, 448 [0176]
- **COHEN et al.** *Adv. Chromatogr.*, 1996, vol. 36, 127-162 [0176]
- **GRIFFIN et al.** *Appl. Biochem. Biotechnol.*, 1993, vol. 38, 147-159 [0176]
- **MYERS et al.** *Nature*, 1985, vol. 313, 495 [0177]
- **ORITA et al.** *Proc. Nat. Acad* [0177]
- PCR Technology, Principles and Applications for DNA Amplification. W.H. Freeman and Co, 1992 [0177]
- Modern Epidemiology. Lippincott Williams & Wilkins, 1998, 609-622 [0182]
- **WEIR B.** Genetic Data Analysis. Sinauer, 1990 [0185]
- **HOSMER ; LEMESHOW.** Applied Logistic Regression. Wiley, 2000 [0187]

- **DALY et al.** *Nature Genetics*, 2001, vol. 29, 232-235 [0188]
- **SCHAFD et al.** *Am. J. Hum. Genet.*, 2002, vol. 70, 425-434 [0189]
- **WESTFALL et al.** *Multiple comparisons and multiple tests*, 1999 [0190]
- **BENJAMINI ; HOCHBERG.** *Journal of the Royal Statistical Society, Series B*, vol. 57, 1289-1300 [0190]
- **WESTFALL ; YOUNG.** *Resampling-based Multiple Testing*. Wiley, 1993 [0190]
- *Modern Epidemiology*. Lippincott Williams & Wilkins, 1998, 643-673 [0191]
- **EWENS ; SPIELMAN.** *Am. J. Hum. Genet.*, 1995, vol. 62, 450-458 [0193]
- **PRITCHARD et al.** *Am. J. Hum. Gen.*, 1999, vol. 65, 220-228 [0193]
- **DEVLIN et al.** *Biometrics*, 1999, vol. 55, 997-1004 [0193]
- **DEVLIN et al.** *Genet. Epidemiol.*, (21), 273-284 [0193]
- **BACANU et al.** *Am. J. Hum. Genet.*, 2000, vol. 66, 1933-1944 [0194]
- **KEHOE et al.** *Hum. Mol. Genet.*, 1999, vol. 8, 237-245 [0194]
- **DRAPER ; SMITH.** *Applied Regression Analysis*. Wiley, 1998 [0195]
- **HASTIE ; TIBSHIRANI ; FRIEDMAN.** *The Elements of Statistical Learning*. Springer, 2002 [0195]
- **WALL et al.** *Haplotype blocks and linkage disequilibrium in the human genome.* *Nat Rev Genet.*, August 2003, vol. 4 (8), 587-97 [0204]
- **GARNER et al.** *On selecting markers for association studies: patterns of linkage disequilibrium between two and three diallelic loci.* *Genet Epidemiol.*, January 2003, vol. 24 (1), 57-67 [0204]
- **ARDLIE et al.** *Patterns of linkage disequilibrium in the human genome.* *Nat Rev Genet.*, April 2002, vol. 3 (4), 299-309 [0204]
- **ERRATUM.** *Nat Rev Genet*, July 2002, vol. 3 (7), 566 [0204]
- **REMM et al.** *High-density genotyping and linkage disequilibrium in the human genome using chromosome 22 as a model.* *Curr Opin Chem Biol.*, February 2002, vol. 6 (1), 24-30 [0204]
- **HALDANE JBS.** *The combination of linkage values, and the calculation of distances between the loci of linked factors.* *J Genet*, vol. 8, 299-309 [0204]
- **MENDEL, G.** *Versuche über Pflanzen-Hybriden.* *Verhandlungen des naturforschenden Vereines in Brünn* [0204]
- **LEWIN B.** *Genes IV.* Oxford University Press, 1990 [0204]
- **HARTL DL ; CLARK AG.** *Principles of Population Genetics*. Sinauer Associates, Inc, [0204]
- **GILLESPIE JH.** *Population Genetics: A Concise Guide*. Johns Hopkins University Press, 2004 [0204]
- **LEWONTIN RC.** *The interaction of selection and linkage. I. General considerations; heterotic models.* *Genetics*, 1964, vol. 49, 49-67 [0204]
- **HOEL PG.** *Introduction to Mathematical Statistics*. John Wiley & Sons, Inc, 1954 [0204]
- **HUDSON RR.** *Two-locus sampling distributions and their application.* *Genetics*, 2001, vol. 159, 1805-1817 [0204]
- **DEMPSTER AP ; LAIRD NM ; RUBIN DB.** *Maximum likelihood from incomplete data via the EM algorithm.* *J R Stat Soc*, 1977, vol. 39, 1-38 [0204]
- **EXCOFFIER L ; SLATKIN M.** *Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population.* *Mol Biol Evol*, 1995, vol. 12 (5), 921-927 [0204]
- **TREGOUET DA ; ESCOLANO S ; TIRET L ; MALLET A ; GOLMARD JL.** *A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm.* *Ann Hum Genet*, 2004, vol. 68, 165-177 [0204]
- **LONG AD ; LANGLEY CH.** *The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits.* *Genome Research*, 1999, vol. 9, 720-731 [0204]
- **AGRESTI A.** *Categorical Data Analysis*. John Wiley & Sons, Inc, 1990 [0204]
- **LANGE K.** *Mathematical and Statistical Methods for Genetic Analysis*. Springer-Verlag New York, Inc, 1997 [0204]
- *The International HapMap Project.* *Nature*, 2003, vol. 426, 789-796 [0204]
- *A haplotype map of the human genome.* *Nature*, 2005, vol. 437, 1299-1320 [0204]
- **THORISSON GA ; SMITH AV ; KRISHNAN L ; STEIN LD.** *The International HapMap Project Web Site.* *Genome Research*, 2005, vol. 15, 1591-1593 [0204]
- **MCVEAN G ; SPENCER CCA ; CHAIX R.** *Perspectives on human genetic variation from the HapMap project.* *PLoS Genetics*, 2005, vol. 1 (4), 413-418 [0204]
- **HIRSCHHORN JN ; DALY MJ.** *Genome-wide association studies for common diseases and complex traits.* *Nat Genet*, 2005, vol. 6, 95-108 [0204]
- **SCHRODI SJ.** *A probabilistic approach to large-scale association scans: a semi-Bayesian method to detect disease-predisposing alleles.* *SAGMB*, 2005, vol. 4 (1), 31 [0204]
- **WANG WYS ; BARRATT BJ ; CLAYTON DG ; TODD JA.** *Genome-wide association studies: theoretical and practical concerns.* *Nat Rev Genet*, 2005, vol. 6, 109-118 [0204]
- **PRITCHARD JK ; PRZEWORSKI M.** *Linkage disequilibrium in humans: models and data.* *Am J Hum Genet*, 2001, vol. 69, 1-14 [0204]
- **ROSES.** *Nature*, 2000, vol. 405, 857, 865 [0234]
- **GOULD ROTHBERG.** *Nature Biotechnology*, 2001, vol. 19, 209-211 [0234]

- **EICHELBAUM.** *Clin. Exp. Pharmacol. Physiol.*, 1996, vol. 23 (10-11), 983-985 [0234]
- **LINDER.** *Clin. Chem.*, 1997, vol. 43 (2), 254-266 [0234]
- **PFOST.** *Trends in Biotechnology*, August 2000 [0237]
- **ROSE et al.** Pharmacogenetic analysis of clinically relevant genetic polymorphisms. *Methods Mol Med.*, 2003, vol. 85, 225-37 [0238]
- **CACABELOS.** Pharmacogenomics for the treatment of dementia. *Ann Med.*, 2002, vol. 34 (5), 357-79 [0238]
- **MAIMONE et al.** Pharmacogenomics of neurodegenerative diseases. *Eur J Pharmacol.*, 09 February 2001, vol. 413 (1), 11-29 [0238]
- **POIRIER.** Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease. *Mol Diagn.*, December 1999, vol. 4 (4), 335-41 [0238]
- **SIEST et al.** Pharmacogenomics of drugs affecting the cardiovascular system. *Clin Chem Lab Med.*, April 2003, vol. 41 (4), 590-9 [0238]
- **MUKHERJEE et al.** Pharmacogenomics in cardiovascular diseases. *Prog Cardiovasc Dis.*, May 2002, vol. 44 (6), 479-98 [0238]
- **MOOSER et al.** Cardiovascular pharmacogenetics in the SNP era. *J Thromb Haemost.*, July 2003, vol. 1 (7), 1398-402 [0238]
- **MCLEOD et al.** Cancer pharmacogenomics: SNPs, chips, and the individual patient. *Cancer Invest.*, 2003, vol. 21 (4), 630-40 [0238]
- **WATTERS et al.** Cancer pharmacogenomics: current and future applications. *Biochim Biophys Acta*, 17 March 2003, vol. 1603 (2), 99-111 [0238]
- Antisense Drug Technology: Principles, Strategies, and Applications. Marcel Dekker, Inc, 2001 [0240]
- **THOMPSON.** *Drug Discovery Today*, 2002, vol. 7 (17), 912-917 [0240] [0244]
- **LAVERY et al.** Antisense and RNAi: powerful tools in drug target discovery and validation. *Curr Opin Drug Discov Devel.*, July 2003, vol. 6 (4), 561-9 [0241] [0246]
- **STEPHENS et al.** Antisense oligonucleotide therapy in cancer. *Curr Opin Mol Ther.*, April 2003, vol. 5 (2), 118-22 [0241]
- **KURRECK.** Antisense technologies. Improvement through novel chemical modifications. *Eur J Biochem.*, April 2003, vol. 270 (8), 1628-44 [0241]
- **DIAS et al.** Antisense oligonucleotides: basic concepts and mechanisms. *Mol Cancer Ther.*, vol. 1 (5), 347-55 [0241]
- **CHEN.** Clinical development of antisense oligonucleotides as anti-cancer therapeutics. *Methods Mol Med.*, 2003, vol. 75, 621-36 [0241]
- **WANG et al.** Antisense anticancer oligonucleotide therapeutics. *Curr Cancer Drug Targets*, November 2001, vol. 1 (3), 177-96 [0241]
- **BENNETT.** Efficiency of antisense oligonucleotide drug discovery. *Antisense Nucleic Acid Drug Dev.*, June 2002, vol. 12 (3), 215-24 [0241]
- **REYNOLDS et al.** Rational siRNA design for RNA interference. *Nat Biotechnol.*, 01 February 2004, vol. 22 (3), 326-30 [0246]
- **CHI et al.** Genomewide view of gene silencing by small interfering RNAs. *PNAS*, 2003, vol. 100 (11), 6343-6346 [0246]
- **VICKERS et al.** Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents. *J. Biol. Chem.*, 2003, vol. 278, 7108-7118 [0246]
- **AGAMI.** RNAi and related mechanisms and their potential use for therapy. *Curr Opin Chem Biol.*, December 2002, vol. 6 (6), 829-34 [0246]
- **SHI.** Mammalian RNAi for the masses. *Trends Genet.*, January 2003, vol. 19 (1), 9-12 [0246]
- **SHUEY et al.** RNAi: gene-silencing in therapeutic intervention. *Drug Discovery Today*, vol. 7 (20), 1040-1046 [0246]
- **MCMANUS et al.** *Nat Rev Genet*, October 2002, vol. 3 (10), 737-47 [0246]
- **XIA et al.** *Nat Biotechnol*, October 2002, vol. 20 (10), 1006-10 [0246]
- **PLASTERK et al.** *Curr Opin Genet Dev*, October 2000, vol. 10 (5), 562-7 [0246]
- **BOSHER et al.** *Nat Cell Biol*, February 2000, vol. 2 (2), 31-6 [0246]
- **HUNTER.** *Curr Biol*, 17 June 1999, vol. 9 (12), R440-2 [0246]
- **KREN et al.** *Proc. Natl. Acad. Sci. USA*, 1999, vol. 96, 10349-10354 [0247]
- **ROTHBERG.** *Nat Biotechnol*, March 2001, vol. 19 (3), 209-11 [0258]
- Current Protocols in Toxicology. John Wiley & Sons, Inc, [0260]
- **FRUDAKIS et al.** A Classifier for the SNP-Based Inference of Ancestry. *Journal of Forensic Sciences*, 2003, vol. 48 (4), 771-782 [0277]
- **KRAWCZAK.** Informativity assessment for biallelic single nucleotide polymorphisms. *Electrophoresis*, June 1999, vol. 20 (8), 1676-81 [0283]
- Current Protocols in Human Genetics. John Wiley & Sons, 2002, 14.1-14.7 [0286]
- **SAMBROOK ; RUSSELL.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 2000 [0292] [0353] [0354] [0365]
- **TERPE.** Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. *Appl Microbiol Biotechnol.*, 07 November 2002, vol. 60 (5), 523-33 [0298]
- **GRADDIS et al.** Designing proteins that work using recombinant technologies. *Curr Pharm Biotechnol.*, December 2002, vol. 3 (4), 285-97 [0298]

- **NILSSON et al.** Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. *Protein Expr Purif.*, October 1997, vol. 11 (1), 1-16 [0298]
- **BOWIE et al.** *Science*, 1990, vol. 247, 1306-1310 [0300]
- **CUNNINGHAM et al.** *Science*, 1989, vol. 244, 1081-1085 [0302]
- **SMITH et al.** *J. Mol. Biol.*, 1992, vol. 224, 899-904 [0302]
- **DE VOS et al.** *Science*, 1992, vol. 255, 306-312 [0302]
- **Proteins - Structure and Molecular Properties.** W. H. Freeman and Company, 1993 [0305]
- **WOLD, F.** Posttranslational Covalent Modification of Proteins. Academic Press, 1983, 1-12 [0305]
- **SEIFTER et al.** *Meth. Enzymol.*, 1990, vol. 182, 626-646 [0305]
- **RATTAN et al.** *Ann. N.Y. Acad. Sci.*, 1992, vol. 663, 48-62 [0305]
- **Current Protocols in Protein Science.** John Wiley & Sons, 2002 [0307]
- **Molecular Cloning: A Laboratory Manual.** Cold Spring Harbor Laboratory Press [0308]
- **SAMBROOK ; RUSSELL.** Methods in Enzymology: Guide to Molecular Cloning Techniques. Academic Press, 1987 [0308]
- **Current Protocols in Immunology.** John Wiley & Sons [0313]
- **HAGE.** Immunoassays. *Anal Chem.*, 15 June 1999, vol. 71 (12), 294R-304R [0313]
- **LAM et al.** *Nature*, 1991, vol. 354, 82-84 [0322]
- **HOUGHTEN et al.** *Nature*, 1991, vol. 354, 84-86 [0322]
- **SONGYANG et al.** *Cell*, 1993, vol. 72, 767-778 [0322]
- **HODGSON.** *Biototechnology*, 10 September 1992, 973-80 [0327]
- **ZERVOS et al.** *Cell*, 1993, vol. 72, 223-232 [0332]
- **MADURA et al.** *J. Biol. Chem.*, vol. 268, 12046-12054 [0332]
- **BARTEL et al.** *Biotechniques*, 1993, vol. 14, 920-924 [0332]
- **IWABUCHI et al.** *Oncogene*, 1993, vol. 8, 1693-1696 [0332]
- **MORRISON et al.** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 6851 [0335]
- **NEUBERGER et al.** *Nature*, 1984, vol. 312, 604 [0335]
- **WARD et al.** *Nature*, 1989, vol. 334, 544 [0335]
- **SEGAL et al.** *J. Immunol. Methods*, 2001, vol. 248, 1 [0335]
- **CARTER.** *J. Immunol. Methods*, 2001, vol. 248, 7 [0335]
- **TODOROVSKA et al.** *J. Immunol. Methods*, 2001, vol. 248, 47 [0335]
- **HARLOW.** Antibodies. Cold Spring Harbor Press, 1989 [0336]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 256, 495 [0337]
- **HE et al.** *J. Immunol.*, 2002, vol. 169, 595 [0337]
- **HOOGENBOOM ; CHAMES.** *Immunol. Today*, 2000, vol. 21, 371 [0337]
- **LIU et al.** *J. Mol. Biol.*, 2002, vol. 315, 1063 [0337]
- **MORGAN.** Antibody therapy for Alzheimer's disease. *Expert Rev Vaccines.*, February 2003, vol. 2 (1), 53-9 [0339]
- **ROSS et al.** Anticancer antibodies. *Am J Clin Pathol.*, April 2003, vol. 119 (4), 472-85 [0339]
- **GOLDENBERG.** Advancing role of radiolabeled antibodies in the therapy of cancer. *Cancer Immunol Immunother.*, 11 March 2003, vol. 52 (5), 281-96 [0339]
- **ROSS et al.** Antibody-based therapeutics in oncology. *Expert Rev Anticancer Ther.*, February 2003, vol. 3 (1), 107-21 [0339]
- **CAO et al.** Bispecific antibody conjugates in therapeutics. *Adv Drug Deliv Rev.*, 10 February 2003, vol. 55 (2), 171-97 [0339]
- **MEHREN et al.** Monoclonal antibody therapy for cancer. *Annu Rev Med.*, 03 December 2001, vol. 54, 343-69 [0339]
- **HUDSON et al.** Engineered antibodies. *Nat Med.*, January 2003, vol. 9 (1), 129-34 [0339]
- **BREKKE et al.** Therapeutic antibodies for human diseases at the dawn of the twenty-first century. *Nat Rev Drug Discov.*, January 2003, vol. 2 (1), 52-62 [0339]
- **ERRATUM.** *Nat Rev Drug Discov.*, March 2003, vol. 2 (3), 240 [0339]
- **HOUEBINE.** Antibody manufacture in transgenic animals and comparisons with other systems. *Curr Opin Biotechnol.*, December 2002, vol. 13 (6), 625-9 [0339] [0383]
- **ANDREAKOS et al.** Monoclonal antibodies in immune and inflammatory diseases. *Curr Opin Biotechnol.*, December 2002, vol. 13 (6), 615-20 [0339]
- **KELLERMANN et al.** Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. *Curr Opin Biotechnol.*, December 2002, vol. 13 (6), 593-7 [0339]
- **PINI et al.** Phage display and colony filter screening for high-throughput selection of antibody libraries. *Comb Chem High Throughput Screen.*, November 2002, vol. 5 (7), 503-10 [0339]
- **BATRA et al.** Pharmacokinetics and biodistribution of genetically engineered antibodies. *Curr Opin Biotechnol.*, December 2002, vol. 13 (6), 603-8 [0339]
- **TANGRI et al.** Rationally engineered proteins or antibodies with absent or reduced immunogenicity. *Curr Med Chem.*, December 2002, vol. 9 (24), 2191-9 [0339]
- **SMITH et al.** *Gene*, 1988, vol. 67, 31-40 [0358]
- **AMANN et al.** *Gene*, 1988, vol. 69, 301-315 [0358]
- **STUDIER et al.** *Gene Expression Technology: Methods in Enzymology*, 1990, vol. 185, 60-89 [0358]

- **GOTTESMAN, S.** Gene Expression Technology: Methods in Enzymology. Academic Press, 1990, vol. 185, 119-128 [0359]
- **WADA et al.** *Nucleic Acids Res.*, 1992, vol. 20, 2111-2118 [0359]
- **BALDARI et al.** *EMBO J.*, 1987, vol. 6, 229-234 [0360]
- **KURJAN et al.** *Cell*, 1982, vol. 30, 933-943 [0360]
- **SCHULTZ et al.** *Gene*, 1987, vol. 54, 113-123 [0360]
- **SMITH et al.** *Mol. Cell Biol.*, 1983, vol. 3, 2156-2165 [0361]
- **LUCKLOW et al.** *Virology*, 1989, vol. 170, 31-39 [0361]
- **SEED, B.** *Nature*, 1987, vol. 329, 840 [0362]
- **KAUFMAN et al.** *EMBO J.*, 1987, vol. 6, 187-195 [0362]
- Current Protocols in Molecular Biology. John Wiley & Sons [0373]
- **HOGAN, B.** Manipulating the Mouse Embryo. Cold Spring Harbor Laboratory Press, 1986 [0379]
- **LAKSO et al.** *PNAS*, 1992, vol. 89, 6232-6236 [0380]
- **O'GORMAN et al.** *Science*, 1991, vol. 251, 1351-1355 [0380]
- **WILMUT, I. et al.** *Nature*, 1997, vol. 385, 810-813 [0381]
- **PETTERS et al.** Transgenic animals as models for human disease. *Transgenic Res.*, 2000, vol. 9 (4-5), 347-51345-6 [0383]
- **WOLF et al.** Use of transgenic animals in understanding molecular mechanisms of toxicity. *J Pharm Pharmacol.*, June 1998, vol. 50 (6), 567-74 [0383]
- **ECHELARD.** Recombinant protein production in transgenic animals. *Curr Opin Biotechnol.*, October 1996, vol. 7 (5), 536-40 [0383]
- **HOUEBINE.** Transgenic animal bioreactors. *Transgenic Res.*, 2000, vol. 9 (4-5), 305-20 [0383]
- **PIRITY et al.** Embryonic stem cells, creating transgenic animals. *Methods Cell Biol.*, 1998, vol. 57, 279-93 [0383]
- **ROBL et al.** Artificial chromosome vectors and expression of complex proteins in transgenic animals. *Theriogenology*, 01 January 2003, vol. 59 (1), 107-13 [0383]
- **ALTSCHUL. J. Mol. Biol., 1990, vol. 215, 403-410 [0388]**
- **BRUTLAG. Comp. Chem., 1993, vol. 17, 203-207 [0388]**
- **SACKS et al.** *Am. J. Cardiol.*, 1991, vol. 68, 1436-1446 [0398]
- **SHEPHERD et al.** *N Eng J Med*, 16 November 1995, vol. 333 (20), 1301-7 [0398] [0401]
- **PACKARD et al.** *N Eng J Med*, 19 October 2000, vol. 343 (16), 1148-55 [0398]
- **M.A. LANNONE et al.** *Cyrometry*, 01 February 2000, vol. 39 (2), 131-140 [0400]
- **GERMER S. ; HOLLAND M.J. ; HIGUCHI R.** *Genome Res.*, 2000, vol. 10, 258-266 [0400]
- **PACKARD et al.** *N Eng J Med*, 19 October 2000, vol. 343 (16), 1148-55 [0401]

专利名称(译)	与心血管疾病和药物反应相关的遗传多态性，检测方法及其用途		
公开(公告)号	EP1926491B1	公开(公告)日	2013-03-20
申请号	EP2006815404	申请日	2006-09-25
[标]申请(专利权)人(译)	诊断CELERA		
当前申请(专利权)人(译)	塞雷拉基因组公司		
[标]发明人	IAKOUBOVA OLGA DEVLIN JAMES J		
发明人	IAKOUBOVA, OLGA DEVLIN, JAMES, J.		
IPC分类号	C12Q1/68 G01N33/53		
代理机构(译)	WEBER , MARTIN		
优先权	60/720274 2005-09-23 US 11/526137 2006-09-22 US		
其他公开文献	EP1926491A4 EP1926491A2		
外部链接	Espacenet		

摘要(译)

本发明基于与心血管疾病相关的遗传多态性的发现，特别是与心肌梗塞和中风等急性冠状动脉事件相关的遗传多态性，以及与患有心血管疾病的个体对该疾病的治疗的反应性相关的遗传多态性。他汀类药物。特别地，本发明涉及含有多态性的核酸分子，由这种核酸分子编码的变体蛋白，用于检测多态性核酸分子和蛋白质的试剂，以及使用该核酸和蛋白质的方法以及使用方法。用于检测的试剂。

1/2”